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GENERAL ABSTRACT 
Antiretroviral therapy (ART) has revolutionised outcomes of HIV infection among 
people living with HIV (PLWH). But despite these great strides, ongoing concerns of 
drug-drug interactions, widespread use of herbal medication while using ART, safety 
in pregnancy and breastfeeding are challenges of HIV treatment in PLWH. Potent new 
ART are not widely used in most low and middle income countries (LMIC) due to 
insufficient safety data and fear of adverse events. This Thesis aimed at evaluating 
the pharmacokinetic (PK) safety of DTG in pregnant and breastfeeding women, drug 
drug interaction of DTG and Artemisinin Combination Therapy (ACT), and evaluate 
the factors that affect ART in PLWH such as use of herbal medication among PLWH. 
Therefore the thesis evaluated the following: 
 
Chapter 2 reviewed the clinical PK and pharmacogenetic, drug-drug interactions and 
safety of DTG in diverse populations from different studies, and concluded that DTG 
has a variable PK influenced by factors such as food, research conditions and 
population variability.  
Chapter 4 evaluated the PK of DTG in 3rd trimester of pregnancy and postpartum 
women and found no clinically significant difference in DTG PK between pregnancy 
and postpartum period in women. Safety and efficiency of HIV control was also 
evaluated and concluded that DTG efficiently control viral load within a short period 
of time even when women present late in pregnancy. 
xx 
 
Chapter 5 evaluated the drug-drug interaction of DTG and ACT, and concluded that 
DTG can be co-administered with ACT in treatment of malaria among PLWH on DTG. 
Chapter 6 evaluated the impact of pharmacogenetics and pregnancy on tenofovir and 
emtricitabine Pharmacokinetics. An estimated 1-2-fold increase in FTC blood 
concentration was observed in pregnant and postpartum women with ABCC2 
12:g.154962860T>C T allele allele compared to women with CT and CC allele. Sample 
size was small and was recognise as a limitation. Therefore require verification with 
larger clinical studies and result should be interpreted with caution. 
Chapter 7 evaluated the widespread use of herbal medicines amongst PLWH and 
contamination of herbal medicines with ART in Nigeria as a recognised challenge of 
ART in sub-Saharan Africa. 
In conclusion, approximately 2-4% of maternal plasma DTG concentration was 
excreted in BM, and DTG PK changes were not clinically significant in both pregnancy 
and postpartum period. DTG Ctrough decreased by 37%, when DTG was administered 
with AL, 42% when administered with AS-AQ and 24% decrease in AUC0-24 when 
administered with AS-AQ, but were all above the protein adjusted IC90 for the Ctrough 
and does not warrant dose adjustment. An estimated 41.8% use of herbal medication 
was recorded amongst 742 PLWH attending HIV clinics. Herbal use preceded HIV 
therapy in 38.4% while 14.5% were yet to commence ART. A total of 3 (2%) out of 
138 herbal samples evaluated, were contaminated with detectable levels of tenofovir 
and emtricitabine which is a concern, though implication is unknown.  
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Chapter 1 
 
Investigating the Effectiveness of Antiretroviral therapy 
in sub-Saharan Africa 
 
1.1 Introduction 
Antiretroviral therapy (ART) against HIV is efficacious in reducing mortality and 
improving life expectancy in all geographical locations (1). It results in viral load 
suppression, immunological recovery and improves quality and quantity of life of 
people living with HIV (PLWH) (2). ART has revolutionised HIV outcomes in both high 
income countries (HIC) and low and middle income countries (LMIC), but more needs 
to be done in the latter. Though ART is beneficial to PLWH, access to care is variable. 
In LMIC, less than 50% of PLWH have access to ART while > 90% have access in HIC 
(3). These regional differences in access and quality of treatment across the globe 
impacts significantly on outcomes (4, 5). Less impact has been seen in sub-Saharan 
Africa (SSA) compared to HIC of Europe and America. Mortality and morbidity are still 
high despite great strides to intensify ART access (3). HIV burden still remains a great 
problem in SSA. It accounted for 67% (25.5 million out of the 36.7 million PLWH 
globally) of global burden in 2016 making it an important target region in the quest 
to end HIV epidemic (6). Mortality, transmission rates and morbidity remain high in 
SSA.  Over 73% (730,000 out of 1 million) AIDS related death and 64.4% (1.160 million 
out of the 1.8 million) new infections were recorded in SSA in 2016 (3). Despite the 
high disease burden and deaths in the region, only 61% of adults and 51% of children 
were receiving ART in East and Southern Africa and 36% of adults and 22% of children 
in west and central Africa compared to >95% of women and children and 75-95% of 
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adults in France, United Kingdom, United State, Australia and Canada (3). A total of 
20.9 million people have access to ART globally, but only an estimated 11 million 
(approximately 1.1 million from West and central Africa and about 10 million from 
South and Eastern Africa) are from SSA despite accounting for 69.5% (25.5 million) of 
the global burden of infection (3, 7). Over 50% of PLWH in SSA are women of 
reproductive age. A large proportion of future mothers are likely to expose their 
babies to HIV, risk of vertical transmission and increased burden of paediatric HIV 
infections is likely (3). Disproportionate access to ART (approximately 28% in West 
and Central Africa) is likely to deterrent to the success of the proposed efforts to end 
HIV epidemic by 2030 (3, 8). It is necessary to critically evaluate the effectiveness of 
ART programmes as we aim at improving access to ART. Drug safety, appropriate use 
of drugs and adherence will need to be ensured for these targets to be met. Limited 
access to ART promotes herbal/traditional medicine use, poor adherence, increased 
transmission rates and mortality from complications of AIDS (9, 10).  
1.2 Pregnancy and Breastfeeding 
An important component of ending the HIV epidemic is intensifying treatment among 
women of reproductive age (>15 years) who account for 48.5% of global, and 51% of 
SSA HIV burden (3). In 2016, women of reproductive age (15-24years) accounted for 
26% of new infection in East and Southern Africa and 22% in West and Central Africa 
(3). New infection was largely promoted by human right abuses, child marriages, 
transactional relationships between young girls and older men as a means of 
affording their basic needs, conflicts and lawless societies which make more young 
women vulnerable to an imbalance of power and gender-related abuses (3). New HIV 
infection during pregnancy is also a concern, as most women are likely to be 
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diagnosed late, exposing the baby to high risk of infection. This high prevalence of 
HIV infection among women of reproductive age has a direct association with 
increases in the risk of vertical transmission, and incidence of paediatric HIV 
infections. Therefore, a consistent rise in the incidence of new infections in women 
of reproductive age is detrimental to the success of ending vertical transmission of 
HIV to neonates. Increased education, HIV testing, safe sex practices, prevention of 
unwanted pregnancies, treatment of all diagnosed cases and high standard antenatal 
care is required during pregnancy to ensure healthy babies and no compromise to 
maternal health. Embarking in practices that will improve access to ART, optimise 
adherence and ensure drug safety in pregnancy and breastfeeding are essential in 
eliminating vertical transmission. Apart from optimum highly active antiretroviral 
(HAART) treatment, taking all recommended safety precautions to prevent 
transmission during breastfeeding is important in protecting babies from HIV 
infection. Exclusive breastfeeding for six months, prompt cessation of breastfeeding 
in case of nipple cracks, ulcers, infection or abscess are all important precautions to 
protect babies from infection. Failure to have efficient system for preventing vertical 
transmission will increase the rate of HIV infection in children, as observed in many 
SSA countries where care and access to ART is poor (11).  
1.3 Children and vertical transmission 
SSA alone accounts for approximately 90% of vertical transmission, paediatric HIV 
and AIDS related deaths (3). In 2016, UNAIDs estimated 2.1 million children < 15 years 
living with HIV globally and majority are from sub-Saharan Africa (3). It was the 
leading cause of death among children and adolescent accounting for 120,000 deaths 
globally. Although there is a decline in the rate of transmission since intensifying 
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PMTCT programs, ART only reduces the risk of transmission, but does not eliminate 
transmission risk. Therefore, it is highly dependent on the effectiveness of the 
system. Vertical transmission in SSA still remains relatively high compare to other 
regions of the world (3, 12). This reflects the effectiveness of PMTCT program and 
need of system strengthening in ensuring program success in the region. Clinical 
studies that aim at identifying factors mitigating against eliminating paediatric HIV 
require attention for maximising prevention of vertical transmission. Though 
successes have been significant, early testing and diagnosis of HIV in paediatric SSA 
population has been poor, resulting in many undiagnosed cases and poor disease 
outcomes (3, 13, 14). In 2016, only 43% of HIV exposed children were tested for HIV 
and few HIV positive children were treated (3, 15). In 2015 West Africa alone 
accounted for 45% of new HIV infection in children (3) and Nigeria alone accounted 
for an estimated 41,000 new cases of paediatric HIV (15). In 2017, only 59% of 
children in East and Southern African and 26% in Central and Western Africa were 
receiving ART compare to over 90% of children in most HIC (16). Although priority is 
given for prompt treatment of diagnosed HIV in children, 57% (1.2 million) of children 
living with HIV are not on ART. Most of these are from SSA, and this is due to low 
rates of HIV testing. This low rate of testing was attributed to lack of expertise, 
polymerase chain reaction (PCR) machines and other peculiar logistics in the region 
such as unstable of power (17, 18) .   
1.4 Prevention of Mother to Child Transmission of HIV (PMTCT) 
1.4.1 Scale of the problem: 
 Women of reproductive age have the highest burden of HIV in SSA with risk of 
transmission to their babies (3). Poor access to HIV services, late presentation and 
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delayed diagnosis during the antenatal period results in increased risk of vertical 
transmission in LMIC. Therefore, mitigating against achieving the desired UNAIDS 
targets (8, 19). Prior to 2016, WHO recommended ARVs to all HIV positive pregnant 
women during pregnancy, and discontinuation after delivery or breast feeding (20-
22). The practice was associated with poor maternal health and risk of resistance to 
exposed drugs and reduced chances of successful treatment with the same drugs in 
future (23). However, since changes in 2016, all diagnosed PLWH are required to have 
ART commenced immediately and maintained for life (24). Current treatment does 
not just aim at treating disease in infected persons, but using treatment as a 
prevention strategy (25, 26). Integrating HIV testing and treatment as part of 
antenatal care significantly reduced HIV burden in children, but without adequate 
treatment vertical transmission still occur more frequently than expected (27). In 
2012, over 90% of paediatric new infections were due to vertical transmission, 
despite UNAID report of 2017 revealing decline in paediatric infections. This means 
the current progress is far off the expected pace needed for 2020 targets (8, 19). 
Prevention of infection in women of reproductive age and unintended pregnancies 
among infected women is significant in preventing paediatric HIV infections (20).  Pre-
exposure prophylaxis among high risk women of reproductive age is an important 
strategy in reducing the burden of HIV among women of reproductive age (28).  
Mother to child transmission risk is increased in the following: New HIV infection 
acquired during pregnancy, maternal high viral load at delivery, treatment failure due 
to resistant viruses, poor adherence to ART and late presentation for antenatal and 
ART during pregnancy. Therefore adequate treatment of pregnant women with ART 
that lower the viral load as fast as possible is required when women present late (24). 
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1.4.2 Difference between sub-Saharan Africa and Europe 
There is no difference in treatment outcomes of HIV between SSA, Europe or America 
when ART is deployed for treatment of HIV. But when factors such as access to ART, 
quality of care, inappropriate use of drugs, poor monitoring, adverse events and drug 
drug interactions are taken into account, obvious differences are observed in the 
outcomes of HIV infections between SSA and Europe. Linkage to HIV care following 
diagnosis of HIV is high in Europe as reported by a systematic review that evaluated 
linkage to care following diagnosis in European population (29), while it is poor in 
SSA. Reports from SSA population revealed that retention of diagnosed HIV patients 
and ART initiation is poor (30), and loss to follow up after testing is high. Access to 
ART is difficult in some cases and drug options for treatment are limited. Diagnostic 
tools are lacking, and these factors significantly impacts outcome of HIV treatment. 
Other differences of HIV care between Europe and SSA include: Lack of adequately 
trained physicians and other health care workers to offer best clinical HIV services to 
patients, lack of hospital HIV treatment policies, protocols and adequate laboratory 
services for monitoring in SSA compare to Europe (31).  
1.5 Pre-Exposure Prophylaxis (PrEP) 
Prevention of HIV among high risk groups is one of the new approaches of preventing 
HIV infections. High risk groups who are HIV negative are commenced on ART with 
the aim of preventing them from getting infected by their partners who are HIV 
positive. Pilot studies such as PROUD  provided encouraging result and currently 
recommended more frequently as a preventive measure for high risk group (32, 33). 
TFV and FTC combination are commonly used in PrEP (33, 34). It is well accepted by 
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high risk groups such as sex workers, men who have sex with men (MSM) and uptake 
is increasing (35, 36). 
1.6 Breastfeeding 
1.6.1 Breastfeeding and drug safety: 
 In many SSA countries, prevalence of breastfeeding among women is low, though 
higher than HIC. Exclusive breastfeeding is also not commonly practice among 
women who breastfeed their babies (37, 38). Mixed feeding is commonly practice 
and associated with increased infant mortality and diarrhoeal diseases among 
children (11, 39-41). WHO recommend exclusive breastfeeding by all mothers, 
including HIV positive mothers despite risk of HIV transmission because it is the 
acceptable, feasible, affordable, sustainable and more reliable safe method of 
feeding babies in most LMIC settings (42). However, due to risk of HIV transmission, 
all European guidelines universally recommend against breastfeeding (43-45). 
Breastmilk remains the best source of nutrition, but is complicated in HIV by risk of 
HIV transmission (46, 47). Fear of excretion of toxic concentration of drug in breast 
milk, concerns of transmission of multiclass resistant HIV virus during breastfeeding 
(48, 49) and poor pharmacovigilance of HIV transmission during breastfeeding are 
major research gaps that require attention to guarantee absolute prevention of 
breastfed infants of HIV positive mothers who breastfeed.  
1.6.2 Mother to child transmission risk in breast feeding 
Breastfeeding is associated with increased risk of MTCT especially in untreated HIV 
(11, 50-52). Despite risk and limited evidence, WHO still recommend exclusive 
breastfeeding as the preferred feeding method in HIV exposed infants (42). Use of 
ART to optimally suppress viral load in mothers is important in decreasing the risk of 
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transmission during breastfeeding (53), hence the importance of good PMTCT 
programs.  Transmission risk is variable depending on breastfeeding method adopted 
by the mother (54). Exclusively breastfed babies have lower risk of HIV infection 
during breastfeeding compare to mixed fed babies (55). Risk of MTCT in exclusively 
breastfed babies may be lower than in mixed fed or predominantly breastfed babies 
during the postnatal period. In a study comparing the exclusively breastfed babies, 
mixed fed and predominantly breastfed babies followed up to 2 years, postnatal  
transmission risk was [4.03 (95% CI 0.98, 16.61), 3.79 (95% CI 1.40–10.29), and 2.60 
(95% CI 1.21–5.55) greater risk at 6, 12, and 18 months, respectively when exclusively 
breastfed infants were compared with mixed fed babies, and predominantly 
breastfed babies were associated with a 2.63 (95% CI 0.59–11.67), 2.69 (95% CI 0.95–
7.63) and 1.61 (95% CI 0.72–3.64) great risk when compared with exclusively 
breastfed babies (56, 57). Increased risk of MTCT is associated with CD4 cell count of 
<200 cells/µL, birthweight <2500g and high maternal VL (58). Maternal HIV Env-
specific neutralizing and non-neutralizing responses also reduces the risk of MTCT 
during breastfeeding (59).  
 
1.7 Monitoring PLWH 
1.7.1 Relationship of immunological recovery and viral load suppression in ART 
treatment:  
There is an inverse relationship between the CD4 cell count and HIV associated or 
opportunistic disease. Peripheral blood CD4 count and viral load changes are reliable 
surrogate markers of disease severity (2). In settings where routine viral load 
measurement is available, it is recommended at 6 months, 12 months and then after 
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every 12 months for monitoring ART response while CD4 count can be suspended in 
individuals who are virally suppressed, to be recommended only when clinically 
indicated (60). Access to viral load monitoring and CD4 cell count is poor in SSA, 
making follow-up ART monitoring and investigations difficult. Improving access to 
treatment with potent ART ensures adequate viral suppression, improve quality of 
life and reduce transmission rate (61). 
1.8 HIV co infections 
1.8.2 Malaria 
The geographical overlap of malaria and HIV as highly endemic diseases in SSA impact 
significantly on the frequency and outcomes of disease (62). HIV associated 
immunosuppression increases the severity and incidence of malaria (62), while HIV 
coinfection with malaria increases mortality (63). Previous studies were unsure of the 
impact of HIV and immunosuppression on the severity of malaria (64), but more 
recent studies have related the use of antimalarial prophylaxis with improved 
outcomes of HIV. Intensified use of ARVs and malaria prophylaxis among HIV patients 
decreases severity of both malaria and HIV (65), but potential of drug-drug 
interaction should always be a consideration in treating HIV/malaria co infection to 
prevent recrudescence. Evaluating potential drug-drug interaction between ARVs 
and antimalarial drugs such as artemeter, lumefantrine, amodiaquine, mefloquine, 
primaquine, artesunate, sulphadoxine and pyrimethamine is important in this region 
before introduction of any new ARV even if reports have not raised safety concerns 
of ARVs and commonly prescribed antimalarial (66, 67).  
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1.9 Drug-drug interactions 
Polypharmacy is common in PLWH especially if there are associated coinfections or 
comorbidities. Treatment of HIV together with other diseases is associated with drug-
drug interaction from shared metabolic pathways or inducing action of some drugs 
(68). Common inducers like rifampicin use in treatment of TB may induce CYP 2B6 (an 
important enzyme in metabolism of EFV and nevirapine) (69, 70), CYP3A4 and UGT 
(important enzymes in metabolism of DTG). Interaction with tropical diseases 
treatment should be anticipated in HIV treatment because of shared regional 
prevalence and concomitant treatment of diseases together in sub Saharan Africa. 
Investigating drug interaction for TB, malaria, parasitic infections, helminths, 
neglected tropical diseases and all other tropical diseases prior to introduction of new 
ART will ensure safety in the sub-Saharan Africa population. 
 
 
1.10 Pharmacology of HIV Drugs 
Description of zidovudine antiviral activity in 1985 and subsequent approval for HIV 
treatment in 1987 by US Food and Drug Administration (FDA) paved way for several 
advances in the treatment of HIV (71). Another major milestone was also achieved in 
1996 where a combination of three highly active antiretroviral therapy (HAART) 
introduced for use in treating HIV treatment. For improved efficacy and prevention 
of resistance to monotherapy with (HAART), combination therapy with three drugs 
(triple therapy) was subsequently introduced. Triple therapy (three drugs from two 
different classes) revolutionised outcomes of HIV treatment and several modalities 
are currently used to optimise health outcomes of PLWH. Understanding the life cycle 
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of HIV virus has been the basis of antiretroviral drug development, presenting ten 
(10) potential targets of interfering with the life cycle as targets for ARV development.  
Ability to interfere with any of the ten (10) steps of viral replicative cycle reduces the 
viral load (72). Based on these targets, ARVS can be classified into the following: Entry 
inhibitors, Nucleoside/nucleotide reverse transcriptase inhibitors, Non-nucleotide 
reverse transcriptase inhibitors, protease inhibitors and integrase inhibitors (figure 
1). 
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Figure 1:  1.10 HIV Life cycle 
   
 
 
 
 
HIV life cycle and Ten Targets for 
antiretroviral drug development. 
These Targets are: Virus adsorption, 
Virus-cell fusion, uncoating, reverse 
transcription, integration, 
transcription, translation, 
proteolytic processing, viral protein 
and RNA assembly and budding. . 
These targets have been used over 
the years for development of ARVS. 
HIV is a retrovirus which depends 
on reverse transcription of viral 
RNA and integration of proviral DNA 
to host (human genome) to 
progress in the cycle. Targeting 
these different stages halt the 
process and cause viral load 
suppression, with a corresponding 
immunological recovery, since the 
virus attacks the CD4 lymphocyte. 
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1.10.1 HIV Entry Inhibitors 
These are group of ARV that target multistep process of HIV entry to CD4+ T 
lymphocyte by inhibiting viral envelop glycoproteins (gp120 and gp41) and targeting 
CD4+ T lymphocyte chemokine co-receptors (CCR5 and CXCR4) (73). The process of 
viral interaction with CD4+ T lymphocyte results in delivery of viral core and RNA into 
the cytoplasm of host cell (73). The HIV core entry begins with binding of gp120 to 
cellular receptor of CD4+ T lymphocyte. The interaction result in a conformational 
change of gp120 and binding to co-receptors (CCR5 and CXCR4) that subsequently 
trigger gp41 to interact with fusion peptide, bringing the virus and CD4 cell 
membrane to fuse. Entry inhibitors are classified into fusion inhibitor (enfuvirtide) 
and chemokine co-receptors (CCR5 and CXCR4 receptor) antagonist (CCR5 inhibitors: 
maraviroc, cenicriviroc in phase II clinical trials). 
The fusion inhibitor class has enfurvitide as its only member. This is a synthetic 
oligopeptide that targets gp120 and gp41 (74, 75).  After binding of gp120 to 
receptors on cell surface of CD4 cell, the transmembrane protein gp41 mediates 
fusion with cellular membrane by causing a conformational change in viral core 
structure and membrane fusion. Enfurvitide inhibits helical regions 1 and 2 (HR1 and 
HR2) of gp41 preventing conformational change and inability of gp120 to block fusion 
of viral core membrane, preventing entry. It is administered by subcutaneous 
injections and has minimal toxicity, but side effect of injection site reaction is a 
problem that discourages its use. 
The chemokine (CCR5) receptors antagonists, such as maraviroc, are CCR5 
antagonists that block the MIP 1 alpha and RANTES mediated cell signalling pathway. 
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Another member of this group is cenicriviroc (In phase II clinical trials). Tropism is 
required before clinical use because efficacy is determined by the presence of X4 or 
R5 strains of virus. Side effects include:  Orthostatic hypotension in some cases and 
more frequently headache, asthenia, dizziness, gingivitis and nausea (76). 
 
1.10.2 NRTI: Chemistry, Mechanisms of action, Side effects, Pharmacogenetics 
Nucleoside and Nucleotide reverse transcriptase inhibitors are synthetic analogs of 
de-oxyribo and ribo-nucleosides or nucleotide (tenofovir). They exert their activity by 
mimicking nucleotides, and subsequent inhibition of the reverse transcriptase 
enzyme through its P66 subunits. NRTI inhibit both RNA and DNA polymerase activity, 
but do not have any action on RNase activity. They are activated intracellularly by 
phosphorylation to their active form in order to exert antiviral activity. Commonly 
used members of this group include: abacavir, zidovudine, lamivudine, emtricitabine 
and tenofovir. They are recommended as the NRTI backbone of WHO first line 
regimen (60).  Side effects include: HLA associated hypersensitivity with abacavir, 
nephrotoxicity and bone toxicity with tenofovir, and zidovudine associated anaemia. 
They are mostly eliminated by the kidneys via drug transporters that can be 
influenced by mutations and polymorphism of drug transporter genes. 
Tenofovir (TFV): This is an acyclic nucleoside phosphonate analogue of adenosine 5′-
monophosphate administered as a prodrug tenofovir disoproxil fumarate or 
tenofovir alafenamide to enhance stability for formulation and oral bioavailability 
and absorption(77). Following administration, tenofovir is cleaved by esterase 
hydrolysis before absorption (78, 79). It competes with the natural substrate 
deoxyadenosine 5′-triphosphate for incorporation into DNA during HIV transcription. 
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It has activity against retroviruses and hepadnaviruses and it is also used in the 
treatment of hepatitis B infections. It is not a substrate of CYP enzymes and has no 
relevant clinical interactions with most ART, except atazanavir and didanosine (79). It 
is eliminated predominantly unchanged via renal transporters (80). 
Emtricitabine (FTC): This is a cytidine analogue commonly prescribed in combination 
with TFV for treatment of HIV, or HBV (81). It has a low barrier to resistance and as 
such it is rarely prescribed alone, but it has synergistic potency in combination with 
TFV.  It is eliminated unchanged via renal transporters in the kidney and well 
tolerated by patients. Side effects include lactic acidosis and increased risk of liver 
damage in chronic liver disease. 
Zidovudine (ZDV): Zidovudine was the first licenced antiretroviral and was initially 
prescribed alone as monotherapy before the era of combination therapy (cART). As 
reverse transcriptase inhibitors their antiviral activity is aimed at competing with 
essential substrates of proviral DNA (82). Its major side effect is haematological, 
usually associated with anaemia and other haematological complications (83, 84). 
Complication such as stillbirths, preterm delivery, small for gestational age, and 
neonatal death have also been reported in infants exposed to ZDV during pregnancy 
and breastfeeding (85) 
Abacavir (ABC): This NRTI is associated with HLA-B*5701 hypersensitivity and should 
be avoided in HLA-B*5701 positive patients (86, 87). It is highly potent against HIV-1 
virus and commonly prescribed in combination with lamivudine (88, 89). Abacavir is 
a substrate of human ABCB1 and ABCG2. While ABCB1/ABCG2 have a modest effect 
on its transplacental kinetics at term, it is frequently used in pregnant women and 
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have minimal adverse effect on the baby and mother during pregnancy (88, 90). It is 
metabolised in the liver and eliminated via the kidneys. 
Lamivudine (3TC): This NRTI exacts its antiviral activity via an intracellular anabolite 
lamivudine 5′-triphosphate (lamivudine-TP), eliminated slowly from the cell with a 
half-life of 15 to 16 h (91). Over 70% of lamivudine is excreted unchanged via the 
kidneys, and plasma concentration is known to increase in renal pathology (92). It is 
well tolerated but some side effects include lactic acidosis, which can be associated 
with severe adverse events (92). Pharmacokinetics can be influenced by drug-drug 
interactions (93), pregnancy (94), renal pathology and pharmacogenetic 
polymorphisms in some transporters (95).  
 
 
 
1.10.3 NNRTI: Chemistry, Mechanisms of action, Side effects, Pharmacogenetics 
This group of compounds, like the NRTI, also inhibit the activity of the reverse 
transcriptase enzyme by binding non-competitively to a different receptor binding 
site to cause disruption of the enzyme at it catalytic site. Unlike the NRTIs, this class 
of compounds do not require activation since they are not prodrugs. Highly 
bioavailable, but can easily develop resistance, so they are recommended for use 
with other potent ARVs. They are metabolised by many cytochrome P 450 enzymes. 
Side effects include: rash (especially after discontinuation of therapy), hepatotoxicity 
(most common with nevirapine), CNS symptoms and exacerbation of depression 
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(associated with efavirenz). Some examples include: efavirenz, nevirapine, 
delarvidine, etravirine and rilpivirine. 
Efavirenz (EFV): This is a highly potent reverse transcriptase inhibitor with sustained 
antiviral activity when used in combination with other ART (96). It is commonly 
prescribed with other NRTI for the treatment of HIV. Due to its ability to cross the 
blood brain barrier in significant amount, EFV exhibits significant central nervous 
system (CNS) side effects (97). EFV is predominantly metabolised by CYP enzymes in 
the liver and plasma concentration is influenced by enzyme inducers such as 
rifampicin. It is associated with significant interpatient variability and could 
sometimes require therapeutic drug monitoring to ensure optimal dosing (98, 99). It 
is metabolised significantly by CYP 2B6 and polymorphisms of the enzyme impacts on 
plasma drug levels(100). Glucuronidation by UGT2B7 and polymormophisms of 
ABCB1 genes are all associated with changes in EFV concentrations (101, 102). CYP 
3A4 induction and polymorphisms of CYP2A6 also influences EFV concentration 
(103). 
Nevirapine (NVP): This is a dipyridodiazepinone compound potent in the treatment 
of HIV (104). It is a selective noncompetitive inhibitor of the reverse transcriptase 
enzyme and an inducer of CYP P450 enzyme (104, 105). It could be associated with 
significant hypersensitivity reaction (Stevens Johnson syndrome) (106, 107) and 
interact with some anti TB medications such as bedaquiline (108). 
Rilpivirine (RPV): This is a potent NNRTI with diarylpyrimidine structure that enables 
tight allosteric binding to reverse transcriptase enzyme (109, 110). After oral 
administration, Cmax is achieved 4-5 h (111). Terminal half-life is 34-55 h enabling once 
daily dosing (111, 112). It is over 99% protein bound and plasma exposure is affected 
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by protein rich drinks (112). Rilpivirine is a CYP 3A4 inducer, primarily metabolised by 
CYP 3A, and clearance is affected by drugs metabolised by the same pathway. Its 
absorption is pH dependent, and should not be administered with proton pump 
inhibitors and H2-receptor antagonist (112). Sustained released injectable 
formulation makes it potentially good in improving adherence in HIV patients (109, 
113). 
 
1.10.4 PI: Chemistry, Mechanisms of action, Side effects, Pharmacogenetics 
Protease inhibitors mimic protease enzyme and inhibit maturation of viral proteins 
by replacing peptide bonds with hydoxyethylene bond that cannot be easily split by 
hydrolase enzyme. Thereby inhibiting cleavage of peptides, that is required for 
maturation of the viral precursor proteins. They mostly have a central core with a 
hydroxyethylene bond. They interact with the enzyme by fusion with the central 
cavity to inhibit peptide formation and halt viral replication. Commonly used 
members include: darunavir (DRV), atazanavir (ATV), lopinavir (LPV) and ritonavir 
(RTV) (which is mostly used for pharmacological boosting). Other members of the 
group include: saquinavir, indinavir, amprenavir, nelfinavir and fosamprenavir. They 
are mostly metabolised by the cytochrome P450 enzymes. Common site effects 
include: dyslipidaemia, insulin-resistance, cerebrovascular diseases and 
lipodystrophy/lipoatrophy. They are commonly administered with a pharmacological 
boaster, an inhibitor of CYP 3A4 to prolong drug half-time. 
Darunavir (DRV): It is a non-peptide protease inhibitor with high potency and 
resistance barrier that inhibit HIV gag and gag pol protein to prevent viral maturation 
(114, 115). Darunavir is rapidly absorbed and bioavailability is increased with food. It 
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reaches maximum plasma concentration (Cmax) rapidly in 2.5-3 h after oral 
administration of low dose ritonavir boosted darunavir (114, 115). It is better 
tolerated than LPV (115), and recommended as an alternative second line regimen 
by WHO for HIV treatment. Its use for treatment of HIV is limited compare to ATZ and 
lopinavir (LPV) due to evidence gap especially in pregnancy and breastfeeding (60). It 
interacts with both inducers, inhibitors and substrates of CYP3A4. 
Lopinavir (LPV): Is a peptidomimetic inhibitor of protease enzyme. It is administered 
with small amount of ritonavir for CYP 3A4 inhibition and increased plasma 
concentration and activity of the drug (116). It can potentially interact with other 
drugs via CYP enzymes, as seen in other protease inhibitors (116). It is therapeutically 
effective and has a high resistance barrier. It is well tolerated by patients, but 
associated with some disturbing side effects such as lipodystrophy, changes of body 
fat distribution (especially redistribution from arms, legs, face, neck, breasts, and 
waist),  insulin resistance and metabolic syndromes. These LPV associated side effects 
could be attributed to its role in decreasing glucose uptake by both adipose tissue 
and muscle, resulting in lipoatrophy and glucose intolerance (117).  
Atazanavir (ATV): Exacts its antiviral activity by inhibiting viral gag and gag-pol 
polyprotein processing in HIV infected cells to prevent maturation of virions (118, 
119). Unlike other protease inhibitors, ATV is an inhibitor of UGT1A1, and can 
potentially interact with integrase inhibitors with resulting pharmacological boosting 
of the activity of integrase inhibitors or toxicities (120). It was thought to be 
associated with increase cardiovascular risk (121), however recently some studies 
have also reported the contrary, when compared with other PI. Cobicistat, inhibits 
CYP 3A4 to increase bioavailability of PI. It is currently used for pharmacological 
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boosting of ATV (122), non-active against HIV, but better tolerated and devoid of side 
effects such as lipodystrophy and other metabolic syndromes. 
Ritonavir (RTV): This is a protease inhibitor with potent antiviral activity. It has a long 
half-life compared to other PI enabling twice daily dosage. It is well tolerated, well 
absorbed and reaches Cmax within 2-4 hours after oral administration (123). It is a 
potent CYP3A4 inhibitor and currently co-formulated in small quantity with other PI 
to prolong their activity (124). Its advantages in pharmacological boosting via CYP3A4 
inhibition is considered for application in surgery, cancer medicine and treatment of 
hepatitis C (125, 126). 
 
 
1.10. 5 Integrase inhibitors (INSTI) 
These are a group of compounds that inhibit the strand transfer of viral DNA to host 
DNA by preventing nicking, ligation and covalent linkage of viral and host DNA in the 
nucleus (127). They inhibit the active site of the enzyme after 3’ processing and 
chelate divalent metal ions by catalytic triad of Asp-Asp-Glu. The integrase enzyme is 
a protein consisting of three functional domains, encoded by gag and pol genes. 
Activity of the INSTI is mediated by polyvalent metals and metabolised via uridine 5’-
diphospho-glucoronosyltransferase (UGT) enzymes (128, 129). Members of this class 
of drugs include raltegravir (RAL), elvitegravir (ELV), dolutegravir (DTG) and 
Bictegravir (BIC). 
Raltegravir (RAL): This is the first generation of integrase inhibitors that targets 
proviral DNA-strand transfer. It is potent against HIV virus resistant against other 
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antiviral agents (130, 131). It is metabolised mainly via UGT1A1 with minor 
contributions from CYP3 A4. Its half-life is approximately 9 h, dose is once daily and 
is well tolerated. Plasma concentration is affected by fatty meals (132) and pregnancy 
is associated with lower drug exposure to mother but not clinically significant to 
warrant dose adjustment (133).  
Elvitegravir (ELV): This is a potent integrase inhibitor for HIV treatment commonly 
boosted using a CYP 3A4 inhibitor cobicistat for once daily dosing. It is mainly 
metabolised via CYP 3A4 and coadministration with CYP3A4 enzyme inhibitor to 
prolong its half-life. Following oral administration, ELV is rapidly absorbed within 1-
2.5 h and with cobicistat or ritonavir boasting, half-life could be prolonged from 3.5 
h to 9.5 h (134). ELV PK is influenced by several health conditions such as liver disease, 
renal disease and age. It is also influenced by food and drug-drug interactions. 
Dolutegravir (DTG): DTG was approved in 2013 by the FDA and is currently under 
evaluation for safety in pregnant women and neonates (DOLPHIN 1&2 
ClinicalTrials.gov Identifier: NCT02245022 & NCT03249181). It is metabolised via 
UGT1A1 with minor contributions from CYP 3A4. It has a high genetic barrier to 
resistance and is well tolerated by patients (135). Following oral administration, it 
does not require pharmacological boasting like ELV. Steady state half-life is 
approximately 14 h enabling once daily dosing. 
In the 2016 WHO Guidelines, integrase inhibitors were recommended for wider use 
following a systematic review which reported that NRTI+INST are more effective 
compared to EFV+NRTI combination in ART naïve individuals (60). Lower potential for 
drug resistance, high genetic resistance barrier and shorter time to viral suppression 
compared to EFV made it to be recommended for wider use in low and middle income 
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countries. These led to the recommendation of DTG+NRTI combination as a first line 
regimen of treating HIV (60). 
However, WHO and ViiV Healthcare issued a statement of potential increase in risk 
of neural tube defect among women who become pregnant while on DTG recently. 
This is because four (4) cases of neural tube defects were reported out of 426 
neonates of women who became pregnant while on DTG. This was considered to be 
high (0.9%) compared to 0.1% risk previously reported for other ART. WHO stated 
that until there are more data to guide recommendations, women should continue 
current treatment, but pharmacovilance programs should be strengthen including 
monitoring of birth outcomes (136).   
Bictegravir (BIC): This is a newly licenced integrase inhibitor with activity against all 
strains of viruses against integrase inhibitors (137). It is currently coformulated with 
FTC and TAF for a once daily dose. Current available data shows consistency in PK 
with other INSTI (7, 138). Primarily metabolised by UGT1A1 and minor contribution 
by CYP 3A4 (138). It is well tolerated and efficacy is non inferior to fixed dose of DTG, 
ABC and 3TC (138). 
 
1.10.6 Other new treatment and strategies of integrase inhibitors 
Cabotegravir: Is a potent INSTI, a structural analogue of DTG formulated as oral 
tablets and injectable nanosuspension for treatment and prevention of HIV (139). 
Nanoformulation prolongs the half-life to approximately 40 days enabling monthly 
intramuscular administration. It is currently in Phase III clinical trials and is a 
promising option to reduce frequency of dosing. As an analogue of DTG, it is 
metabolised via UGT1A1, and phase 1 and 2 clinical studies have established that it 
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has a low propensity to drug-drug interactions (140). Evaluation of tolerability 
revealed that it is well tolerated and accepted by patients despite minor discomfort 
at the injection site (141). Currently several clinical trials are ongoing to establish 
pharmacokinetic safety of the drug (142, 143). 
Nanoformulations: for paediatric use and for development of long acting injectable 
ART are currently evaluated for future use (144). Other strategies of HIV treatment 
include increasing the role of pharmacogenetics, personalised medicine and medical 
robotics in management of patients. 
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Drug Class Regarding food Dose 
(mg) 
Steady 
State 
(days) 
AUC 
GM (µg.h/mL) 
Cmax 
GM (µg/mL) 
C24 / Ct/Cmin 
GM (µg/mL) 
Renal Clearance (Cl/F 
(L/h)) 
 
T½ (h) 
 NNRTI  
EFV Without food 600 OD 6-7 57.90  4.07  1.76  <1% unchanged 40-55 
Rilpivirine With food 25 OD 10-15 2096 (198-7307)*** 204±76 *** 73 (2-288) *** <1% unchanged 45-50 
NVP With or without food 200 b.d/ 
400* OD 
14-28 109.0(96.0-143.5)  5.74 (5.00-7.44)  3.73 (3.20-5.03)  <3% unchanged 25-30 
NRTI  
ABC  With or without food 300 b.d  6.02±1.73  3.0±0.89  0.01  <2% 1.5 
ABC With or without food 600 OD  11.95±2.51   4.26±1.19    <2%  1.5 
AZT With or without food 300 b.d  2.24   2.29  0.02   Exceeds  Cr clearance 1.1 
3TC With or without food 150 b.d  4.7   1.2   0.09   >70% renal 5-7 
3TC With or without food 300 OD  8.9   
 
2.0   0.04   >70% renal 5-7 
TDF With or without food 245 OD  3324 *** 326 *** 64.4 *** 32±10% unchanged ˜12-18 
FTC With or without food 200 OD  10.0±3.1   1.8±0.7  0.09±0.07   ˜86% renal 10 
PI  
ATV With food 300/100® 
OD 
 654  *** 4466 *** 654 *** 7% unchanged in 
kidneys 
8.6 
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(*) modified released, (©) boosted with cobicistat, (®) boosted with ritonavir, (˜) approximately, (%) Percentage, (µg) microgram, OD once daily, (b.d) twice daily, (e) treatment experienced 
HIV patients (a) Asymptomatic HIV patients, (mL) millilitre, (ng) nanogram, (**) mean (%CV), (Cr) creatinine, (***) ng/mL or ng.h/mL 
Table 1: Summary of ART Pharmacokinetics 
ATV With food 400 OD  273 *** 3152 *** 273 *** 7% unchanged in 
kidneys 
6.5 
DRV With food 600/100® 
b.d 
 116796±33594,114302
±32681,124698±32286 
*** 
6500 *** 3490±1401, 
3386±1372, 
3578±1154 *** 
13.9% (r) 15 ® 
DRV With food 800/100 ® 
or 800/150 
© OD 
 93026±27050, 
93334±28626 (r) or 
100152±32042, 87909 
(20232), 85972 (22413) 
©***  
8826 *** (C) 2282±1168, 
2160±1201(r) 
Or 
2043±1257, 1899 
(759), 1813 (859) © 
*** 
 9.4 
Ritonavir With food 100 b.d  6.2   0.89   0.22   3.5% unchanged ˜5 
Lopinavir With food 400/100®b.
d 
 82.8±44.5   9.6±4.4   5.5±4.0   <3% 5-6 
INSTI  
RAL With or without food 1200 OD       
RAL With or without food 400 b.d 2 6.91   
 
2.17   68.6 *** 32% of dose ˜9 
Elvitegravir With fat meals 150 OD Expected 
3-4 days 
23.0±7.5 ©   
18.0±6.5 (r) 
   
1.7±0.4 ©   
1.5±0.37 ® 
 
0.45±0.26 © 
0.35±0.20 ® 
 
Minor route ˜12.9 © 
˜8.7-13.7 ® 
Dolutegravir With or without food 50 OD ˜5 53.6   3.67   1.11   31% of oral dose ˜14 
Bictegravir With or without food 50 OD 10 102 (26.9%) **  6.15 (22.9%) **  2.61 (35.2%)**  35% renal clearance 17.3 
CCR5 INHIBITORS  
maraviroc With or without food 300 b.d  2908 (H), 2550 (a), 1513 
(e) *** 
888 (H), 618 (a), 
266 (e) *** 
43.1 (H), 33.6 (a), 
37.2 (e) *** 
˜8% unchanged of 
oral dose 
13.2 
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1.11 Pharmacogenetics of ART 
Pharmacogenetics describe the genes that determine responses to drugs and mutations in 
different individuals that significantly influence how individuals respond to drugs due to 
several factors (145). Variability in drug responses observed and interactions are influenced 
by mutations in genes. Mutations in genes result in polymorphisms that can impacts on 
enzymes or transporters functions (146, 147). A relevant pharmacogenetics impact of genetic 
polymorphisms in HIV medicine is ABC hypersensitivity associated with HLA-B*5701 (148), 
where presence of the gene is associated with a 2.7% incidence of hypersensitivity  (148). 
Other associated adverse events include: increased EFV associated CNS toxicity with CYP 2B6 
poor metabolisers, and NVP associated hypersensitivity reactions (149). Correlation of certain 
HLA alleles with hypersensitivity and  associated Stevens Johnson Syndrome (SJS) are all 
examples of the role of pharmacogenetics in ART (145). Polymorphisms in genes associated 
with cytochrome P450 enzymes, UGT enzymes and transporters responsible for metabolism 
of ART have significant influence on drug exposure, interactions and safety (149). 
1.11.1 Genetic polymorphisms:  
Mutations in genes that encode metabolic enzymes and transporters gives rise to genes that 
alter drug metabolism. Polymorphisms of CYP enzymes, transporters, and UGT enzymes 
impact on ART exposure. Polymorphisms in CYP enzymes (2B6, 2D6, 3A4,) significantly affects 
the PK of ART such as EFV, NVP and PI. Nucleotide polymorphisms of transporters such as ABC 
and SLC also affect TFV, FTC and 3TC PK. Other enzyme polymorphisms such as UGT1A1 
polymorphism have significant impact on DTG, RAL and ATV exposure. 
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1.11.2 Cytochrome P450 Enzymes (CYP) 
Cytochrome P450 enzymes (CYP) are microsomal mixed function oxidase system of enzymes 
involve in biotransformation of therapeutic drugs to render them soluble for elimination 
(150). Multi-allelic genetic polymorphisms influenced by several factors leads to 
pharmacogenetic phenotypes that influence metabolism of the drugs (151), a major source 
of variability in drug pharmacokinetics and pharmacodynamics. These enzymes are involved 
in metabolism of several classes of ART including NNRTI, PI, and INSTI. The NNRTI EFV is 
primarily metabolised via CYP 2B6, with secondary contributions from CYP 2A6, and minor 
contributions from CYP 1A2, and CYP 3A4/5. CYP 3A4 and 2B6 are the major enzymes in NVP 
metabolism, with minor contributions from CYP 3A5, 2D6 and 2D9 (152). PIs are metabolised 
mainly via CYP3A4 with minor contributions from other CYP enzymes, UGT and transporters 
depending on the protease inhibitor (149). Integrase inhibitors, though not primarily 
metabolised by CYP enzymes, have minor contributions of CYP 3A4, and ELV is predominantly 
metabolised through CYP 3A pathway. These enzymes are prone to mutation and 
polymorphisms with significant induction of variability on drug PK between individuals, 
resulting in either reduced function or increased elimination (153). 
1.11.3 Transporters 
These are membrane polypeptides that facilitate transport of drugs across membranes. They 
significantly regulate drug pharmacokinetics via the subclasses of transporters (154). 
Transporters are classified as ATP binding cassette (ABC), or Solute carriers (SLC) transporters.  
The ABC transporters are further sub classified as P-glycoprotein (encoding for multigene 
family of ABCB1 and ABCB2), Multidrug resistance associated proteins (MRP belonging to 
ABCC subfamily), breast cancer resistant protein (BCRP encoded by ABCG2).  The SLC 
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transporters are further classified into Organic anion transporting polypeptides (OATPs) 
responsible for drug uptake into cells, Organic anion (OAT) and cation (OCT) transporters. 
Other SLC transporters include: Concentrative (CNT) and equilibrative  nucleoside 
transporters (ENT), belonging to the SLC28 and SLC29 subfamilies (155). Transporters play 
important role in the PK properties of ART (156) and mediate transport across different 
barriers in the body including: blood brain barriers, blood-intestinal mucosal barriers and 
blood testicular barriers (157). NRTI depends on renal transporters for their elimination and 
can be influenced by polymorphisms. 
1.11.4 UGT enzymes 
UGT enzymes are a family of membrane proteins encoded by genes located in chromosome 
2q37.1 for UGT1 and 4q13.2 for UGT2 (158). Important in ART is UGT1 which is involved in 
metabolism of integrase inhibitors and PIs. These enzymes are involved in biotransformation 
and solubilisation of ARVS before elimination from the body.  The enzymes also mediates drug 
interactions of co-administered drugs metabolised by the same pathway. UGT1A1 is the 
major metabolising enzyme of DTG, raltegravir and ATV. Mutations and resultant genetic 
polymorphisms in this enzyme significantly affects drug PK (159).  
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ART Substrate Enzymes (CYP 450 and UGT) Transporters 
Inhibitor Inducer Inhibitor Inducer 
NNRTI  
EFV CYP3A4, 2B6 (minor) CYP 2C9, CYP 2C19 CYP 3A4 (potent), CYP 
2B6, UGT1A1 
  
Rilpivirine CYP3A4 (major), CYP 2C19, 
1A2, 2C8/9/10 (minor) 
 CYP 2C19, (moderate), 
CYP1A2, 2B6 and 3A4 
(weak) 
OCT2  
NRTI  
Tenofovir –DF P-gp, MRP4, BCRP   MRP1, MRP2, MRP3, Pgp  
Tenofovir Alafenamide P-gp, BCRP; minimal 
metabolism via 3A4 
3A4 (weak- in vitro)  
 
   
FTC MRP1   MRP1, MRP2, MRP3, Pgp  
Abacavir (ABC) Pgp, MRP4, BCRP   MRP1, MRP2, BCRP  
3TC BCRP   MRP1, MRP2, MRP3  
PI  
ATV Mainly CYP3A 
P-gp, MRP1 
3A4, UGT1A1 >>2C8  P-gp, MRP1, OATP1B1, 
OATP1B3, BCRP 
 
Darunavir Mainly CYP3A, P-gp CYP3A4 CYP1A2   
Ritonavir CYP3A4, P-gp, MRP1 CYP3A4 (potent)> 
>2D6* 
>2C9 >2C19 >2A6 
>1A2>2E1. 
UGT, CYP1A2, 
CYP2C9/19, 2B6  
P-gp, OATP1B1, 
OATP1B3, BCRP, 
OATP2B1, OCT2 
 
Lopinavir CYP3A4 CYP3A4, CYP2D6 UGT, CYP1A2   
INSTI      
Raltegravir UGT1A1 NIL NIL   
Elvitegravir CYP3A4  CYP2C9 (modest)   
Dolutegravir UGT1A1 (major), CYP3A4 (10-
15%) 
  OCT2 (strong), MATE1  
HIV CCR5 INHIBITORS  
Cenicriviroc CYP3A4, 2C8.  unknown NIL   
Maraviroc CYP3A4, P-gp NIL NIL   
[156], https://hivclinic.ca/.../ARV-and-DAA-pharmacokinetic-characteristics-summary-table... 
 Table 2: Substrates, inhibitors and inducers of ART 
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1.12 Thesis Hypothesis: 
Dolutegravir remains safe and effective across diverse population when deployed as a first 
line ART in sub-Saharan Africa. 
1.13 Thesis Aims: 
Following the WHO recommendation of DTG as first line ART and the likelihood of this 
regimen being rolled out for widespread use in sub-Saharan Africa, DTG safety in various 
thematic areas of care will need to be evaluated to ensure limited adverse event and optimal 
therapeutic benefit to patients. Therefore, this thesis aimed at the following: 
Developing and validating a novel method of quantifying DTG in dried breast milk spots to be 
used for evaluating drug safety in breastfeeding. The developed method was subsequently 
applied in an ongoing DolPHIN 1&2 clinical trial (NCT02245022) to quantify the amount of 
drug excreted in breast milk. DTG concentrations were also quantified in plasma and PK of 
DTG in corresponding mothers evaluated as part of the clinical trials to determine the PK 
safety of DTG in pregnant women and their breastfed neonates.  
Evaluating the drug-drug interactions between DTG and commonly prescribed antimalarial 
agents, collectively known as artemisinin combination therapy (ACT) (artemether 
lumefantrine (AL) and artesunate amodiaquine (AQ)). Since malaria is also highly prevalent in 
sub-Saharan Africa accounting for approximately 445 000 malaria related deaths in 2016 
(160). Co-infection with malaria is likely to be a common encounter among HIV patients in 
this region.  
Evaluating drug transporters with high allele frequency in a Nigerian pregnant and 
postpartum women population to determine the pharmacogenetic impact of pregnancy on 
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TFV and FTC PK. This is because these two NRTI are widely used and are likely to be co-
formulated with DTG for PMTCT and general population in the region. 
Finally, to evaluating the prevalence of herbal medication use in relation to ARV initiation and 
contamination of herbal medications with ART.  
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CHAPTER 2  
 
Dolutegravir: A Review of Clinical Pharmacokinetics and 
Pharmacogenetics, Drug-Drug Interactions and Safety in 
Diverse Patient Populations 
 
 
2.1 Introduction 
Dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI) recommended by WHO in 
2016 guidelines as an alternative for first line treatment of HIV (161). It demonstrated safety 
and efficacy against INSTI resistant viruses in early studies (135), and  efforts are currently 
made for affordable generic formulations in low and middle income countries (LMIC). South 
Africa, Kenya and about 90 other LMIC launched plans and agreed with other global 
stakeholders to make DTG available and accelerate rollout to intensify and ensure universal 
access to treatment (162). Lack of pharmacokinetic (PK) safety data in pregnancy and breast 
feeding, safety in children < 12 years, and PK drug-drug interaction data with some 
antimicrobials such as rifampicin and antimalarials make approval for use in these clinical 
condition delayed (159, 163-165). Furthermore, dramatic physiological changes of pregnancy 
and pharmacogenetics /pharmacokinetics (PGx/PK) impacts on safety and disposition of drug 
in many ways (128, 166). Diverse genetic polymorphisms across different populations also 
influence drug-drug interactions, safety and efficacy of DTG (128, 167). 
37 
 
 
2.2 Pharmacokinetics 
DTG is characterised by a highly stable and predictable pharmacokinetic (PK)-
pharmacodynamic relationship due to limited variability in PK parameters (159, 168). It is 
readily absorbed after oral administration and can be influenced by food (fasted, low fat, 
moderate and high fat diet) (169). At plasma steady state, DTG exposure significantly 
correlate with HIV RNA viral suppression, with a linear relationship between PK parameters 
and viral suppression (168). DTG distribution in cervical and vaginal tissue is significantly high 
(mostly above the protein binding-adjusted 90% inhibitory concentration  (IC90) (170), and it 
is widely distributed in other body tissues and fluids including central nervous system (CNS) 
and cerebrospinal fluid (CSF) (171).  Its half-life is approximately 14 h and steady state is 
achieved in approximately 5 days (172). Interactions with mineral supplements containing 
divalent cations (ferrous fumarate and calcium carbonate, magnesium and aluminium) results 
in decreased drug exposure (173, 174). Other pharmacological agents could potentially 
interact with DTG since it is a lifelong HIV treatment (175-177).  Transplacental transfer, 
neonatal toxicities and concerns of secretion in breast milk are currently evaluated in 
different clinical studies (PANNA, IMPAACT, and DOLPHIN etc) (178-180). DTG was reported 
to accumulate in neonate (four times the accepted trough concentration) but adverse events 
reported in the neonate were thought to be low compare to the benefits of the drug in 
prevention of vertical transmission of HIV (166). 
PK of DTG can be influenced by disease conditions including renal and liver disease. However, 
no significant changes in DTG PK were observed in the few published reports of both renal 
and mild to moderate liver impairment (181-183). Pregnant women, children and the elderly 
38 
 
also experience associated changes in DTG PK.  The immature UGT enzymes in children lead 
to   decreased metabolic efficiency, resulting in DTG accumulation; as such DTG is only 
recommended for children aged greater than12 years (184, 185). Though these impacts may 
not be sufficient to warrant dose adjustment (182, 186), there should be cautious use of DTG 
in these group of patients especially when plasma concentration cannot be monitored. There 
are several ongoing PK and PGx studies of DTG in healthy volunteers, people living with HIV 
(PLWH) and special populations (pregnant women, children and elderly),  to evaluate drug 
safety , which will help in providing sufficient safety data for regulatory institutions and 
approvals for use in the mentioned populations (166, 182, 187).  
2.3 Pharmacogenetics (PGx) 
DTG is not a known drug-metabolising enzyme inducer or inhibitor, but it is metabolised via 
minimal cytochrome P 450 enzyme (CYP 3A4) contributions and predominantly Uridine 5'-
diphospho-glucuronosyltransferase (UGT1A1) enzymes. It has the potential to be influenced 
by enzyme polymorphisms. The potential impact of such polymorphisms is to cause a change 
in plasma drug concentrations, drug-drug interactions and suboptimal drug exposure or 
toxicities. It is an inhibitor of organic cation transporter 2 (OCT2), and increase possibility of 
drug-drug interaction with OCT2 substrates (examples: metformin, prazosin, dopamine, 
cimetidine) by decreasing the excretion of drugs that utilise the OCT2 pathways, with 
resultant increase in plasma concentration and risk of toxicities (188). UGT1A1 is a highly 
polymorphic enzyme responsible for glucuronidation of DTG to its soluble form. CYP3A4 
minor contribution to DTG oxidative biotransformation pathway is via oxidative 
defluorination and glutathione substitution to soluble product for excretion (189). The 
UGT1A1 enzyme pathway is primarily responsible for biotransformation of DTG to the inactive 
ether glucuronide metabolites (189). It is highly polymorphic and functional polymorphisms 
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in UGT1A1 could result in decrease enzyme activity which impact on DTG elimination and 
drug accumulation in the body (163, 164, 190, 191). Some polymorphisms of UGT1A1 have 
been reported to be associated with reduced metabolic activity of the enzyme (159). Poor 
metabolisers with UGT1A1 *28/*28, *28/*37 and *37/*37 genotypes were associated with 
decrease clearance (CL/F), increase Cmax and increase AUC, but not significant enough to 
warrant any dose adjustment (159). 
This review aims at collating different DTG PK studies to determine the mean DTG PK 
parametres.  It aimed to collate DTG PK data of DTG administered alone for both HIV-positive 
and healthy volunteers in different clinical settings. It also aimed at evaluating DTG PK 
changes in pregnant women, children <12 years, the elderly, kidney disease and liver disease 
patients. 
2.4 Data source and study selection 
Relevant studies were identified from PubMed, Web of Science, Google Scholar and abstract 
presentations from conferences (CROI 2016) from 2012-2018 that evaluated the PK of DTG 
alone as an arm of a study (Table 1& figure 1). Search key words were DTG and PK (PubMed, 
Web of Science and Google scholar). Studies were screened and duplicates removed by 
checking in the search engines.  Eligibility criteria included: All studies that evaluated the PK 
of DTG in plasma in human subjects, reported on the PK of administered alone, even if the 
study also reported on DTG co-administered with other drugs, studies reported in English and 
described the PK of a 50 mg once daily dose. Studies considering treatment switching or viral 
response in relation to dose without careful attention to PK analysis and twice daily 50 mg 
dose or <50 mg dose were excluded.  
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Figure 1: Flow Diagram of stages of literature search 
 
 
Records after duplicates and unrelated studies removed. 
(n = 143) 
Records screened and only 
relevant PK studies 
included. 
(n = 79) 
Full-text articles assessed 
for eligibility. 
(n = 46) 
Studies included in 
qualitative synthesis. 
(n = 21) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =  21) 
Records excluded. 
(n = 64) 
Full-text articles 
excluded, due to 
unrecorded PK data or 
twice daily 50 mg or <50 
mg dose of DTG. 
(n = 22) 
Review Article (2) did 
not report PK of DTG 
administered alone 
Conference paper (1) 
 
Additional records identified 
through Google Scholar. 
(n = 2580) 
Records identified through Web 
of Science. 
(n = 162) 
Records identified through 
Pubmed/Medline. 
(n = 116) 
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2.5 Data extraction and statistical analysis 
Statistical advice was obtained to determine the appropriate statistical methods required for 
this review. The advice included: The appropriate extraction method, how the data should be 
analysed and studies to be excluded.  Since the PK data were heterogeneous, comparing DTG 
PK of different drugs and mineral components of diverse chemical structures and properties, 
meta-analysis cannot be used. Furthermore, it is important that PK data of HIV patient should 
be evaluated separately from that of the healthy volunteers because of impact of HIV on drug 
PK.  
The review identified 21 studies where DTG PK was evaluated after 50 mg DTG was 
administered alone.  A total of 640 volunteers (327 HIV infected and 313 healthy volunteers) 
were evaluated in the 21 studies. Extracted data included: Sample size, healthy volunteers or 
HIV infected, nutrition state (fed or fasted), steady state or Single dose PK, (GM (IQR) or GM 
(%CV) of AUC, Cmax, C24 or Ct, Cl/F (L/h), Tmax (h) Median (range), and half-life (h). Pooled 
geometric means (GM) and interquatile range (IQR) or GM and percentage coefficient of 
variance (%CV) of the evaluated pharmacokinetic parametres were evaluated for highest and 
lowest measured PK parameter using Microsoft Excel (2013). 
2.6 Results 
A total of 32 ‘DTG alone’ study arms from 21 clinical studies were evaluated including 379 
subjects (122 HIV infected and 257 healthy volunteers) were evaluated. Abstracts included 
were 2, and the highest evaluated AUC24 (GM (IQR)) µg/mL and GM (%CV) were 71.1 ( 13.05, 
84.96), and 68.186 (%CV 30), Cmax (GM (IQR)) µg/mL or GM (%CV) 5.10 (3.75 - 7.23) and 5.29 
(15.8%), C24 or Ct  (GM (IQR)) µg/mL and GM (%CV) 1.70 (0.76 - 2.00) and1.500 (24.0), Cl/F 
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(L/h) (GM (IQR) and  GM (%CV) 1.27 (1.02-1.94) and 1.2 (CV 39%), Tmax (h)/Med (range) 4.0 
(1.0–4.0), t½ (h) 14.5 (13.1, 16.1) (Table 1).  
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Study Title and Trial 
registrationnumber 
Sample 
size 
Instructions 
regarding 
food 
AUC 
GM (IQR) 
ug*h/mL  
Cmax 
GM (IQR) 
ug/mL 
C24 or Ct 
GM (IQR) 
ug/mL 
Cl/F (L/h) 
GM (IQR) 
 
Tmax (h) 
Med 
(range) 
T½ (h) 
SPRING 1: 
ClinicalTrials.gov: 
NCT00950859 (192) 
15b** Without 
regard to 
food 
48·1 (40%) 3·4 (27%)     
Lowered DTG in pregnant 
woman Case report (193) 
1b**  48  4.0, 0.9   12 h 
DTG Postpartum woman, 
Case report (193) 
**  106  5.4  3.3    22 h 
IMPAACT P1026s Second 
Trimester (180) 
9b** With or 
without food 
58.4 (47.6 - 
64.5) 
4.5 (3.8 - 
5.2) 
0.8 (0.6 - 
1.9) 
0.8 (0.7 - 
1.0) 
2 (2 - 4) 10.5 (8.7 - 
12.6 
IMPAACT P1026s Third 
Trimester (180) 
15b** With or 
without food 
48.7 (40.3-
57.6) 
3.9 (3.3-
4.4) 
0.9 (0.7-
1.2) 
1.0 (0.8-
1.2) 
4 (2-4) 11.2 
(10.3-
13.0) 
IMPAACT P1026s 
Postpartum (180) 
9b** With or 
without food 
71.1 (5.0 - 
83.1) 
5.1 (3.7 - 
7.2) 
1.7 (0.9 - 
2.2) 
0.7 (0.6 - 
0.8) 
2 (2 - 4) 12.3 (10.5 
- 15.6) 
IMPAACT 1093: DTG in 6-
12 Year Old HIV Infected 
Children: 48-Week 
Results (194) 
21b**  50.4 (63%)  0.9 (89%)    
IMPAACT P1093 48 
WEEKS (195) 
22b** Standard 
research 
food 
43.1 (13.1, 
84.9) 
3.4 (1.1, 
6.0) 
0.9 (0.2, 
2.1) 
78.0 (0.5, 
3.8) 
3.0 (1.0, 
6.0) 
11.8 (8.2, 
24.8) 
Single and multiple dose 
PK of DTG in the genital 
tract of women. Clinical 
8b* Standard 
research 
food 
55.4 (43.3–
62.2) 
3.7 (3.4–
5.2) 
0.1 (0.1–
0.1 
 2.5 (1.3–
4.0) 
14.8 
(13.6–
16.1) 
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trial identifier 
NCT01404806(170) 
Effects of boceprevir and 
telaprevir PK of DTG 
NCT01563328 Cohort 1 
(196) 
16b* Moderate fat 
meal. 
61.5 (53.5, 
70.8) 
4.6 (4.1, 
5.1) 
1.3 (1.1, 
1.5) 
 2.5 (1.0, 
4.0) 
13.2 
(12.0, 
14.5) 
Effects of boceprevir  
telaprevir PK of DTG 
ClinicalTrials.gov 
(NCT01563328 Cohort 2 
(197) 
16b* Moderate fat 
meal 
68.9 (60.3, 
78.6) 
4.9 (4.4, 
5.6) 
1.5 (1.3, 
1.9) 
 3.0 (1.0, 
4.0) 
14.5 
(13.1, 
16.1) 
Drug-Drug Interaction 
Period 1 (177) 
12b* Standard 
research 
food 
66.6 (17.0) 5.3 (15.8) 1.5(24.0)  3.0 (1.0, 
6.0) 
15.5 (1.8) 
Increase in DTG trough, 
but equivalent total DTG 
exposure with simeprevir 
in HIV/HCV NCT02404805 
(198) 
24b* Standard 
research 
food 
68.2 (30) 5.2 (23) 1.3 (38) 7.3(24) 2.5 (41) 12.8 (17) 
Antiviral activity, safety, 
and PK/PD of DTG (168) 
10b**  43.4 (20) 3.3 (16) 0.8(26)  2.0 (0.9–
4.0) 
12.0 (22) 
PK of DTG co-
administered with acid-
reducing agents and 
multivitamins in healthy 
volunteers (199) 
16a* Standard 
research 
food 
34.6 (31) 2.0 (25) 0.5 (38)    
PK of DTG co-
administered with acid-
12a* fasted 31.0 (53) 1.8 (44) 0.5 (63)    
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reducing agents and 
multivitamins in healthy 
volunteers (199) 
Comparative Clinical PK/ 
PD [9]  
10b**  43.4 (20) 3.3 (16)   2.0 (0.9–
4.0)a 
11–12 
DTG PK with and without 
DCV (200) 
12b*  35.7 (34.7) 2.6 (32.0) 0.7 (41.3) 1.4 (34.7)   
PK of DTG+CaCO3 (173) 12a* fasted 35.6 (62.3) 1.9 (45.9) 0.5 (66.0)  3.0 (0.5, 
6.0) 
13.9 
(32.8) 
PK of DTG + Ferrous 
Fumarate (173) 
11a* fasted 33.6 (39.6) 1.7 (40.6) 0.5 (40.8)  3.0 (1.0, 
6.0) 
 
Effects of enzyme 
inducers EFV & 
tipranavir/ritonavir on 
the PK of DTG 
ClinicalTrials.gov 
(NCT01068925 (201) 
12b*  42.3 (39) 3.1 (30) 0.9 (53)  2.0 (1.0–
4.0) 
 
Effects of enzyme 
inducers EFV & 
tipranavir/ritonavir on 
the PK of DTG 
ClinicalTrials.gov 
NCT01098526 (201) 
14b*  64.5 (28) 4.5 (23) 1.4 (40)  3.0 (2.0–
3.0) 
 
Effect of fosamprenavir-
ritonavir on the PK of 
DTG ClinicalTrials.gov  
(NCT01209065) (202) 
12b*  32.9 ±13.9 2.5 ± 0.9 0.6 ± 0.3 1.7 ± 0.5 2.0 (1.0–
4.0) 
12.3 ± 2.4 
Effects of Etravirine on 
the PK DTG  (203) 
15b*  60.4 (22) 4.3 (19) 1.2 (29) 0.8 (22) 3.0(1.0–
4.1) 
12.4 (21) 
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Effects of Ritonavir-
Boosted PI on the PK DTG  
Cohort (203) 
8b*  47.8 (19) 3.5 (12) 0.9 (33) 1.1 (19) 3.5 (2.0–
4.0) 
11.3 (18) 
Effects of Ritonavir-
Boosted PI on the PK DTG  
Cohort 1(203) 
9b*  45.2 (22) 3.3 (26) 0.9 (40) 1.1 (22) 3.0 (1.0–
12.0) 
10.4 (17) 
Effect of CBZ on DTG PK 
ClinicalTrials.gov 
(NCT01967771(204) 
16b*  53.8 (21.4) 4.1 (14.4) 1.2 (39.1) 0.9 (21.4)  12.9 
(23.8) 
Effect of prednisone on 
PK of DTG 
ClinicalTrials.gov 
(NCT01425099) (205) 
12b*  61.3 ±20.5 4.4 ±1.0 1.4 ± 0.7 0.8 ±0.2 4.0 (1.0–
4.0) 
14.1 ±3.0 
PK of DTG in With 
Hepatic Impairment (206) 
8a*  40.3 (15.1) 1.9 (0.8) 0.6 (0.22) 1.4 (0.7) 3.0 (1.0–
4.0) 
15.3 (3.9) 
PK of once-daily DTG and 
ritonavir-boosted 
darunavir AUC12 (207) 
10b** Standard 
meal  
26.8 
(22.4–28.4) 
3.43 (2.9–
4.0) 
0.6(0.4–
0.2) 
   
PK Interaction of 
Doravirine  and DTG  
(175) 
12a* Standard 
research 
food 
42.9 (37.0, 
49.6) 
3.1 (2.5, 
3.6) 
1.0 (0.8, 
1.2) 
 .5 (0.5, 
3.0) 
 
a 50 mg dose steady state PK, b50 mg dose single dose PK, *Healthy volunteers, ** HIV 1 infected, DTG: Dolutegravir, PK: Pharmacokinetics, 
AUC: Area under the Concentration time curve, CBZ: Carbamazepine, EFV: Efaverenz, DCV: daclatasvir, HCV: hepatitis C virus, PD: 
Pharmacodynamics 
Table 1: Summary of Dolutegravir Pharmacokinetics administered alone in different studies 
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2.7 Quality Assessment 
The quality of included studies and risk of bias was assessed using the Newcastle-Ottawa 
quality assessment scale. This assessed adequacy of case definition, representation, definition 
of controls and end point in the selection process. Comparison of exposure and outcomes 
were all evaluated and scored as recommended by the scale (208). 
2.8 Discussion 
This review evaluated the PK data of various clinical studies that assessed the 
pharmacokinetics of DTG in healthy volunteers and HIV infected patients. PK data reported 
by different clinical studies were collected and evaluated for minimum and maximum 
reported PK parameter. Pharmacogenetics drug-drug interaction data were also pooled to 
determine effect of other treatment on DTG exposure and efficacy. Use of DTG in different 
population groups such as paediatric, pregnancy, liver and kidney disease were also evaluated 
for any changes and reported. 
2.8.1 Safety in Special Populations (pregnant and breast feeding women, children and 
elderly) 
Paucity of information on DTG safety in paediatric population, pregnant women, the elderly, 
some chronic diseases and organ failure such as liver and kidneys is a recognised research 
gap. This was recognised as a major mitigating factor against approvals by regulatory 
authorities in resource-limited countries. Although there are several ongoing clinical studies 
aimed at answering some of the unknown safety concerns of DTG use in these populations, 
lack of adequate monitoring tools is discouraging clinicians from LMIC from prescribing it until 
adequate information is made available. 
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2.8.2 Effect of pregnancy on DTG disposition 
Physiologic changes impact on drug disposition (209), therefore following a 50mg once daily 
dose of DTG at steady state in pregnant women, exposure is reduced compared to non- 
pregnant women, but trough concentrations were well above EC90 of non-pregnant women 
in phase 2 and 3 clinical trials (166, 179, 185, 210). It is well tolerated and viral load 
suppression is achieved within few weeks of commencing therapy. If prescribed with 
suspected or known enzyme inducers such as rifampicin in treatment of pregnant women 
with TB/HIV coinfection, twice daily prescription is considered, and should be  use with 
caution due to limited safety evidence (211)[22]. 
 
2.8.3 Dolutegravir PK in Neonates and children 
DTG is highly transferred through the placenta to the neonates, and has been observed to be 
high in a case report of a premature neonate and other clinical trials (210). But despite high 
concentrations in neonates and 4 fold longer half-life, it is well tolerated (166, 179, 184). 
Safety concerns are currently further evaluated in DOLPHIN 1&2 clinical trials. Poorly 
developed UGT1A1 and low enzyme activity in neonate is suspected to significantly contribute 
to the accumulation. The common indicator of UGT1A1 activity is bilirubin where decrease 
enzyme activity is associated with hyperbilirubinaemia as seen in Gilbert syndrome and 
Crigler-Najjar syndrome associated polymorphic  UGT genes (187), but relationship with DTG 
is not yet evaluated and is unknown. Africans are recognised to have less-efficient UGT1A1 
promoters predicting higher average bilirubin levels, but bilirubin elimination is also thought 
to be influenced by other environmental factors such as ultraviolent radiation therefore the 
need for further evaluation (212). 
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2.8.4 Dolutegravir Excretion in Breast milk 
Breast milk and transplacental transfer of DTG is not fully understood, and was thought to be 
protective against HIV infection (178), but previous reports shows that infants who became 
infected during breast feeding despite ART, were at risk of multiclass drug resistance (48, 49). 
DTG safety in pregnancy and breast feeding is also a concern and is currently being evaluated 
in several clinical trials (178). Clinical data on excretion of DTG in BM, and implication on 
infants health is limited (209), but excretion of drugs in breast milk is known to occur 
especially during the colostral phase (3-4 days after delivery) due to increased size of pores in 
the mammary epithelium (213). Transplacental transfer of DTG to neonates is high and DTG 
concentration persist in neonates after delivery for sometimes. 
2.8.5 DTG in Liver and Renal disease 
UGT1A1 and CYP3A4 are produced in the liver, and excreted unchanged in the kidneys, 
however there are currently  no reports of significant changes in drug elimination that will 
require dose modification (182, 186). Post marketing surveillance and some other 
pharmacovigilance studies should be conducted to further evaluate the impact of liver and 
renal diseases in elimination of DTG since clinical studies in renal and liver diseases are 
difficult to conduct. 
 
2.8.6 Pharmacokinetic of DTG in HIV infected and healthy volunteers  
DTG is well tolerated by HIV-1 infected patients. PK parameters were variable in different 
reports but differences were insignificant between DTG PK in healthy volunteers and HIV 
infected patient. Although the reason for the observed differences in the reported PK 
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parametres is unknown, several factors such as food, population variability and research 
conditions could be responsible for the differences. The highest AUC0-24 of DTG reported in a 
single case report by the PANNA network of postpartum period was 106 µg/mL. Otherwise, 
highest AUC0-24  was GM (IQR) 71.1 (58.0 - 83.1) ug*h/mL, reported by the postpartum arm of 
IMPAACT studies (180). The lowest AUC0-24 was 26.81 (22.44–28.46) µg*h/mL reported by the 
DUALIS study. Similarly, C24 or t of PANNA network of the same single case report of the 
postpartum women reported the highest trough concentration reported (3.3 µg/mL), while 
the lowest recorded trough concentration was 0.12 (0.10–0.15) µg/mL (Table 1). 
 
2.8.7 Drug-Drug Interactions 
Patient exposure to DTG can be influenced by enzyme inducers such as rifampicin. Rifampicin 
is an inducer of CYP3A4 and UGT1A1, the principal enzymes involve in the metabolism of DTG 
(214). Other inducers of CYP3A4 and UGT1A1 such as carbamazepine, phenytoin and 
phenobarbital also affect DTG PK. Its use with the antiretroviral etravirine is contraindicated 
due to significant reduction of DTG exposure via the same pathway.  DTG inhibits renal 
transporters OCT2 (strong) and multidrug and toxin extrusion transporter 1 (MATE1), 
resulting in increased exposure and risk of toxicity. As an integrase inhibitor, it is chelated by 
polyvalent metals such as magnesium, aluminium, zinc and calcium, reducing the 
bioavailability of the drug (174, 214). 
 
2.9 Conclusion 
Variable DTG PK were reported by different clinical studies, influenced by factors such as food, 
research conditions and population variability. No significant differences were observed 
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between HIV infected and non HIV infected participants and DTG shows linear PK parametres. 
Current clinical trials to assess some drug-drug interactions and safety in pregnant and 
breastfeeding women will help in providing information for its wider use. 
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CHAPTER 3. 
Validation and Clinical Application of a Novel Method for the 
Quantification of Dolutegravir in Dried Breast Milk Spots (DBMS) 
using LC-MS 
 
3.1 Background 
It is recommended globally that HIV-positive women receive antiretroviral therapy (ART) 
throughout pregnancy and breastfeeding, or for life, irrespective of clinical disease stage or 
CD4 count (24). In untreated HIV, breastfeeding is associated with increased risk of mother-
to-child transmissions of HIV (51, 52, 215). Despite this risk, exclusive breastfeeding among 
HIV seropositive women in low and middle income countries is recommended by the WHO 
(53, 216-218), as formula feeding is associated with high infant mortality. Excretion of 
exogenous chemicals via the mammary epithelial cells especially during the colostral phase 
(3-4 days after delivery) is known to be high (213, 219), which implies that breastfeeding 
mothers may expose their babies to clinically significant antiretroviral (ARV) concentrations 
over a prolonged period (220). Furthermore, infants of mothers receiving ART who acquire 
HIV via breast milk (BM) have been shown to present with high rates of drug resistance, thus 
compromising their future treatment options (48, 49, 221-223). It is therefore essential to 
determine ARV pharmacokinetics (PK) and transfer into BM in order to assess the potential 
risk of harmful exposure to the infant through breastfeeding, and limit the development of 
drug resistance. 
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The PK of ARV in BM and breast-fed infants can be determined by measuring concentrations 
in paired maternal plasma (MP), infant plasma (IP) and BM, and expressed as BM:MP and 
IP:BM ratios. BM transfer has been assessed for a number of ARV, including the nucleoside 
(NRTI: abacavir, emtricitabine, lamivudine, stavudine, tenofovir, zidovudine) and non-
nucleoside reverse transcriptase inhibitors (NNRTI: efavirenz, etravirine and nevirapine) and 
protease inhibitors (PI: atazanavir, indinavir, lopinavir, ritonavir) (224-226). However, PK data 
on more recently licenced ARV are lacking (178, 227, 228).  
Analytical methods used for measuring ARV in BM are limited. At the current time, there are 
a total of 19 published methods, however, the majority use HPLC-UV (229), with only a few 
studies employing the more sensitive and specific technique of LC-MS (229, 230). To date, 
only analytical methods for the following ARV have been developed: Lamivudine, stavudine, 
efavirenz, indinavir, lopinavir, nevirapine, ritonavir and zidovudine. However, most of these 
methods are in fact modifications of previously validated assays used for plasma and serum 
and provide limited detail on how the BM samples were collected and stored, the type of 
calibration matrix and extraction method used. Furthermore, data to support the stability of 
these drugs in BM following sample processing and long-term storage are limited, or 
completely lacking. The majority of BM methods published used structurally related 
(analogue) internal standards(231). However, ideally stable isotopically labelled internal 
standards (SIL-IS) should be used to correct for matrix effects, as they share the same 
physicochemical properties and co-elute with the unlabelled analyte of interest. The 
commercial availability of these compounds is continuing to increase, such that they are now 
routinely used for LC-MS analysis. 
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Quantification of ARV from BM presents a number of analytical challenges: BM can vary in fat 
content throughout the feeding time, and the nutritional intake of the mother may also cause 
variation in BM fat content (232). Analytical methods previously described for determination 
of ARV in BM predominantly use liquid fractions of whole or skimmed milk which require 
more intensive and time consuming sample clean up procedures, such as Solid Phase 
Extraction (SPE) (233). Physicochemical properties influence the partitioning of drug into BM 
which contains variable lipid, aqueous and protein fractions. Indeed, significant differences in 
drug extraction recoveries between whole and skimmed have been reported which may 
result in misleading results, especially as whole milk is more likely to reflect the fraction 
ingested by the breastfeeding infant. For example, Shapiro and colleagues noted recoveries 
of drug between skimmed and whole BM to be 72% vs 95% for lamivudine, 103% vs 94% for 
zidovudine and 99% vs 89% for nevirapine, and in light of this variability elected to report 
whole milk concentrations(234). 
Dried Breast Milk Spots (DBMS), whereby a relatively small (<50µL) volume of BM is spotted 
directly onto an inert filter card, offer several advantages for drug quantification as compared 
with liquid BM. Use of DBMS enables quantification of drugs in whole BM, which is a direct 
reflection of the milk ingested by the breastfeeding infant. DBMS are also more suitable for 
collection and storage in low resource settings as they can be stored and shipped at ambient 
temperatures without the need for refrigeration or dry ice during transit. We have previously 
developed and validated DBMS methodologies for the NRTI (emtricitabine, lamivudine, 
tenofovir) and NNRTI (efavirenz and nevirapine) (235-237).  
The integrase inhibitor Dolutegravir (DTG) was licensed by food and drug administration (FDA) 
in 2013 for the treatment of HIV infection (24), and more recently, recommended as a first 
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line treatment of HIV in the 2016 WHO guidelines (24). Thus global uptake and the number 
of pregnant women and breastfeeding infants exposed to DTG in limited resource settings is 
predicted to increase significantly over the coming years.  
Well-designed PK studies and robust analytical methods for quantifying DTG in BM are 
therefore needed to address these safety concerns in vulnerable patient populations. Our aim 
was to develop and validate an accurate, sensitive and robust LC-MS method for 
quantification of DTG in BM using dried breast milk spots (DBMS), with application of the 
method in breastfeeding mother and infant pairs.  
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3.2 Materials and methods 
3.2.1 Reagents and Equipment: 
DTG and deuterated internal standard (IS) Dolutegravir-d5 (DTG-d5) were purchased from 
Toronto research chemicals (Toronto, ON, Canada). LC-MS grade Methanol (99.9%), formic acid, 
Propan-2-ol and Tert-butyl methyl-ether (TBME) were obtained from Sigma Aldrich, UK. 
Deionised water (18.2 MΩ purity) was produced from Elga® Option S water purification units, 
Purelab® and Classic Ultraviolet water filtration (UVF) purifier (Elga LabWater, UK). Whatman 
903 Protein Saver cards were obtained from GE Health Care, UK. Blank human breast milk (HIV 
negative breast milk from healthy donors not on any medication and not spiked with any drug 
or ART) was donated by volunteers through the Wirral Mothers’ Milkbank and transferred to the 
lab for use with approval from Liverpool Women Hospital.  
 
The HPLC system consisted of an Accela autosampler (set at a tray temperature of 10°C) and 
an Accela pump (Thermo Scientific, Hemel Hempstead, UK). A reverse phase C18 Waters 
XBridge (3.5µm: 2.1 x 50 mm) column (waters corporation, U.S.A) set at 40°C oven 
temperature and interfaced with a 2 µm C18 Quest column saver (Thermo Fisher Scientific, 
Hemel Hempstead) was used to resolve the analytes. A Thermo Quantum Access mass 
spectrometer with a heated electrospray ionisation source (Thermo Fisher Scientific, Hemel 
Hempstead) was used for quantification. TSQ Tune software was used for compound tuning 
and optimisation, and LCquan (version 2.7 Thermo Fisher Scientific, Hemel Hempstead) was 
used for data acquisition, data processing and reporting.  
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3.2.2 Chromatographic and mass spectrometry conditions 
Mobile phase A (0.1% formic acid in deionised water) and B (0.1% formic acid in methanol) 
were programmed at flow rate of 500 µL/min to generate a solvent gradient for 
chromatographic separation. The Initial gradient was started with 80% mobile phase A and 
held for 0.5 minutes and then decreased to 20% mobile phase A for 2.5 min, during which the 
analytes were eluted. Subsequently the column was washed with 100% mobile phase B for 2 
min and then re-equilibrated to to its original conditions over a total run time of 9 minutes. 
The injection volume was 5 µL and needle was washed with IPA: water [1:1(v/v)] after each 
injection.   
 
The mass spectrometer used electrospray ionisation (ESI) set in a positive ionization mode 
using selective reaction monitoring (SRM). The Spray voltage was 29 V, the capillary 
temperature was 300oC and vaporisation temperature 350oC, respectively. The sheath and 
auxillary gas pressures were set at 50 and 10 arbitrary units. Argon was used as a collision gas 
and delivered at a pressure of 1.5 mTorr. The compounds were tuned using a concentration 
of 1 µg/mL in methanol via direct infusion into the mass spectrometer at a flow rate of 
5µL/min. The m/z transitions were 420.1 → 277.1m/z for DTG and 425.1 → 276.9 for DTG-d5 
with collision energies of 29 and 27 V, respectively. The scan width was set at 0.01 m/z and 
the dwell time at 0.1 seconds.  
 
3.2.3 Preparation of stock solutions, standards, QCs, and internal standards of DBMS and 
DPS  
A primary DTG stock solution (1mg/mL) was prepared in methanol and stored in the 
refrigerator at 4oC until use. This stock was subsequently serially diluted with methanol and 
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water [1:1 (v/v)] to obtain intermediate solutions of 200, 50, and 2.5 µg/ml. The intermediate 
solutions were then used to spike into the blank human BM for preparation of the calibration 
standards (10 levels; 0, 10, 25, 50, 200, 500, 1000, 2000, 3200 and 4000 ng/ml) and internal 
QC (LOQ = 30ng/mL, MQC = 455 ng/mL and HQC = 3700 ng/mL). Exactly 30µL of each 
calibrator and QC was spotted onto the middle of the 12mm circle of the protein saver cards. 
The spots were then dried overnight at ambient temperature before sealing in a ziplock bag 
with desiccant sachets, and stored at -40oC until use.  
 
A 1mg/mL DTG-d5 stock solution was prepared in methanol and stored at 4oC. On the day of 
analysis a working internal standard solution (250 µg/mL) was prepared in 50:50 (v/v) 
methanol:water.  
 
 
3.2.4 Sample pre-treatment 
This method employed a liquid-liquid extraction process to release the drug from the DBMS 
and remove matrix interferences (238). Prior to extraction, 20 µL of DTG-d5 (2.5 µg/mL) was 
spotted directly onto each 12 mm circle of the DBMS using an electronic pipette and allowed 
to air dry for 20 minutes. After drying the spots, the entire 12 mm circle of the DBMS were 
punched and folded into clean 7 mL screw capped glass tubes and pre-soaked in 500 mL of 
1.8 mg/mL EDTA in water for 10 minutes.  
 
2 mL of TBME was added to each sample and the tubes capped and tumbled for 30 minutes. 
The samples were centrifuged at 3398g for 10 minutes to separate the precipitated protein 
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and water from TBME containing drug. Using a cryobath, containing dry ice and methanol, 
the protein, water and paper were frozen out, and non-frozen supernatant decanted into 
clean 12x75mm glass tubes and evaporated to dryness using nitrogen drier for 1 hour. Finally, 
samples were reconstituted using 500 µL of mobile phase [80:20 methanol: water (v/v) in 
0.1% formic acid] and vortexed for 5 seconds. 100 µL of reconstituted sample was transferred 
to 300 µL autosampler vials, sealed with crimp caps (11mm aluminium PTFE/ silicone natural) 
and loaded onto the autosampler tray for subsequent injection to the LC-MS system.  
 
3.2.5 Method validation 
The LC-MS method was validated according the stipulated FDA and EMA guidelines 
acceptance criteria for bioanalytical assay development and validation (239, 240) . 
 
3.2.5.1 Selectivity 
Selectivity was evaluated by comparing the amount of interference from six different blank 
DBMS in relation to the lowest calibrator (LLOQ). Area responses of interfering noise at the 
retention time of DTG were accepted if the interference was less than 20% of the mean 
response of the LLOQ (n = 6). For the internal standard, less than 5% of the mean response 
areas in the 6 LLOQ samples was deemed to be acceptable. 
 
3.2.5.2 Carryover 
Carryover was determined through injection of DBMS calibrators at the upper limit of 
quantification (ULOQ) followed by 4 blank DBMS on 7 separate occasions. Carryover was then 
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expressed as a percentage of the LLOQ and ULOQ, as per the EMA guidelines, and should not 
be >20% of the LLOQ.  
 
3.2.5.3 Precision and accuracy 
Precision and accuracy was determined by analysing five different assay batches, consisting 
of a calibration curve and 6 LLOQ, LQC, MQC, and HQC (separate extractions), run over 5 days. 
Deviation of ≤ ±15% of measured analyte from nominal concentrations was accepted, except 
at LLOQ where ≤ ±20% was accepted. Accuracy was defined as the percentage deviation of 
measured analyte from nominal concentration, and precision as a percentage coefficient of 
variation (%CV). Greater than or equal to 75% of calibration standards and 67% of QC in each 
run were required to have a deviation of ≤±15% from their respective nominal concentrations. 
 
3.2.5.4 Recovery and matrix effect 
The percentage recovery and matrix effects were determined quantitatively in accordance to 
the recommendations of Matuszewski et al (241). The peak area responses of six replicates 
of pre-extracted DBMS QC (C), post-extracted DBMS blanks spiked at an equivalent QC 
concentration (B) and DTG spiked directly in mobile phase (A) without matrix, were 
compared. Overall % recovery (process efficiency; %PE) was determined by comparing the 
peak area response of pre-extracted DBMS to the peak area response of DTG spiked at an 
equivalent concentration in mobile phase (C/A*100). The % matrix effect (%ME) was 
calculated by comparing DTG spiked into blank DBMS extracts with the peak areas at an 
equivalent concentration in mobile phase (B/A*100). The IS-normalized recovery (%Analysis 
RE) was calculated by comparing the peak area ratios of the pre-extracted (C2) and post-
extracted (B2) DBMS QC (C2/B2*100).  
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Given that DTG is known to bind to free metals, the effect of EDTA (a chelating agent) on DTG 
recovery from BM was evaluated by comparing recovery of drug from DBMS pre-soaked in 
1.8mg/mL EDTA in water against DBMS pre-soaked with water without EDTA, prior to liquid 
liquid extraction. Furthermore, the impact of different IS addition procedures on DTG 
recovery from DBMS were assessed. The IS was pipette either directly onto the DBMS, or 
added to the extraction solution.  
3.2.5.5 Dilution Integrity 
Six replicates (n=6) of DBMS were prepared at approximately 1.75 times the assay ULOQ 
(approximately 7000 ng/mL). Blank DBMS were also extracted and used to dilute the 
extracted dilution integrity DBMS by a factor of two and four in order to derive a 
concentration that falls within the calibration range. The resulting values were then back-
calculated with the appropriate dilution factor. 
 
3.2.5.6 Stability  
Stability of DTG in DBMS (QC samples; 6 per level) for different storage and processing 
conditions was evaluated, including bench top stability, heat treatment, autosampler 
stability, re-injection reproducibility, processed and long term stability. 
 
Bench top stability (storage of DBMS at room temperature for 5 days) was evaluated for QC 
by comparing with freshly prepared samples. Heat stability was assessed by heating DBMS at 
50oC for 1 hour before analysis, and autosampler stability was assessed by injecting samples 
after 24 hours of storage in the autosampler. The stability of processed (extracted) samples 
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was assessed by keeping the processed samples in the fridge (4oC) for 24 hours before 
analysis. Long term stability was evaluated by storing DBMS at ambient conditions for up to 
one year. In all cases, concentrations in QC samples were read off freshly prepared DBMS 
standards and QC. Re-injection reproducibility was assessed by re-injecting samples left in the 
autosampler for 72 hours and results of the two runs compared for reproducibility.  
 
3.3 Clinical Application 
The validated method is currently being utilised for determination of DTG in DBMS, obtained 
as part of the ongoing DOLPHIN 1 clinical trial (NCT02245022) which seeks to assess the safety 
and pharmacokinetics of DTG in African HIV-infected pregnant mothers and their neonates. 
HIV-infected pregnant women are randomised at a number of sites, including the infectious 
disease Institute Makere University, Kampala Uganda and the Desmond Tutu HIV Foundation, 
Gugulethu Community Health Center, Cape Town South Africa, to receive either a DTG-based 
regimen or a standard of care regimen (not containing an integrase inhibitor).  
Paired maternal plasma (MP) and BM samples were collected at two time points from 
breastfeeding mothers (1 Ugandan; 1 South African) at approximately 2 weeks post-partum. 
Plasma samples were also collected from the infant (IP) on two occasions to evaluate neonatal 
DTG exposure; one timed relative to a feed at the anticipated maternal Tmax, and one at a 
random time point relative to maternal dosing. In addition, paired MP, IP and BM samples 
were collected at 3 time points post dose following the mother’s discontinuation of DTG (and 
transfer to standard of care).  
BM samples were collected in EDTA containers and exactly 30 µL spotted on Whatman 903 
protein saver cards. The cards were subsequently air dried and sealed in individual ziplocked 
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bags with desiccant. Plasma and DBMS were shipped on dry-ice to the University of Liverpool 
Bioanalytical Facility for analysis. DBMS were stored at -40◦C analysed according to the above 
sample pre-treatment method. DTG concentrations in plasma (MP and IP) were analysed 
using a previously described and fully validated LC-MS methodology (242). Ratios between 
DTG concentrations measured in breast milk and maternal and infant plasma samples were 
calculated arithmetically and expressed as BM:MP and IP:BM ratios.  
3.4 Results and Discussion 
 
3.4.1 Method Development 
3.4.1.1 Chromatographic and mass spectrometry conditions 
DTG and DTG-d5 were eluted from the reverse phase column at approximately 1.8 minutes, 
respectively. Representative chromatograms obtained from extracted DBMS (blank and 
LLOQ) are shown in Figure 1. The m/z transitions were 420.1 → 277.1m/z for DTG and 425.1 
→ 276.9 for DTG-d5 with collision energies of 29 and 27 V, respectively. The scan width was 
set at 0.01 m/z and the dwell time at 0.1 seconds. 
 
3.4.1.2 Sample pre-treatment 
Due to the small volume of BM sample (30µL) applied to each circle, the entire spot was 
punched and subsequently extracted in order to ensure a high signal intensity on the LC-MS. 
Punching the entire circle after spotting with known volume also ensures reliable comparison 
with an equivalent volume of liquid sample, making it more suitable for use in therapeutic 
drug monitoring (TDM) and PK studies. However, a limitation of using the entire DBMS, as 
opposed to a sub-punch, is that the bioanalyst is solely reliant on the expertise of the 
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technician at the site/clinic to accurately pipette the required volume on the filter card. This 
poses an additional challenge in Resource Limited Settings, where volumetric pipettes are 
unlikely to be maintained and calibrated to same standards as accredited research 
laboratories. Furthermore, regional variability, inter-operator differences in pipetting 
technique and on-site training of staff at investigator sites was shown to impact on the 
reproducibility of drug (efavirenz) quantification from Dried Blood Spots (DBS), as was 
observed in a global multicentre trial conducted across diverse health resource settings 
(ENCORE 1) (243).  
Taking a DBMS sub-punch of a pre-defined diameter (e.g. 3-6 mm) is advantageous as study 
personnel do not need to apply an accurate volume to the card, so the technique is less reliant 
on operator skill. However, during early method development it was found that sub-punches 
and smaller BM volumes (<30µl) did not provide a high enough response at the assay LLQ (10 
ng/ml or 0.3 ng/DBMS sample). Furthermore, BM is colourless on the card, therefore, 
punching the entire circle ensures that the entire sample is utilised to measure the drug.  
However, use of protein saver cards are also known to be associated with challenges in 
bioanalysis such as a heterogeneous drug/matrix distribution on the cards, variable drug 
quantification and potential chemical interference from pre-treated cards [18-20]. Here, such 
issues were circumvented by punching the entire circle of the DBMS, and adjusting the 
reconstitution volume of the processed samples to reduce matrix interference. Other 
measures employed to optimise drug recovery were use of 1.8mg/mL EDTA in water to pre-
soak punched cards, which was shown to increase recovery by approximately 50% (Table 2). 
Reasons for this observation is not certain, but binding of integrase inhibitors to polyvalent 
metals (Mg2+, Mn2+, Fe3+, Al3+, Zn2+) rich in breast milk is well documented [21,22]. EDTA 
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chelates polyvalent metals by forming complexes with the metals. Therefore addition of EDTA 
to DBMS samples during processing likely increases the availability of free drug and recovery 
of free drug from the matrix. Further studies are required to understand the clinical 
implication of how BM rich in free metals affects the absorption and disposition of DTG in the 
breastfeeding infant.  
Addition of internal standard to liquid BM prior to  spotting on cards is the optimal method 
for correcting variability and ensuring process efficiency during sample preparation and 
analysis (244). However, such an approach is challenging in resource limited countries, 
particularly in a field based setting, due to lack of standard calibrated pipettes and potential 
operator variability. Thus the only feasible option was to either spot the IS directly on card 
immediately prior to extraction or add the IS in the pre-soak solution before extraction.  The 
addition of IS directly onto the DBMS was found to improve the overall recovery of DTG and 
reproducibility of the method compared with adding IS in solution (Table 2).  
 
 
3.4.2 Method Validation 
3.4.2.1 Selectivity 
The background interference from extracted blank DBMS (n=6) at the retention time of DTG 
was on average <20% of the signal intensity of the assay LLOQ. Similarly, the background noise 
in blank DBMS was <5% of the signal intensity of the internal standard (DTG-d5) for all 6 
batches tested. 
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3.4.2.2 Carryover 
Mean % carryover into the extracted blanks (n=7) after injection of a ULOQ sample (4000 
ng/mL) was 62.74% and 0.17%, 23.32% and 0.06%, 19.32% and 0.05% and 14.03% and 0.04% 
of the LLOQ and ULOQ after injection of first, second, third and fourth extracted blanks, 
respectively. Due to the observed carryover, four extracted blanks were incorporated after 
every injection of ULOQ or QCs and two blanks inserted between patient samples as 
precaution to prevent cross contamination between incurred samples. 
 
 
3.4.2.3 Precision and accuracy 
Five independent validation batches were run over 5 days, with each assay run consisting of 
a zero blank, 9 calibration standards (in duplicate) and 6 QC (LQC, MQC and HQC). The 
calibration was quadratic with a weighing factor of 1/X2, and linearity maintained from 10 
ng/mL to 4000 ng/mL. The Mean regression coefficient (r2 ±SD) was 0.9962 ± 0.0018. Inter- 
and intra-day accuracy and precision were within ±15% for all QC levels and ±20% for the 
LLOQ, as shown in Table 1. 
 
3.4.2.4 Recovery and Matrix effect 
Mean (±CV %), percentage recovery (%RE), process efficiency (%PE) and matrix effect (%ME) 
of DTG from DBMS are summarised in Table 2: The mean % RE, PE and ME (%CV) of DTG from 
DBMS pre-soaked with EDTA, and IS spotted directly onto the spot was 105.07 (11.23), 101.52 
(11.09) and 96.83 (8.18), respectively. The high % recoveries of DTG and limited effect of the 
sample matrix are likely attributed to the inherent properties of the filter cards and the fact 
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that only a small volume (30µL) of sample matrix is applied. One suspected explanation is that 
complex biopolymers are formed between the cellulose of the protein saver cards and the 
proteins, peptides and polysaccharides in BM, which stick together to essentially “hold” the 
matrix components within the card thereby making extraction of free drug and sample 
processing much easier (245, 246) 
Use of protein saver cards are known to be associated with challenges in bioanalysis such as 
a heterogeneous drug/matrix distribution on the cards, variable drug quantification and 
potential chemical interference from pre-treated cards (178, 228, 235). Here, such issues 
were circumvented by punching the entire circle of the DBMS, and adjusting reconstitution 
volume of the processed samples to reduce matrix interference. Other measures employed 
to optimise drug recovery were use of 1.8mg/mL EDTA in water to pre-soak punched cards, 
which was shown to increase recovery by approximately 50% (Table 2). Reasons for this 
observation is not certain, but binding of integrase inhibitors to polyvalent metals (Mg2+, 
Mn2+, Fe3+, Al3+, Zn2+) rich in breast milk is well documented (236, 237). Further studies are 
required to understand the clinical implication of how BM rich in free metals affects the 
absorption and disposition of DTG in the breastfeeding infant.  
Addition of internal standard to liquid BM before spotting on cards is the optimal method for 
correcting variability and ensuring process efficiency during sample preparation and analysis 
(244). However, such an approach is challenging in resource limited countries, particularly in 
a field based setting, due to lack of standard calibrated pipettes and potential operator 
variability. Thus the only feasible option was to either spot the IS directly on card immediately 
prior to extraction or add the IS in the solution before extraction.  The addition of IS directly 
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onto the DBMS was found to improve the overall recovery of DTG and reproducibility of the 
method compared with adding IS in solution (Table 2).  
 
3.4.2.5 Dilution Integrity 
Result of dilution integrity of DTG DBMS method after 1:2 and 1:4 dilution of samples >175% 
of ULOQ (approximately 7000 ng/mL) with extracted blank DBMS was within 15% of 
anticipated concentration with % CV <3%. 
 
3.4.2.5 Stability 
Stability of DTG extracted from DBMS was determined under multiple conditions which are 
summarised in Table 3. DTG was stable in DBMS after 5 days on the bench at room 
temperature, when refrigerated for 24 hours at 4oC, during processing, and when stored in 
the autosampler for up to 24 hours. DTG was stable after heating DBMS at 50oC in oven for 1 
hour and results were reproducible when samples were re-injected after 72 hours (reinjection 
reproducibility). Long term stability was also demonstrated; DTG DBMS were shown to be 
stable when stored at ambient temperature for a period of 1 year. All evaluated conditions 
for standards and QC were within ±15% of their respective nominal concentrations. These 
stability data indicate that DBMS are stable at high temperatures and over a long period of 
time. Therefore DBMS are ideal in middle and low income countries where stable power 
cannot be guaranteed, since refrigerators or freezers are not necessary for storage of DBMS.  
2.4.3 Clinical Application 
Steady state DTG concentrations in BM and MP taken at 2 weeks post-partum in a Ugandan 
mother, were 154.2 and 3786.2 ng/mL and 40.9 and 1210.7 ng/mL at 4 and 24 hours post 
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dose, resulting in BM:MP ratios of 0.05 and 0.04, respectively. Time matched IP 
concentrations in the breastfeeding infant were 67.8 ng/mL and 75.5 ng/mL at 4 and 24 hours 
post dose, resulting in IP:BM ratios of 0.44 and 1.85. Similarly, steady state BM and MP 
collected at post-partum in a South African mother at 3 and 24 hours post dose were 116.3 
and 3029.5 ng/mL and 17.7 and 603.3 ng/mL, with BM:MP ratios of 0.04 and 0.03, 
respectively. The IP concentration at 24 hours post the DTG dose was 16.3 ng/mL (IP:BM 
=0.92). In both women, DTG BM concentrations fell below the assay limit of quantification 
(<10 ng/ml) when sampled 2 days (Ugandan mother) and 9 days (South African mother) after 
the women stopped DTG therapy, whereas corresponding MP (103.8 ng/ml) and IP (58.6 
ng/ml) concentrations remained detectable in the Ugandan mother and her infant for up to 
2 days post DTG treatment cessation. These results should be interpreted with caution due 
to small number of samples evaluated. Transfer of DTG from the mother’s circulation to BM 
is potentially governed by its high (>98%) protein binding and thus sole passage of the 
unbound (free) form (247, 248). The influence of transporters and enzymes on DTG transfer 
across the mammary epithelium to the breastfeeding infant is unknown(178), however 
immature metabolic pathways of UGT1A1 and CYP enzymes may be responsible for the 
relatively high levels of DTG seen in the infants (180). The metabolising enzymes in infants 
reach adult function between 6 months to first year of life (249, 250). 
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3.5 Conclusion 
A sensitive, specific and reproducible electrospray ionization LC–MS methodology has been 
developed and validated for the accurate measurement of DTG in dried breast milk spots 
(DBMS). Assay validation experiments such as extraction recovery, matrix effects and short- 
and long-term stability have been discussed. The method has been used for the quantification 
of DTG in DBMS as part of an ongoing clinical trial investigating the safety and 
pharmacokinetics of DTG in pregnant and breastfeeding mothers and their infants. DBMS 
samples from two breastfeeding mothers (Uganda and South Africa) paired with mother and 
infant’s plasma concentration, were analysed. The concentration of DTG secreted in BM was 
approximately 2-4% of the maternal plasma concentration at all analysed time points. 
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3.6 Future Perspective 
Dolutegravir is emerging globally as an acceptable first line treatment of HIV. It was 
recommended by WHO guideline for treatment of HIV in 2016 (224), and has been rolled out 
in many western countries, while efforts are being made to make it available in low and 
middle income countries. High prevalence of HIV among women of reproductive age in 
resource limited countries (225), requires sufficient safety and pharmacokinetic data to 
ensure protection of neonatal and paediatric patients from adverse events, such as toxicity 
or acquired drug resistance, that may occur during breastfeeding. Robust analytical methods 
for measurement of drugs in localised body fluids like BM are a significant component of 
pharmacokinetic studies that aim to characterise antiretroviral distribution into anatomical 
sites relevant to HIV transmission. This assay will provide a tool for evaluating DTG secretion 
in BM and implication in neonatal safety and prevention of vertical transmission during 
breastfeeding.  
The preparation and extraction of liquid breast milk is generally cumbersome and often 
requires solid phase extraction due to the high amount of fats, polysaccharides and proteins 
in BM (227). Although cellulose of protein saver cards is known to be inert, we suspect that 
cellulose potentially interact with fats, polysaccharides and proteins in BM to form 
biopolymers that stick together and can be easily frozen down to ensure good sample 
cleaning (245, 246). In contrast, this method requires only 30µL of BM spot and samples can 
be easily shipped and stored at ambient temperatures. Although automated volumetric 
absorptive microsampling technologies are fast replacing conventional methods of sampling 
and analysis, it will take a long time for these to be available in resource limited countries 
(226).  
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Table 1: Precision and Accuracy for DTG DBMS 
Nominal Concentrations 
(ng/mL) 
Mean (SD) Precision (CV%) Accuracy (%) 
Inter-assay    
LLOQ 10.39 (1.09) 10.53 3.88 
LQC (30) 26.00 (2.77) 10.64 -13.34 
MQC (455) 440.14 (27.41) 6.23 -3.27 
HQC (3700) 3762.67 (213.45) 5.67 1.69 
Intra-assay  
LLOQ 10.05 (0.69) 6.83 0.53 
LQC (30) 25.8 (1.93) 7.50 -13.95 
MQC (455) 432.45 (13.08) 3.03 -4.96 
HQC (3700) 3703.91 (169.50) 4.58 0.11 
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Table 2. Recovery and Matrix Effect for DTG DBMS following liquid-liquid extraction with and without addition of EDTA, 
and the Internal Standard spiked in the extraction solution or directly onto the DBMS filter paper. 
Method Nominal QC 
Concentration (ng/mL)  
%ME 
(SD) 
%RE (SD) %PE (SD) %Analysis RE (SD) 
(B/A*100) (C/B*100) (C/A*100) (C2/B2*100) 
DBMS extracted with IS 
added to the extraction 
solvent 
30 (LQC) 109.48 (7.80) 35.816 (4.15) 39.21 (5.99) 37.38 (7.94) 
455 (MQC) 129.63 (7.55) 50.53 (1.53) 65.51 (3.30) 55.66 (7.085) 
3700 (HQC) 142.95 (10.32) 39.41 (2.69) 56.33 (4.01) 41.33 (3.41) 
Overall Mean (%CV) 127.35 (13.24) 41.92 (7.96) 53.68 (13.35) 42.07 (25.67) 
DBMS pre-soaked with 
EDTA, and IS added to the 
extraction solvent 
30 (LQC) 90.37 (3.07) 102.23 (9.56) 92.38 (11.50) 98.64 (8.59) 
455 (MQC) 74.27 (7.49) 104.81 (8.46) 77.842 (6.48) 64.74 (5.63) 
3700 (HQC) 85.29 (6.93) 99.26 (11.97) 84.67 (11.49) 71.15 (9.73) 
Overall Mean (%CV) 83.31 (8.12) 102.10 (11.92) 84.97 (13.58) 78.18 (23.03) 
DBMS pre-soaked with 
EDTA, and IS spotted 
directly onto the spot 
30 (LQC) 97.10 (4.02) 92.94 (10.27) 90.24 (12.11) 102.10 (12.87) 
455 (MQC) 88.46 (8.62) 114.82 (14.33) 101.56 (11.08) 86.84 (10.58) 
3700 (HQC) 104.93 (12.03) 107.47 (15.18) 112.77 (7.45) 78.15 (10.12) 
Overall Mean (%CV) 96.83 (8.18) 105.07 (11.23) 101.52 (11.09) 89.03 (13.62) 
A=Mean peak area response of analyte in mobile phase; B= Mean peak area response of analyte spiked after extraction of matrix (Spiked post extraction of 
blank plasma); C= Mean peak area response of analyte spiked prior to extraction (spiked pre-extraction); %ME= Matrix effect, defined as ratio of mean peak 
area of analyte spiked post extraction (B) to mean peak area of analyte in mobile phase (A) X 100; %RE= Extraction yield, derived by dividing the mean peak 
area response of analyte spiked pre-extraction (C) with mean peak area response of analyte spiked post extraction (B) and multiplying by 100; %PE= Process 
efficiency calculated by dividing mean peak area response of analyte spiked pre-extraction (C) by mean peak area of analyte in mobile phase (A) and 
multiplying by 100; B2 is defined as response ratio of analyte spiked post extraction and internal standard; C2 is the response ratio of analyte spiked pre-
extraction and internal standard; %Analysis RE calculated by dividing the mean response ratio of analyte spiked pre-extraction (C2) to mean response ratio 
of analyte spiked post extraction (B2), multiply by 100;  
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Table 3. Short and long term stability of DTG DBMS 
Stability QC Precision (%CV) Accuracy 
(%bias) 
Bench top (RT; 5 days) LQC 4.70 0.37 
HQC 3.90 -7.59 
Processed stability (4oC; 24 hr) LQC 10.47 1.26 
HQC 7.05 1.26 
Heat treatment (50oC; 1 hr) LQC 4.78 8.96 
MQC 10.41 -4.78 
HQC 5.65 6.78 
Autosampler stability (10oC; 24 hr) LQC 5.79 -10.29 
HQC 4.04 -9.61 
Long term stability (RT; 12mths) LQC 9.32 2.47 
HQC 3.11 16.53 
Re-injection Reproducibility (72 
hr) 
LQC 12.20 -2.84 
MQC 6.35 -5.73 
HQC 3.67 -0.89 
RT = room temperature 
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Figure 1: Chromatograms of (A) a blank DBMS and (B) the 
assay lower limit of quantification (LLOQ) 
Figure 1:  
A)B)  
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Figure 2: Chromatogram of patient DBMS sample taken at 4 
hours post the dolutegravir dose 
Figure 2.  
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CHAPTER 4 
 
Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV 
Mothers and their Neonates 
 
4.1 Introduction 
Dolutegravir (DTG) is a potent integrase inhibitor that can reduce risk of mother to 
child transmission (MTCT) of HIV during pregnancy by rapidly suppressing viral load. 
Impact of pregnancy on DTG pharmacokinetics (PK) and safety is unknown and 
requires evaluation before it is widely rolled out for use in pregnancy. HIV burden 
among women of reproductive age on the other hand is significant with an estimated 
17.8 million women age 15-24 years currently living with HIV and over 1.5 million HIV 
positive women in sub-Saharan Africa get pregnant annually (251, 252).. Women 
constitute over 56% of new adult infections, a large proportion between age 15-25 
years SSA  (253). Despite efforts to intensify ART access, high proportion of HIV 
positive women still get pregnant prior to commencing ART (254), predisposing there 
neonates to risk of HIV in-utero or during delivery. 
Great strides have been made in integrating HIV and antenatal care (255), but many 
women still present at third trimester of pregnancy or in labour with high viral loads, 
so there is limited time to achieve viral suppression with ART before labour, further 
increasing the risk of vertical transmission during delivery. Integrated antenatal care 
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(ANC) includes screening of blood born viruses (HIV, HCV, HBV and syphilis) as part of 
routine antenatal care in most sub-Saharan African countries (256). This practice has 
enabled diagnosis of many women during antenatal visits, and ART treatment 
initiated accordingly to prevent transmission to their neonates. Late presentation 
therefore allows little or no time for adequate virological suppression before delivery 
if HIV diagnosed during antenatal care. The widely available NNRTI based regimen 
[standard of care (SoC)] approved in most sub-Saharan African countries for 
treatment of women during pregnancy is NNRTI (EFV) plus 2 NRTI which can take 
approximately 84 days (or 2-3 months) to successfully suppress the viral load below 
50 copies/mL (257). Thus, women presenting late for ANC who are prescribed this 
regimen are at risk of reaching term and labour without successful viral suppression 
below detectable levels. Previous practice of option B in PMTCT which recommended 
that ART (NNRTI (EFV or NEV) plus 2NRTI) is stopped 6 weeks after delivery or 
cessation of breast feeding (258), also suggest that there may be associated drug 
resistance from these medications in a significant number of women from previous 
exposure (259), further making viral suppression before labour unlikely. 
Compounding to the problem in this region is the lack of facilities for resistance 
testing which is not part of the routine ART investigations. Therefore diagnosis of 
resistance prior to commencing ART is difficult, and relies on lack of clinical response.  
  
 DTG an integrase strand inhibitor (INST) with a plasma half-life (t1/2) of approximately 
14 h, maximum plasma concentration (Cmax) 3.67 µg/mL, minimum plasma 
concentration (Cmin)1.11 µg/mL and 24 h area under the concentration curve (AUC0-
24) 53.6 µg.h/mL after a once daily dose of 50 mg of DTG respectively from a 
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population pharmacokinetic data (172). It is highly potent and rapidly suppresses viral 
load (approximately 28 days) after drug initiation, with a corresponding 
immunological recovery within a short duration of time (260). It also has a high 
resistance barrier, as individuals previously resistant to NNRTI and other INST such as 
raltegravir (RAL) were found to respond to DTG with efficient viral suppression within 
2 weeks after drug initiation (135, 261). It is well tolerated by many patients and 
known to have minimal side effects (192). Pregnancy and breastfeeding data are 
limited and this was recognised as a research gap by WHO in the 2016 guidelines 
(262). Therefore they recommend cautious use in pregnancy, breastfeeding and in 
children <12 years (262). Fear of teratogenicity, transplacental drug transfer and 
feotal toxicities are limitations to its use in pregnancy for prevention of MTCT of HIV. 
Limited Pregnancy and breastfeeding safety data is a major factor mitigating national 
approval of DTG due to the difficulty of asserting safety during this period. 
DOLPHIN-1 (NCT02245022) was a multicentre, multinational randomised controlled 
trials of newly diagnosed HIV positive pregnant women initiating treatment between 
28-36 weeks gestation in Uganda and South Africa that randomised women into 2 
groups (DTG group and EFV (standard of care) group). This study aimed at evaluating 
the steady-state pharmacokinetics of DTG in third trimester of pregnancy and two 
weeks post-partum. It also evaluated the transfer of DTG in breast milk during 
treatment and infant exposure during breast feeding, both within the dosing interval 
and following drug cessation. Other aims of the study were to evaluate the viral load 
(VL) response, safety and tolerability of DTG by pregnant and breastfeeding HIV 
infected women. 
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4.2 Methods 
4.2.1 Study Design 
DOLPHIN-1 was an open labelled randomised trial of DTG vs EFV-containing ART in 
pregnant women initiating treatment in late (28-36w) pregnancy and postpartum. It 
evaluated VL, safety and tolerability of DTG, transplacental neonatal exposure, breast 
milk exposure and DTG elimination in neonates. Women were randomised 1:1 to EFV 
(SoC) or a DTG arm. Those randomised to the EFV arm were commenced on EFV 
containing ART immediately as recommended by the guidelines, while those on the 
DTG arm received EFV immediately after referral and were subsequently switched to 
a DTG containing regimen within 7 days of initiating EFV based regimen. 
Subsequently, the women were switched to SoC regimen after the postpartum visit. 
Breast milk samples, cord blood at delivery and maternal plasma after cessation of 
DTG were also collected in the study for evaluation of cord: maternal ratio (Cord: 
MP), infant plasma: maternal plasma ratio (IP:MP), breast milk : maternal plasma 
ratio (BM:MP). VL and other recommended antenatal care were monitored 
throughout pregnancy and standard care was ensured throughout the study period. 
Baseline demographics, clinical and laboratory data, birth outcome data were 
recorded, and all infants were exclusively breastfed according to study protocol. The 
inclusion criteria of the study were: Ability to provide signed informed consent after 
adequate information provided and required precautions explained to the patient, 
willingness to participate, age 18 years and above, pregnant and untreated HIV 
infection in late pregnancy at ≥28 – 36 weeks gestation. Exclusion criteria were: 
Received antiretroviral drugs in previous 6 months, if ever received INST, serum 
haemoglobin < 8.0 g/dl, elevations in serum levels of alanine aminotransferase (ALT) 
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>5 times the upper limit of normal (ULN) or ALT >3xULN and bilirubin >2xULN (with 
>35% direct bilirubin), eGFR < 50mL/min, active Hepatitis B infection, history or 
clinical suspicion of unstable liver disease, or subjects with severe liver disease, 
severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or 
liver, abnormalities (e.g. grade 2 or above proteinuria, elevation in serum creatinine 
(above 2.5 x ULN), total bilirubin ALT or AST), paternal non-consent (where disclosure 
to male partner has been made) and clinical depression or clinical judgement 
suggests increased risk of suicide.  
The primary endpoint was pharmacokinetics of DTG and secondary endpoint were 
viral load changes, tolerability and safety. The sample size was derived from studies 
of non-pregnant HIV infected adults because of lack of pregnancy data (168), with 
the assumption that CV 20% will give a > 80% power (168). Clinical adverse events 
were recorded as recommended by DAIDs (263). 
 
4.2.2 Sample collection 
For the DTG arm, patients were initiated on once daily 50mg DTG (DTG 50 mg +2 
NRTI) with sampling on days 1, 7 and 14 for baseline, one week and 2 weeks VL 
monitoring. Rich PK sampling (0-24h) was done on day 14 and 2 weeks post-partum. 
Similarly, samples were also collected at the same time points for viral load 
monitoring in the EFV arm (Figure 1). Breast milk samples were also collected 
postpartum at 3-5 h post dose, 24 h post dose and 1-3 days post DTG cessation. 
Maternal and infant plasma samples were also collected at 3-5 h post dose, 24 h post 
dose and 1-3 days post DTG cessation. Plasma samples and breast milk samples were 
collected and stored at -80oC until shipment to appropriate laboratory for analysis. 
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All sample collection and processing at the sites of the trials were conducted by 
designated technical staff. PK and measurement of drug levels was done in Liverpool 
bioanalytical facility, while plasma and BM VL were analysed at National health 
laboratory service, Division of Virology Cape Town South Africa. Other baseline 
investigations and evaluation of participants were done at the study site. 
 
4.2.3 Bioanalysis of DTG 
DTG bioanalysis was performed within 3 h of removal of the samples from the -40 
freezer. Samples were thawed, and analyse using equal volume (100µL) of sample as 
used in the calibration standards and dolutegravir-d5 internal standard. Tert-butyl-
methyl-ether (TBME) was used for extraction and the samples were subsequently 
dried in a nitrogen drier. Samples were reconstituted in required proportion of 
methanol: water and 0.1% formic acid (80:20 v/v) for subsequent injection onto the 
LC-MS. The analytes were resolved using reverse phase C18 XBridge waters (3.5µm: 
2.1x50mm) column (Waters Cooperation USA) and quantified by a Thermo TSQ 
Access triple quadrupole mass spectrometer. Data acquisition was performed using 
LQUAN software (Thermo Scientific) (242). The dried breast milk spots (DBMS) were 
analysed by spotting 30 µL of breast milk sample on a 12 mm circle of a whartman 
protein saver card and allowed to dry. Dolutegravir-d5 was spotted on the card and 
allowed to dry prior to processing as described in chapter 3. My role in this trial was 
to validate and develop a novel method for quantifying DTG in BM spots and analysis 
of samples, plasma samples analysis and non compartmental modelling of the 
measured DTG concentrations to derive PK parametres. All analysis were done under 
the supervision of senior laboratory personals.  
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4.2.4 Statistical analysis 
DTG PK parameters (Cmax, Tmax, t1/2, Cmin, C0-24 and AUC0-24), were calculated using 
WinNonlin, Phoenix, (version 6.1, Pharsight, Mountain View, CA) for non-
compartmental PK analysis of data. Other statistical analysis of associations and 
relationships were done using Geometric means, Geometric mean ratios and 
parametric test (t-test). 
 
4.2.5 Ethical Approvals 
The study adhered to the Helsinki declaration and current applicable regulatory 
requirements. Research ethics as stipulated in the protocol and compliance with ICH-
GCP were strictly followed to the latter. Protocol and ethical approval were obtained 
from Joint Clinical Research Centre Institutional review board, Ugandan National 
Council for Science and Technology and Research integrity, The Governance and 
University of Liverpool research ethics committee, Liverpool UK and Desmond Tutu 
hospital research committee. A signed inform consent including paternal consent was 
obtained before enrolling participants after carefully providing information on the 
study, the risk and precautions that participants are required to adhere to. 
Participants were also free to withdraw from the study at any time they deem risky 
to continue with the study or to be withdrawn by the clinician if he/she judge 
participant to be at risk of complications.  
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4.3 Results 
At the time of writing this thesis, only 16 [8 on DTG and 8 on EFV arm (SoC)] VL and 
safety data were available and a total of 28 PK data of both third trimester and 
postpartum mothers. Median gestational age was 29.5w (range 28-35w) at 
enrolment. Baseline VL was log10 4.15 (2.43-4.88) copies for DTG, and log10 4.13 (2.88-
6.07) copies for EFV. The proportion of VL reported as <50 copies/mL or undetectable 
at 2 weeks and at 4 weeks of therapy was 5/8 and 4/8 in mothers on DTG, and 1/5 
and 2/7 in mothers on EFV, respectively. At 2 weeks post-partum 5/6 and 4/7 
mothers on DTG and EFV had VL <50 copies. Two mothers in the DTG arm were 
withdrawn for virological failure; the first had no detectable drug in plasma and was 
non-adherent, the second had evidence of 3 class drug resistance (reverse 
transcriptase (RT) and protease mutations) (Table 1).  
  
4.3.1 Maternal DTG Pharmacokinetic in Third Trimester of Pregnancy and 2 weeks 
postpartum 
DTG PK parametres t1/2, Tmax, Cmax, C0-24 and AUC0-24 were not different from 
previously reported studies (Table 3, 4 and 5). Geometric mean (%CV) of the following 
PK parameters: t1/2, Tmax, Cmax, C0-24 and AUC0-24 were 10.05 (24.46) h, 2.94 (52.29) h, 
2534.33 (27.42) ng/mL, 641.83 (74.39) ng/mL and 35322.10 (31.98) ng.h/mL 
respectively in third trimester of pregnancy (n=28), and t1/2 11.12 (26.23) h, Tmax 2.43 
(53.27) h, Cmax 2843.27 (23.92) ng/mL, C0-24 695.98 (39.61) ng/mL, and AUC0-24 
37574.55 (26.60) ng.h/mL respectively in the postpartum period of the same women 
(n=27). Although overall difference between pregnancy and postpartum was not 
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significant, there was a slight decrease (approximately 5%) in DTG exposure during 
pregnancy (Table 3, Figures 2 and 3). 
 
4.3.2 Infant and BM DTG exposure intrapartum, postpartum and after cessation of 
DTG 
BM DTG exposure was evaluated 1-5 h and 24 h post maternal DTG dose and 1-3 days 
after cessation of DTG therapy (Tables 6 and 7). BM DTG transfer was approximately 
3% of the maternal plasma concentration, however concentrations in BM fell below 
the assay limit of quantification (LLQ) (10 ng/mL) after 1-3 days of treatment 
cessation. Sampling closer to time of delivery has an impact on infant plasma DTG 
concentration due to contributions from placental transfer. Cord to maternal plasma 
DTG ratio (C:M) was Geometric mean (90% CI)  1.19 (1.01, 1.38), consistent with 
values previously reported by the PANNA studies (264). Furthermore, IP:MP ratios 
were higher after drug cessation (as compared with the dosing interval) due to a 
persistent IP concentration, whereas DTG was rapidly eliminated in the mother. 
Given that BM DTG concentrations after 24 h were <LLQ suggests that the 
persistently high DTG concentrations in infants is driven by inefficient elimination of 
DTG in neonates. One sample was done 9 days after cessation of DTG, and all samples 
(MP, IP, BM) were found to be undetectable (Tables 6 and 7).  
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4.3.3 Safety of DTG in Third Trimestre of pregnancy 
A total of 4 severe adverse events (SAEs) were reported in the study as follows: One 
(1) stillbirth in the DTG arm, 1 grade 3 hypertension in the EFV arm, 1 baby with 
polydactyly in the DTG arm, and other adverse events summarised in table 2. Out of 
the four SAEs reported, two were in one participant in the DTG arm and two in the 
EFV arm: JU9 (DTG arm) had a fresh stillbirth attributed to asphyxia due to cord 
around the neck and liver event (ALT 5 x ULN, total bilirubin 2.3 x ULN), which 
resolved after discontinuation of DTG. Patient also had ingested physalis minima Linn 
(herbal medication) prior to event, thought to be possibly related to the event, 
considering our poor understanding of the role of herbal medication in drug 
metabolism. VR0 (EFV arm): Developed pregnancy induced hypertension 
necessitating induction of labour. While EK6 (EFV arm): Infant polydactyly left foot (9 
digits) and syndactyly of 2nd, 3rd and 4th digits were all considered unrelated since 
embryological development of these structures occurred prior to 3rd trimester of 
pregnancy, when patients were exposed to DTG, and it occurred in patient not 
exposed to DTG at all. 
 
4.4 Discussion 
DTG steady state exposure after 50 mg once daily dose in third trimester of pregnancy 
decreased by approximately 5% compared to postpartum period, and was not 
statistically significant. This was because postpartum sampling was done median 8 
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days (2-28 days) and does not reflect return to normal physiology. Unlike other 
reports of PANNA and IMPAACT 1026, there was a significant difference between 
third trimester pregnancy and postpartum because sampling was done ≥2 weeks 
postpartum (Tables 3, 4, 5).. Ctrough concenctrations were all above the protein 
adjusted 90% inhibitory concentration (IC90) of DTG which is 64ng/mL. Minimum 
effective concentration (MEC) of DTG is unclear, but only 9 out of 28 samples had 
Ctrough below reported MEC of 324ng/mL. A value derived from a 10 days ranging 
studies of DTG monotherapy (168, 176). Despite decrease in DTG exposure during 
pregnancy [AUC0-24 = 35322.10 (19195.73, 67922.24) ng.h/mL], undetectable viral 
loads (<50 copies/mL) were still achieved within 2 weeks after commencing DTG. 
Intrapartum and postpartum Infants exposure to DTG is governed by transfer of DTG 
through membranes. DTG is able to pass through the placental membrane in utero, 
resulting in high infant exposure that persist in high concentration even after 
delivery. Postpartum DTG exposure is mainly through breast milk, which is 
determined by the amount of DTG excreted in BM. Transplacental transfer of DTG in 
utero was high during pregnancy as previously reported [132]. Median ratio of cord 
to plasma concentration at delivery was 1.23 suggesting high transplacental transfer. 
This is consistent with previous reports of high DTG transfer across the placenta to 
foetus resulting in high in utero exposure of neonates to DTG. Elimination of DTG in 
neonates was prolonged compared to the postpartum women (undetectable levels 
of DTG in MP and BM 1-3 days after DTG cessation) and was consistent with other 
reports of DTG elimination in infants (265). The persistent high levels of DTG in infants 
was attributed to immature metabolic pathways of UGT1A1 and CYP enzymes in the 
liver of infants (266-268). Transplacental transfer of DTG coupled with an 
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underdeveloped liver UGT1A1 and BM DTG exposure was thought to be responsible 
for the high neonatal DTG concentration (269). Previous reports of children exposed 
to low dose ART during PMTCT programmes and observation in some adults in 
current study who were previously exposed to ART in PMTCT, suggest that previous 
exposure to ART could promote resistant clades of virus against antiretroviral agents 
(23, 270).  
4.4.1 DTG transfer to breast milk and Infant exposure 
Steady state BM DTG concentrations were quantifiable at 2-4 hours and 24 hours 
post maternal dose in postpartum Ugandan and South African mothers. This resulted 
in median BM:MP ratios of 0.03 at 2-4 hours and 24 hours post maternal dose. 
Transfer of DTG from the mother’s circulation to BM is potentially governed by its 
high (>98%) protein binding and thus sole passage of the unbound (free) form(247, 
248).The influence of transporters and enzymes on DTG transfer across the 
mammary epithelium to the breastfeeding infant is unknown (178, 248). Time 
matched IP concentrations in breastfeeding infant 2-4 and 24 hours post dose and 
MP resulted in median IP:MP ratio 0.05 and 0.12 respectively. In all the women, DTG 
BM concentrations was less than LLQ (<10 ng/mL) when sampled 1-3 days after 
cessation of DTG therapy, whereas corresponding MP and IP concentrations 
remained detectable (>10ng/mL) in infants for up to 3 days post DTG treatment 
cessation. DTG MP elimination was consistent and concentrations measured were 
low 3 days after cessation of DTG, while IP DTG elimination was slower, giving rise to 
high IP:MP of 0.46 (Table 7).  Infant Plasma concentration was not measured beyond 
3 days after cessation.  
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4.4.2 Safety and efficiency of viral suppression of DTG in Third trimester 
pregnancy 
Administration of medications during pregnancy is complex and risky due to potential 
of inducing teratogenicity to embryos in utero. But in pregnant HIV positive women, 
it is essential in preventing MTCT. This study was conducted in third trimester of 
pregnancy, and less teratogenicity is expected since organogenesis occurs in first 
trimester (271). A recent interim report from an ongoing NIH funded study (Tsepamo) 
in Botswana suggested that there could be an increased risk of neural tube defect in 
neonates of women who become pregnant while taking DTG. Cautious use of DTG in 
women of reproductive age who want to become pregnant (272) was recommended 
by WHO while awaiting more data. In this study, abnormalities were noted at birth, 
but were thought not be related to DTG. Pregnancy induced hypertension observed 
in one participant was a known obstetric complication of unknown cause and 
polydactyly and syndactyly observed in 1 neonate were not considered to be related 
to DTG since limb and bone development takes place in first trimester of pregnancy 
(271) and DTG was only administered in third trimester, therefore highly unlikely to 
be related to DTG. A still birth recorded, was thought to be an obstetric complication 
of asphyxia secondary to cord round the neck and the cause of liver event (5X 
elevated ALT and 2.3 times ULN bilirubin) was unclear due to the presence of other 
confounders in the patients such as ingestion physalis minima Linn (herbal 
medication), and unknown UGT1A1 genotype of the woman, since polymorphisms in 
UGT1A1 could affect bilirubin metabolism (212).  
The majority (80%) of patients on DTG achieved an undetectable viral load (<50 
copies/mL) 2 weeks after commencing DTG compared to the EFV regimen (SoC) 
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which was approximately 10% (Table 1). One patient previously exposed to ART had 
high level multiclass resistance to NNRTI, NRTI and PI, resulting in treatment failure 
and VL of 145 copies/mL after 28 days DTG, and 2217 copies/mL 2 weeks postpartum. 
Out of the 6 who had no problem, 4 had VL of <50 copies/mL 14 days after starting 
DTG and 5 out of the 5 VL measured were <50 copies/mL 2 weeks postpartum. In 
contrast, only 1 out of the 8 patients on SoC regimen had VL<50 copies/ mL 14 days 
after starting ART, and 4 out of 8 2 weeks postpartum. 
4.4.3 Limitations 
Lack of sufficient safety data in early pregnancy is a concern to women who become 
pregnant on DTG regimen especially after the recent report of Tsepamo 
observational study in Botswana, which reported increased incidence of neural tube 
defect in infants of mothers who became pregnant while on DTG. DTG safety data in 
first trimester is still insufficient, when most organogenesis occurs and 
recommendations are still inconclusive. Several questions would need to be 
answered which include: Would women be advised to use contraception while on 
DTG? Will their DTG regimen be switched to other regimen prior to becoming 
pregnant and continued after first trimester? Is stopping DTG a risk of promoting class 
resistance? What happen to women who are resistant to switch options? Are there 
plans to evaluate safety of DTG in children <12 years? What is the long term effect of 
high neonatal DTG exposure to infant born to mothers on DTG regimen? These are 
questions that will need to be answered in subsequent studies. This study was 
conducted in small sample size, postpartum sampling collected median 8 days after 
delivery and does not reflect return to normal physiology. Therefore no difference 
was observed between third trimestre and postpartum. UGT1A1 is highly 
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polymorphic and activity is likely to vary from one individual to another. These 
limitations were noted and DOLPHIN 2, a definitive trials aim at providing clarity to 
the limitations. 
4.5 Conclusion 
DTG exposure during pregnancy is sufficient to induce viral suppression to 
undetectable levels within 2 weeks of commencement, irrespective of reduced 
concentrations. It efficiently reduce the risk of vertical transmission during delivery. 
However transplacental in utero exposure to neonates with poorly developed 
UGT1A1 and persistently high foetal exposure over a long period of time is a concern 
since implication on foetal health and development is unknown. Still birth and liver 
event encountered in this study were thought not to be related to DTG, but additional 
safety data throughout pregnancy and postpartum period (including breastfeeding) 
is required. Further evaluation of pharmacogenetics of UGT1A1 and CYP enzymes, 
viral loads in breast milk, DTG excretion profiles in BM and safety in the paediatric 
age group < 12 years is required and likely to be evaluated further in DOLPHIN 2 
clinical trial.   
Table 1: Viral Load 
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Participant 1 had high level resistance (NNRTI, NRTI and PI) from baseline sample, suggesting previous, 
ART exposure 
^Participant 14 had not been taking study drug, as evidenced by undetectable concentrations on the 
day,  
  of intensive PK   ~Protocol did not initially require a repeat VL at randomization in the EFV arm 
  ND: not done; PD: protocol deviation 
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Table 3: Maternal DTG Pharmacokinetic Parametres Geometric means (Geomean) 
and Geometric mean ratios (GMR) of women in third trimester pregnancy and 
Postpartum 
DTG PK 
Parametres 
Pregnant at 3rd Trimester 
(n=28) Postpartum  (n=27) GMR (90% CI) 
Cmax (ng/mL) 
2534.33 (1461.99, 
3986.37) 
2843.27 (1397.94, 
4224.19) 0.91 (0.82, 1.01) 
Tmax (h) 2.94 (2.40, 3.47) 2.63 (2.04, 3.21) 1.23 (0.82, 1.82) 
AUC0-24 
(ng.h/mL) 
35322.10 (19195.73, 
67922.24) 
37574.55 (14933.21, 
59633.24) 0.95 (0.74, 1.23) 
C0-24 (ng/mL) 641.83 (188.16, 3087.91) 695.98 (204.05, 1443.35) 0.93 (0.76, 1.14) 
t1/2 (h) 10.05 (6.50, 16.74) 11.12 (6.13, 17.34)  
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Table 4: IMPAACT P1026s (266)  
Parameter Third trimester (30-
38 wks) 
Postpartum (6-32 
wks)  
GMR (90% CI) T3/PP 
n subjects 28 22 22 
C24 ng/ml 930 (680-1340) 1280 (800-1950) 0.66 0.52 0.84 
Cmax ng/ml 3540 (2660-4240) 4850 (3830-5970) 0.75 0.64 0.88 
AUC24 ng.h/ml 49200 (36400-
62000) 
65000 (47800-
88400) 
0.71 0.63 0.81 
Values are expressed as median (IQR) 
Table 5: PANNA (264) 
Parameter Third trimester (31-
38 wks) 
Postpartum (3-7 
wks)  
GMR (90% CI) T3/PP 
n subjects 8 5 5 
C24 ng/ml 700 (109) 1100 (71) 0.66 0.32 1.36 
Cmax ng/ml 3400 (33) 3000 (41) 1.07 0.78 1.47 
AUC24 ng.h/ml 42900 (39) 44800 (56) 0.95 0.60 1.48 
Values are expressed as geometric mean (CV%)    
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Table 6: Infant and BM DTG exposures 2-4 and 24 hours dose postpartum 
IDI Uganda 
Postpartum 
Post-delivery (days) GM (90%CI) Post-delivery 
(days) 
Median (min-max) 
5.6 (3.6, 7.5) 6.0 (2.0-14.0) 
[DTG]  GM (90% CI) Ratio GM (90%CI) 
Infantmax ng/ml 199.64 (123.79,275.50) IP:MPmax 0.08 (0.05,0.11) 
Infanttrough ng/ml 151.06 (103.24,198.88) IP:MPtrough 0.23 (-0.02,0.49) 
BMmax ng/ml 64.67 (39.42,89.92) BM:MPmax 0.03 (0.02,0.04) 
BMtrough ng/ml 23.55 (17.31,29.79) BM:MPtrough 0.03 (0.02,0.04) 
South Africa 
Postpartum 
Post-delivery (days) GM (90%CI) Post-delivery 
(days) 
Median (min-max) 
10.1 (8.6,11.7) 11.0 (7.0,18.0) 
[DTG]  GM (90%CI) Ratio GM (90%CI) 
Infantmax ng/ml 58.47 (-29.83,146.77) IP:MPmax 0.02 (-0.01,0.06) 
Infanttrough ng/ml 50.48 (-8.62,109.57) IP:MPtrough 0.06 (-0.05,0.18) 
BMmax ng/ml 75.85 (64.78, 86.92) BM:MPmax 0.03 (0.03, 0.04) 
Bmtrough ng/ml 23.78 (19.00, 28.56) BM:MPtrough 0.03 (0.02, 0.04) 
Combined South Africa and Uganda 
Postpartum 
Post-delivery (days) GM (90%CI) Post-delivery 
(days) 
Median (min- max) 
7.9 (6.4, 9.3) 8.5 (2.0, 18.0) 
[DTG]  GM (90%CI) Ratio GM (90%CI)                   
Infantmax ng/ml 110.73 (49.79, 171.66) IP:MPmax 0.05 (0.02, 0.07) 
Infanttrough ng/ml 87.32 (47.41, 127.24) IP:MPtrough 0.12 (-0.02, 0.26) 
BMmax ng/ml 70.47 (57.65, 83.29) BM:MPmax 0.03 (0.03, 0.04) 
BMtrough ng/ml 23.78 (19.00, 28.56) BM:MPtrough 0.03 (0.02, 0.04) 
IP = infant plasma, MP = maternal plasma, CD = cord blood, BM= breast milk 
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Table 7: Infant and BM DTG exposures 1-3 days after DTG cessation 
IDI Uganda 
Postpartum (1-3 days post cessation of DTG) 
Post-delivery (days) GM (90%CI) Post-delivery 
(days) 
Median (min-max) 
9.0 (7.0, 11.0) 8.5 (5.0-18.0) 
Post final dose (days) GM (90%CI) Post final dose 
(days) 
Median (min-max) 
1.9 (1.5, 2.3) 2.0 (1.0, 3.0) 
[DTG]  GM (90%CI) Ratio GM (90%CI) 
Infant1-3days ng/ml 60.24 (14.90, 105.59) IP:MPmax 0.73 (0.27, 1.19) 
BM1-3days ng/ml <LLQ BM:MPmax <LLQ 
South Africa 
Postpartum (1-3 days post cessation of DTG) 
Post-delivery (days) GM (90%CI) Post-delivery 
(days) 
Median (min-max) 
13.9 (12.0, 15.8) 13.0 (10.0, 25.0) 
Post final dose (days) GM (90%CI) Post final dose 
(days) 
Median (min-max) 
2.1 (1.2, 3.0) 2.0 (1.0, 9.0) 
[DTG]  GM (90%CI) Ratio GM (90%CI) 
Infant1-3days ng/ml 34.18 (9.16, 59.20) IP:MPmax 0.33 (-0.46, 1.11) 
BM1-3days ng/ml <LLQ BM:MPmax <LLQ 
Combined Uganda and South African study sites 
Postpartum (1-3 days post cessation of DTG) 
Post-delivery (days) GM (90%CI) Post-delivery 
(days) 
Median (min-max) 
11.5 (9.9, 13.1) 12.0 (5.0, 25.0) 
Post final dose (days) GM (90%CI) Post final dose 
(days) 
Median (min-max) 
2.0 (1.5, 2.5) 2.3 (1.0-9.0) 
[DTG]  GM (90%CI) Ratio GM (90%CI) 
Infant1-3days ng/ml 44.22 (19.34, 69.11) IP:MPmax 0.46 (-0.02, 0.95) 
BM1-3days ng/ml <LLQ BM:MPmax <LLQ 
IP = infant plasma, MP = maternal plasma, CD = cord blood, BM= breast milk, LLQ = 
lower limit of quantification 
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Figure 1: Study Design. Intensive PK, infant and maternal viral load sampling time 
points 
 
 
 
Figure 2: Paired PK profiles of DTG concentrations during third trimester pregnancy 
and postpartum period 
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Figure 3: Unpaired PK profiles of DTG concentrations during third trimester 
pregnancy and postpartum period 
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CHAPTER 5 
DOLUTEGRAVIR INTERACTIONS WITH ARTEMETHER-
LUMEFANTRINE AND ARTESUNATE-AMODIAQUINE 
 
5.1 Introduction 
Malaria and HIV are highly prevalent in sub-Saharan Africa, causing high number of 
deaths especially among children and immunocompromised patients (160). In 2016, 
212 million new cases of malaria were reported globally of which 90% were from 
Africa (160, 273). Also in 2015, 429,000 malaria related deaths were recorded, and 
92% were from Africa (160, 273). Over 25 million people are currently living with HIV 
in sub-Saharan Africa, and 730,000 AIDS related deaths were reported in 2016 (3, 
274). Therefore evaluating the safety of simultaneous treatment of the two diseases 
in the population is urgently needed, particularly before dolutegravir (DTG) is rolled 
out and widely prescribed in the region. Important in the natural history of these 
tropical diseases is while HIV is chronic in nature requiring lifelong treatment, malaria 
treatment is short duration, approximately 3 days. This makes co-administration of 
the two treatments and potential drug interaction an important challenge since DTG 
will not be stopped while malaria is been treated. Drug interactions with 
antiretroviral (ARV) and other antimicrobial medications is a well recognised 
challenge in HIV patients on ARV treatment especially as both drug classes are 
metabolized via similar pathways. Malaria treatment with artemisinin containing 
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therapies (ACTs, the most commonly prescribed group of antimalarials globally) in 
HIV patients on ARVs is common in the region, but there have been limited number 
of interaction studies (275, 276).  ACT are known to interact with several classes of 
drugs which have been reported in several studies (277). Depending on the 
interaction, activity of the antimalarial is either associated with sub-optimal 
pharmacotherapy, with resultant decrease in clearance of plasmodia species and 
promoting recrudescence of malaria or enhanced activity with associated toxicities 
(278, 279). 
 
It is worth nothing that HIV associated immunosuppression promotes infection with 
microbial agents, severe disease and poor outcomes (280). In malaria endemic 
regions, malaria/HIV co-infection is common, and presents with severe forms of 
malaria (280).  New treatment of either disease need to be evaluated for safety of 
co-administration because of potential drug interactions (63, 278, 281). Sub-Saharan 
Africa is malaria endemic, so malaria is one of the most commonly encountered 
clinical conditions. Simultaneous management with HIV is complex due to potential 
drug-drug interactions (279, 282) and polypharmacy from multiple pills. 
Pharmacokinetic evaluation of the potential interaction of DTG with commonly 
prescribed antimalarial drugs [Artemether lumefantrine (AL) and artesunate-
amodiaquine (AS-AQ)], as sample of ACT is a relevant and important study that will 
ensure evidenced based best practices in the region when using DTG and ACT 
simultaneously for treating HIV patients. Treatment should aim at reducing 
therapeutic failure, recrudescence rate of malaria treatment and drug safety. ACT are 
effective in treatment of malaria and minimal resistance have been reported against 
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the drugs (283-285). Likewise DTG is potent antiretroviral agent and favoured for a 
potentially wider choice as first line treatment of HIV (60). It sufficiently suppresses 
viral loads to undetectable levels (<50 copies per mL) within few weeks (VIKING and 
SAILING trials) (286-289). 
 
Genetic variations of highly polymorphic UGT1A1 (major enzyme involve in the 
metabolism of DTG) in African populations (290), supports evaluation of these drugs 
in diverse ethnic groups to establish safety profiles in all populations in case of genetic 
variability in drug metabolism (187, 291, 292). The major metabolizing enzyme of 
DTG is UGT1A1 with a 10-15% contribution of CYP enzymes (CYP 3A4) (128). 
Artemisinin derivatives (artemether and artesunate) are converted to 
dihydroartemisinine (DHA) by CYP 3A4/5, 2B6 and 2A6 for artesunate (293). They in 
turn undergo glucoronidation by UGT1A1, to improve solubility for subsequent 
elimination (293). Both artemisinins and their metabolite DHA have antimalarial 
properties and induce rapid parasite clearance. Lumefantrine, from the halofantrine 
class of drugs is metabolized via CYP 3A4 and contributions from CYP 3A5 to its 
metabolite desethyl-lumefantrine (DBLF) (294, 295). Lumefantrine is long acting 
(half-life (t1/2) 3-6 days) and highly lipophilic, its bioavailability is increased by fatty 
meals and is highly variable. Both AL and DBLF are active against plasmodium (293). 
Amodiaquine is a 4-aminoquinoline with short elimination t1/2 of approximately 4-5 h 
(296, 297). It is converted to desethyl-amodiaquine (DEAQ), a potent metabolite with 
a terminal elimination t1/2 of 6-18 days (297). Amodiaquine undergoes oxidative bio-
activation to its metabolite N-desethyl-amodiaquine (DEAQ) via CYP enzymes 
(including CYP3A4, CYP2D6, CYP2C8 and CYP2C9) in the liver. DEAQ bio-activation is 
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also thought to be mediated via CYP2C9, CYP2D6 and CYP3A4 (298). Because of long 
elimination t1/2 of lumefantrine, amodiaquine and metabolites DEAQ and DBLF, 
recrudescence is prevented in malaria treatment due to their prolonged activity (299, 
300). Therefore combined effect of rapid parasite clearance from artemisin 
derivatives and prolonged clearance of parasites by the long-acting agents makes ACT 
an effective treatment option for malaria. 
 
Lack of adequate DTG safety data is still a concern and limits use in settings where 
patients cannot be properly monitored. Evaluating the pharmacokinetic safety of co-
administered DTG and ACT will contribute significantly to approval process by 
regulatory authorities. In view of the significance of simultaneous malaria and HIV 
treatment in the region, we sought to evaluate the pharmacokinetic drug-drug 
interaction of DTG and ACT (AL and AS-AQ) in healthy volunteers to determine if DTG 
can be safely use for treatment of HIV simultaneously with malaria in an African 
population.  
 
 
 
5.2 Methods 
5.2.1 Study Design 
DolACT (Clinical trials Identifier: NCT02242799) was a prospective, open label, fixed 
sequence healthy volunteer study of Ugandan HIV negative male or female (consent 
to use contraception throughout the trial period) subjects at Infectious Diseases 
Institute, Makerere University College of Health Sciences, that evaluated the 
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pharmacokinetic interactions between DTG and artemisinin based combination 
therapies (AL and AS-AQ). The study was divided into study A and B due to the long 
t1/2 of antimalarial metabolites. Study A, a cross over design, randomized (1:1) 14 
patients into two sequences of 7 patients each (sequence 1 and 2), calculated to have 
a power of >80% to detect changes in AUC outside the FDA limit of bioequivalence 
for DTG, with the assumption that LF CV ≤30% and ≥32% changes in DHA. Study B, a 
parallel group study design randomized 30 subjects into 2 equal arms of 15 each 
(arms 1 and 2) (Figure 1) was similarly calculated to yield 80% power to detect AUC 
difference of >25-30% (DTG and DEAQ), and a ≥42% change in DHA.  Study A (AL study 
group): Sequence 1 (S1)subjects received 6 doses of AL (80 mg artemether and 480 
mg lumefantrine) over 3 days, with rich PK sampling on day 3 (AL alone). Thirteen 
(13) time points (0-264 h post dose) were collected followed by a 21 day washout, 
after which a once daily 50mg of DTG was administered for 6 days with rich PK 
sampling (DTG alone) on day 34, and 8 time points (0-24h post dose) collected. AL 
and DTG were then administered for 3 days with PK (DTG and AL combined) on day 
38, and vice versa for S2. Study B subjects were randomised to Arm 1 or Arm 2 
(A1/A2) due to the long t1/2 of amodiaquine and its metabolites, making retention of 
volunteers unfeasible in a cross over design . A1 subjects received AS-AQ (4 mg/kg 
body weight of artesunate and 10 mg/kg body weight of amodiaquine) once daily for 
3 days with rich PK sampling (AS-AQ alone) on day 3 and 13 time points (0-264 h). A2 
subjects received 7 days of once daily 50 mg of DTG with PK sampling (DTG alone) on 
day 7 of 8 time points (0-24 h) , followed by 3 days of DTG and AS-AQ once daily and 
PK (AS-AQ and DTG in combination) on day 10. 
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Inclusion criteria were: Well informed and signed consent, willingness of participants 
to comply with all study requirements and schedules, age ≥ 18 years, weight ≥40kg, 
negative malaria blood film screening, HIV antibodies negative, willingness to use 
mosquito bednet throughout the study period and willingness to use barrier 
contraception throughout study duration. Exclusion criteria were abnormal 
creatinine levels, serum alanine transaminases, pregnant women or unwilling to use 
required contraception, abnormal ECG (prolong QT), known injection drug user, 
hepatitis B surface antigen positive, participant judged by clinician to likely be poorly 
adherent to treatment, other neurological, gastrointestinal and respiratory 
symptoms judged by clinician to be worsened by participating in the trial. The primary 
endpoint of this study were changes of pharmacokinetic parameters of antimalarials 
and DTG, and secondary endpoint were safety and tolerability of the drugs when co-
administered.  All clinical and laboratory adverse events were reported using DAIDs 
criteria (263). 
 
5.2.2 Sample Collection 
All drug administration were supervised and administered with moderate fatty meals 
to enhance absorption (301, 302). DTG steady state PK measurements were taken at 
0, 1, 2, 3, 4, 8, 12 and 24 hours post dose while AL and AS-AQ PK measurement were 
taken at 0, 1, 2, 3, 4, 8, 12, 24, 48, 72, 96 ,168 and 264 h post dose, and 0, 1, 2, 3, 4, 
8, 12, 24, 48, 72, 96, 120, 228, and 624 h post dose respectively. Blood samples were 
collected in lithium heparin collection tubes for AL and AS-AQ PK measurements to 
minimize ex-vivo degradation of artemisinins to DHA by plasma esterases (303), and 
ethylenediaminetetraacetic acid (EDTA) tubes to chelate polyvalent metals (242) for 
110 
 
DTG PK measurements. Blood samples were delivered to the laboratory within 15 
minutes of collection for separation of plasma within 3 hours of collection of blood 
samples. Approximately 2 mL of plasma was collected and stored at -80 oC until 
shipment (on dry ice) to the Bioanalytical Facility at The University of Liverpool for 
DTG analysis and Wellcome trust Mahidol Oxford Tropical Medicine Research Unit 
(MORU) for ACT analysis, using liquid chromatography-mass spectrometry (LC-MS), .  
5.2.3 Safety assessments 
Safety assessment included: Medical history, physical examination, 
electrocardiogram (ECG), urine pregnancy test, rapid malaria and HIV tests and safety 
bloods (haemoglobin, white cell count, platelets, urea, creatinine, electrolytes, ALT). 
Standard 12-lead ECG was performed at screening, intensive PK and at end of study. 
Safety blood investigations were repeated at every intensive PK visit and prior to 
discharge from the study. All laboratory and clinical abnormalities were noted and 
graded for severity according to the U.S National Institutes for Health Division of AIDS 
(DAIDS) Table for Grading Severity of Adult and Pediatric Adverse Events. 
 
5.2.4 Ethical Approvals 
This study was conducted in accordance with the principles of Helsinki declaration 
and current applicable versions of regulatory requirement. The study strictly adhered 
to the standards of research ethics as stipulated in the protocol and compliance with 
the ICH-GCP requirements. Protocol and ethical approval were obtained from Joint 
Clinical Research Centre Institutional review board, Ugandan National Council for 
Science and Technology and Research integrity and Governance and University of 
Liverpool research ethics committee, Liverpool UK. A signed inform consent was 
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obtained from each volunteer after clearly explaining the risk associated with the 
study and expected precautions subject were required to adhere to. Participants 
were free to withdraw from the study at any time they deemed risky to continue with 
the study.  
 
 
5.2.5 Bioanalysis 
DTG samples were analysed using a validated LC-MS method for measuring DTG in 
plasma [calibration range 10-4000 ng/ml and precision of 5% at low quality control 
(LQC)] at the Liverpool bioanalytical facility (BAF), A GCP accredited laboratory that 
participate in external Quality Assurance programmes. In brief, DTG was extracted 
using a liquid-liquid extraction method with tert-butyl-methyl ether (TBME) 
containing a stable isotope labelled internal standard dolutegravir-d5. Plasma 
samples were extracted, dried in a nitrogen drier and reconstituted in required 
proportion 80:20 (v/v) methanol/water, and 0.1% formic acid. The sequence was 
acquired using LQUAN software (Thermo Scientific, Hemel Hempstead, UK) and 
analytes resolved using reverse phase C18 XBridge (3.5µm: 2.1x50mm) column 
(Waters, Corporation, U.S.A) for quantification by a Thermo TSQ Access triple 
quadrupole mass spectrometer. 
DHA, artemether, artesunate, lumefantrine, DBLF, amodiaquine and DEAQ for AL and 
AQ-AS were analysed at MORU tropical health Network Laboratory Bankok, also a 
GCP accredited laboratory that participate in external Quality Assurance programmes  
using validated LC-MS methods (calibration ranges 1.14-575 ng/mL for DHA and 
artemether (assay coefficient of variation < 6%)  , 7.77-23000 ng/mL for lumefantrine 
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(coefficient of variation < 6%)    and 0.808-884 ng/mL for DBLF(coefficient of variation 
< 6%).  Calibration ranges of DHA in study B was 1.57-2875 ng/mL (coefficient of 
variation < 7%), artesunate was 0.952-837 ng/mL (coefficient of variation < 7%), 
amodiaquine was 0.864-302 ng/mL and DEAQ was 1.13-702 ng/mL (coefficient of 
variation < 8%) respectively (303-305).  
 
5.2.6 Statistical analysis 
5.2.6.1 Study A 
Pharmacokinetic parameters for DTG [Maximum plasma concentration (Cmax), time 
to maximum concentration (Tmax), t1/2, minimum plasma concentration in 24 hours 
(C0-24) and area under the concentration curve (AUC0-24)], artemether [Cmax, Tmax, t1/2, 
plasma concentration from time zero to trough concentration (C0-t) and area under 
the concentration curve from time zero to trough concentration (AUC0-t)] and DHA 
(Cmax, Tmax, t1/2, C0-t and AUC0-t), and lumefantrine and DBLF (Cmax, Tmax, t1/2, C0-t, AUC0-
t) were estimated using non-compartmental analysis (WinNonlin, Phoenix, version 
6.1, Pharsight, Mountain View, CA). Subject changes were assessed using geometric 
mean ratios (GMR) with 90% confidence intervals (GMR 90% CI), by log-
transformation of PK data and geometric mean ratios (GMR), with 90% CI evaluated 
using paired (Study A) or unpaired (Study B) t-tests which were then back-
transformed to absolute ng/mL concentrations.  
 
5.2.6.2 Study B 
Pharmacokinetic parameters for DTG (Cmax, Tmax, t1/2, C0-24 and AUC0-24), artesunate 
(Cmax, Tmax, t1/2, C0-t and AUC0-t and DHA (Cmax, Tmax, T1/2, C0-t and AUC0-t), amodiaquine 
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and DEAQ (Cmax, Tmax, t1/2, C0-t and AUC0-t) were calculated using (WinNonlin, Phoenix, 
version 6.1, Pharsight, Mountain View, CA) and geometric means and GMR to 
determine associations. AS-AQ PK data were log-transformed and the 90% CI derived 
using an unpaired t-test, after which the values were back-transformed to absolute 
ng/mL concentrations. An analysis of variance (ANOVA) was performed by SPSS 
(Windows Standard version 22, SPSS, Chicago) on PK parameters (AUC0-t, Cmax, C24) to 
assess potential sequence and period related effects.  
 
5.3 Results 
A total of 48 adult male or female subjects age 21-34 years were recruited in the 
study, and 39 completed the study. Study A sequence 1 and 2 had 14 volunteers 
randomized to sequence 1&2 of 7 each in a crossover study design which evaluated 
the pharmacokinetic interaction of AL and DTG. In Study B (Arm 1 and 2) 13 subjects 
were randomized to arm1 and 12 subjects in arm 2 in a parallel study design that 
evaluated the pharmacokinetic interaction of AS-AQ and DTG. All subjects were 
healthy by history, vital signs, physical examinations, electrocardiograms and 
laboratory results. There was good adherence to drugs and drugs were well tolerated 
by subjects throughout the study period (Table 5). 
 
5.3.1 Study A 
5.3.1.1 Impact of Artemether lumefantrine on Dolutegravir Pharmacokinetics 
Artemether lumefantrine had no significant impact on DTG AUC0-24 Cmax or Tmax in 
both study arms (Table 1 and figure 2). There was a 37% decrease in the DTG C0-24 
114 
 
[0.63 (0.48, 0.82)], however this was thought to be driven by an unexplained rise in 
C0-24 values of some subjects in DTG alone arm as shown by the individual PK plots; 
(figures 4 and 6) who appeared to have a spike in the DTG concentrations after the 
C12 time point. Despite a statistically significant decrease in the DTG C0-24, the 
minimum measured C0-24 concentration of 1543.11 ng/mL was higher than the mean 
trough concentration (1100 ng/ml) reported in prior phase II trials (172, 306, 307). 
Geometric means (%CV) of the following pharmacokinetic parameters: t1/2, Tmax, Cmax, 
C0-24 and AUC0-24 in DTG alone arms were 24.29 (61.26) h, 3.94 (103.65) h, 5018.44 
(22.24) ng/mL, 2456.50 (34.10) ng/mL and 78753.39 (22.73) ng.h/mL respectively. 
When DTG was administered with AL, the PK parameters [Geomean (%CV)] were 
13.01 (42.67) h, 3.00 (68.61) h, 5216.45 (25.02) ng/mL, 1543.11 (54.27) ng/mL and 
73738.47 (30.48) ng.h/mL respectively (Table 1 and Figures 2-7), and there were no 
significant difference from the DTG only phase. The ANOVA showed no significant 
sequence effect upon DTG pharmacokinetics, but there was a significant period effect 
(DTG alone versus. DTG plus AL) for DTG C24 in both arms (p=0.025).  
 
5.3.1.2 Impact of DTG on PK of AL and its metabolites (Artemether, 
Dihydroartemisinin (DHA), lumefantrine and Desbutyl-lumefantrine (DBLF)) 
DTG administration had no significant impact on artemether, DHA, lumefantrine (LF) 
and desbutyl-lumefantrine (DBLF) PK parameters (Table 3 & figure 8). The t1/2, Tmax, 
Cmax, C0-t and AUC0-t of parent drug and metabolite were not significantly altered with 
or without DTG. Geometric means (%CV) of artemether for the following: t1/2, Tmax, 
Cmax, C0-t and AUC0-twere: 4.92 (62.69) h, 2.03 (40.31) h, 31.93 (64.43) ng/mL, 2.88 
(69.09) ng/mL and 129.58 (70.15) ng.h/mL for AL alone, and 7.28 (55.92) h, 2.16 
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(39.40) h, 27.88 (93.12) ng/mL, 2.05 (105.97) ng/mL and 136.44 (85.19) ng.h/mL for 
AL plus DTG, respectively. The geometric means (%CV) of artemether metabolite 
(DHA) PK parameters (t1/2, Tmax, Cmax, C0-t and AUC0-t) were 2.54 (39.12) h, 2.31 (31.13) 
h, 110.43 (34.36) ng/mL, 3.01 (68.24) ng/mL and 389.26 (25.37) ng.h/mL for AL alone 
and 3.01 (95.80) h, 2.70 (53.91) h, 89.91 (42.50) ng/mL, 3.97 (79.21) ng/mL and 
357.26 (47.85) ng.h/mL for AL plus DTG respectively (Table 3 and Figures 8-28).  
Lumefantrine (LF) and its metabolite DBLF were also not impacted by DTG. Geometric 
means (%CV) of the following LF PK parameters (t1/2, Tmax, Cmax, C0-t and AUC0-t ) were 
83.44 (18.87) h, 3.92 (64.52) h, 9975.96 (35.89) ng/mL, 6638.10 (38.99) ng/mL, 
280.05 (30.43) ng/mL and 389350.00 (31.08) ng.h/mL for AL minus DTG, and 86.13 
(24.66) h, 6.48 (121.62) h, 11203.12 (32.21) ng/mL, 7797.55 (31.64) ng/mL, 
302.93(29.87) ng/mL and 429736.05 (25.38) ng.h/mL for AL plus DTG respectively. LF 
metabolite DBLF geometric mean (%CV) t1/2, Tmax, Cmax, C0-t and AUC0-t were 141.57 
(17.85) h, 4.78 (54.86) h, 51.75 (54.36) ng/mL, 46.68 (54.71) ng/mL, 11.27 (49.72) 
ng/mL and 6299.72 (48.12) ng.h/mL for AL minus DTG, and 162.12 (36.28) h, 9.52 
(91.94) h, 49.95 (35.87) ng/mL, 46.16 (36.38) ng/mL, 11.34 (31.29) ng/mL and AUC0-t 
6048.71 (29.36) ng.h/mL for AL plus DTG respectively (Table 3 and Figures 8-28). The 
ANOVA showed no evidence of a significant sequence or period effect upon AL 
pharmacokinetics. 
5.3.2 Study B 
5.3.2.1 Impact of AS-AQ on DTG Pharmacokinetics  
Co-administration of AS-AQ with DTG resulted in an approximate 42% and 24% 
decrease in DTG C24 and AUC0-24 [0.58 (0.50, 0.69) and 0.76 (0.69, 0.84)] respectively 
(Table 2 and Figures 2). However, despite the decreased DTG concentration, the 
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minimum measured concentration (1543.11 ng/mL) was higher than the reported 
trough concentration derived from population modelling (172). Therefore although 
statistically significant, it is not clinically significant to warrant any recommendation 
for dose adjustment when administered together. DTG was well tolerated with AS-
AQ and geometric mean (%CV) of PK parameters t1/2, Tmax, C0-24, Cmax and AUC0-24 were 
16.21 (34.77) h, 3.69(49.49) h, 2174.32 (51.70) ng/mL, 5114.41 (22.18) ng/mL and 
77936.06 (26.34) ng.h/mL for DTG alone, and 13.31 (29.22) h, 2.66 (58.60) h, 1271.93 
(37.90) ng/mL, 4666.70 (31.27) ng/mL, 59490.93 (24.06) ng.h/mL respectively for AS-
AQ plus DTG (Table 2, figures 2 and 30-32) .  
 
5.3.2.2 Impact of DTG on AS-AQ PK and metabolites (Dihydroatemisinin (DHA), 
and Desethylamodiaquine (DEAQ)) 
AS-AQ is a combination of two potent antimalarials artesunate and amodiaquine. 
Although statistically significant changes were observed in the DTG PK parameters 
C24 and AUC0-24 when co-administered, no significant impact was observed for the 
antimalarial and their metabolites (Table 4 and Figure 29-36). When AS-AQ was 
administered alone, the geometric mean (%CV) of artesunate PK parameters t1/2, 
Tmax, Cmax, C0-t, and AUC0-t were 1.85 (104.15) h, 1.17 (65.37) h, 61.29 (60.56) ng/mL, 
0.72 (162.19) ng/mL, and 128.38 (55.19) ng.h/mL respectively. DHA PK parameters 
were t1/2 2.22 (170.10) h, Tmax 1.58 (52.38) h, Cmax 217.66 (52.8) ng/mL C0-t 3.56 
(157.48) ng/mL, and AUC0-t 788.25 (42.45) ng.h/mL. Amodiaquine geometric mean 
(%CV) PK parameters t1/2, Tmax, Cmax, C0-t, and AUC0-t were 15.83 (20.80) h, 2.36 (94.28) 
h, 17.97 (33.44) ng/mL, 0.43 (0) ng/mL, and 256.14 (27.25) ng.h/mL and DEAQ were 
t1/2 243.68 (11.77) h, Tmax 2.68 (57.01) h, Cmax 393.96 (35.47) ng/mL, C0-t 15.13 (21.29) 
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ng/mL and AUC0-t 31492.83 (18.92) ng.h/mL. When co-administered with DTG, 
geometric means (%CV) artesunate PK parameters (t1/2, Tmax, Cmax, Ct and AUC0-t) were 
1.17 (50.54) h, 1.66 (56.54) h, 52.01 (67.78) ng/mL, 0.53 (61.36) ng/mL and 115.71 
(50.32) ng.h/mL respectively. DHA PK parameters were t1/2 1.60 (23.97) h, Tmax 2.02 
(46.90) h, Cmax 290.43 (56.64) ng/mL, C0-t 3.33 (171.73) ng/mL and AUC0-t 946.78 
(38.23) ng.h/mL. PK parameters for amodiaquine were t1/2 14.79 (29.58) h, Tmax 1.97 
(50.59) h, Cmax 19.17 (33.46) ng/mL, C0-t 0.43 (0) ng/mL and AUC0-t 225.02 (23.68) 
ng.h/mL and DEAQ were t1/2 182.45 (40.74) h, Tmax 3.38 (54.68) h, Cmax 385.57 (20.66) 
ng/mL, C0-t 232.56 (24.61) ng/mL and AUC0-t 26943.12 (29.72) ng.h/ml respectively 
(Table 4 and Figures 29 and 33-36). 
 
5.4 Discussions 
We report for the first time that AL and AS-AQ combinations are both well tolerated 
and can be safely co-administered to patients receiving DTG. The study evaluated the 
PK interaction of AL and DTG and found changes in PK parameters of DTG, 
artemether, DHA, lumefantrine or DBLF when co-administered in healthy volunteers. 
The statistically significant decrease in DTG C0-24 by 37% was difficult to explain. 
Artemether and its metabolite DHA are known to induce CYP 3A4 and artemisin 
autoinduction is detectable for up to a week after administration which can affect 
medications pharmacology even after several days (308). Additional administration 
of DTG prior to next dosing was unlikely, because exact pills were given to 
participants and drug administration was closely monitored. 
AS-AQ and DTG interaction resulted in statistically significant decrease in DTG C0-24 
and AUC0-24 by 42% and 24% respectively, but in both instances, C0-24 (1.27 µg/mL) in 
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the AS-AQ +DTG study group was still above minimum concentrations (Cmin) (1.11 
µg/mL after a once daily 50mg dose) reported in previous trials steady state DTG Cmin 
and population PK (172, 309).  
 
Decrease in DTG C0-24 (AL arm) and DTG C0-24 and AUC0-24 (AS-AQ arm) is unlikely to be 
clinically significant to warrant dose adjustment since. Subjects who received DTG 
with AL or AS-AQ, with DTG had comparable Ctrough to or above 1100ng/mL (192). 
(The mean Ctrough observed in previous DTG phase III adults trials and FDA approval 
trial study). The target minimum effective concentration for DTG is unknown, 
although a DTG minimum effective concentration (MEC) of 324ng/mL has been 
proposed (168, 176). A value derived from a phase II ten days dose ranging study of 
DTG monotherapy, found to be associated with virological efficacy. C0-24 (Ctrough) in all 
subjects were higher than previously reportedclinical trials (195), and were 
considerably higher than the estimated protein adjusted IC90 (64 ng/ml) of DTG (176). 
Assuming DTG concentration of less than 324 ng/mL is considered to be the sub-
therapeutic level of DTG and given the t1/2 of approximately 14 h, it will require about 
2 missed doses (48-72 h post dose) for DTG Ctrough concentration to be less than 324 
ng/mL (170, 310), and since antimalarial treatment is just for three days, DTG 
decrease is not expected to be below 324ng/mL before completion of malaria 
treatment. 
Previous reports of DTG PK has been predominantly in Caucasian populations or 
mixture of different ethnicities, but this study was exclusively conducted in African 
population and high plasma concentration could be associated with some genetic 
polymorphisms. Therefore evaluation of other factors such as polymorphisms of CYPS 
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and UGT1A1 enzymes to determine potential genetic reason for the higher 
concentrations measured will help answer some of the unexplained findings.  
Previous reports of interactions of AL and AS-AQ with other antiretrovirals have 
suggested potential interaction of artemether and artemisinin with inhibitors of 
CYP3A4 such as Cobicistat, ritonavir, and elvitegravir (308, 311). DHA was also 
reported to be largely glucuronidated via UGT1A9 and DTG is a substrate of UGT1A9, 
suggesting potential interaction of DTG with drugs metabolized via these pathways, 
but that was not observed in this study (279). DTG was therefore observed to have a 
low propensity to drug-drug interaction and there was no drug-drug interaction 
between DTG and ACT. Therefore no dose adjustments is required in co-
administration of the two medications. 
This study was conducted in healthy volunteers who have negative malaria smear 
and are HIV negative. However, drug absorption in HIV positive patients differs from 
HIV negative subjects (293, 312, 313). It is influenced by changes in gut mucosa, 
microbiome and other pathological changes induced by HIV. Antimalarial PK and PD 
is also highly variable in malaria patients (314). The PK-PD changes in the course of 
treatment is influenced by parasite density (315). This makes antimalarial PK 
evaluation in malaria patients difficult. Conducting studies in healthy subjects 
provides baseline information for PK-PD modelling of antimalarial AL and AS-AQ that 
can be used in a population PK model to predict PK-PD parameters in an infected 
patients. 
 
All adverse events (AEs) were Grade 1 or 2 in severity with more predominantly 
gastro-intestinal AEs, among participants who received AS-AQ, and no serious 
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adverse events were reported. Haematological (haemoglobin, white blood cells and 
platelets), biochemical (electrolytes, creatinine, urea and ALT) and 
electrocardiographic (QT interval) parameters evaluated throughout the trial period 
for both AL and AS-AQ were within normal ranges and no safety concerns were 
encountered throughout the trial. Although the chemical similarity of halofantrine 
and lumefantrine, was a potential risk of QT prolongation and arrhythmias among AL 
arm subjects, none was encountered throughout the study. Other established side 
effects of artemether lumefantrine such as headache, loss of appetite and 
generalized body weakness were also well tolerated. Known side effects of 
amodiaquine such as nausea, vomiting, vertigo and generalized body weakness were 
minimal and well tolerated by volunteers, so was also the side effects of DTG. 
 
 
5.5 Conclusion 
This Study is relevant and timely considering the planned roll out of DTG in low and 
middle income countries. The data will guide co-administration of DTG and ACT in 
HIV patients, without risk of inadequate parasite clearance and recrudescence from 
sub-optimal drug exposure. The short duration of antimalarial therapy, and clinically 
insignificant impact of DTG on ACT concentration makes it safe for DTG to be co-
administered with ACT. This data will provide useful information that will guide 
national policy makers and DTG approval process in malaria endemic regions of the 
world. 
Figure 1: Schedules and procedures of study 
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Table 1: Pharmacokinetic parameters [geometric mean (90% CI)] and Geometric 
Mean Ratio (GMR) of DTG in Study A (DTG+AL) 
 
 
Table 2: Pharmacokinetic parameters [geometric mean (90% CI)] and Geometric 
Mean Ratio (GMR) of 
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DTG in Study B (DTG+AS-AQ)
 
Figure 2: Geometric mean ratios (90% Confidence intervals) of Dolutegravir in 
study A and B (GMR; Geometric mean ratio, LCL; lower confidence level, UCL; 
upper confidence level) 
 
 
 
 
Pharmacokinetic Summary of DTG: Study A 
Geometric mean (90% confidence intervals) pharmacokinetic profile  
 
Figure 3. Summary of DTG PK Data (DTG ± AL) 
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STUDY A: SEQUENCE 1 (n=7)  
Individual PK profiles [Geometric mean shown by solid black line] 
Figure 4. DTG Alone  
 
Figure 5. DTG +Artemether Lumefantrine  
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STUDY A: SEQUENCE 2 (n=7)  
Individual PK profiles [Geometric mean shown by solid black line] 
Figure 6. DTG Alone (Day 6; n=7)  
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Figure 7. DTG +Artemether Lumefantrine (Day 10; n=7)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
0 5 10 15 20 25
D
TG
 C
o
n
ce
n
tr
at
io
n
 (n
g/
m
L)
Time (h)
1209
1211
1212
1213
1214
1247
1248
Gmean
126 
 
Table 3: Pharmacokinetic parameters [geometric mean (90% CI)] and Geometric 
Mean Ratio (GMR) 
Artemether and Lumefantrine 
Study A 
(n=14) AL alone  AL+ DTG GMR (90%CI) 
Artemether  
Cmax (ng/mL) 31.93 (20.60, 43.26) 27.88 (10.30, 45.47) 
0.87 (0.67, 
1.14) 
Tmax (h) 2.03 (1.64, 2.43) 2.16 (1.75, 2.56) 
1.06 (0.84, 
1.34) 
AUC0-t 
(ng.h/mL) 129.58 (79.35, 179.82) 136.44 (60.29, 212.59) 
1.05 (0.84, 
1.32) 
Dihydroartemisinin  
Cmax (ng/mL) 110.43 (92.86, 127.99) 89.91 (71.07, 108.74) 
0.81 (0.64, 
1.03) 
Tmax (h) 2.31 (1.98, 2.64) 2.70 (1.99, 3.42) 
1.17 (0.92, 
1.49) 
AUC0-t 
(ng.h/mL) 389.26 (344.52, 434.01) 
357.26 (274.89, 
439.63) 
0.92 (0.79, 
1.07) 
Lumefantrine 
Cmax (ng/mL) 
9975.96 (8318.44, 
11633.47) 
11203.12 (9533.23, 
12873.02) 
1.12 (0.97, 
1.29) 
Tmax (h) 3.92 (2.49, 5.35)* 6.48 (1.43, 11.54)# 
1.65 (1.02, 
2.69) 
AUC0-t 
(ng.h/mL) 
389350.00 (333607.59, 
445092.41) 
429736.05 
(379911.49, 
479560.61) 
1.10 (0.96, 
1.27) 
Desbutyl-lumefantrine 
Cmax (ng/mL) 51.75 (37.50, 66.00) 49.95 (41.54, 58.35) 
0.97 (0.79, 
1.18) 
Tmax (h) 4.78 (3.43, 6.12) 9.52 (4.48, 14.56)# 
3.00 (2.06, 
4.36) 
AUC0-t 
(ng.h/mL) 
6299.72 (4803.87, 
7795.57) 
6048.71 (5235.34, 
6862.09) 
0.96 (0.80, 
1.15) 
127 
 
 
 Figure 8: Geometric means (90% Confidence Intervals) of Artemether DHA, 
Lumefantrine and DBLF (GMR; Geometric mean ratio, LCL; lower confidence level, 
UCL; upper confidence level) 
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Pharmacokinetic Summary (Artemether-lumefantrine; AL) 
Artemether 
 
Geometric mean (90% confidence intervals) Artemether pharmacokinetic profile  
 
Figure 9: AL ± DTG 
 
SEQUENCE 1 (n=7)  
Individual Artemether PK profiles [Geometric mean shown by solid black line] 
Figure 10: AL Alone 
 
Figure 11: DTG +AL  
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SEQUENCE 2 (n=7) 
Figure 12: AL Alone 
 
Figure 13: DTG +AL 
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Dihydroartemisinin (DHA) 
 
Geometric mean (90% confidence intervals) DHA pharmacokinetic profile  
 
Figure 14: AL ± DTG 
 
 
Individual DHA PK profiles [Geometric mean shown by solid black line] 
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Figure 15: AL Alone  
 
Figure 16: DTG +AL  
 
 
 
STUDY A: SEQUENCE 2 (n=7)  
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Figure 17: AL Alone 
 
Figure 18: DTG +AL 
 
Lumefantrine Geometric mean (90% confidence intervals) pharmacokinetic profile  
Figure 19: AL ± DTG 
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Individual Lumefantrine PK profiles [Geometric mean shown by solid black line] 
SEQUENCE 1 (n=7) Figure 20: AL Alone 
 
Figure 21: DTG +AL  
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SEQUENCE 2 (n=7)  
Figure 22: AL Alone
 
Figure 23: DTG +AL 
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Desbutyl-lumefantrine (DBL)  
Geometric mean (95% confidence intervals) pharmacokinetic profile  
Figure 24: AL ± DTG 
 
Individual DBL PK profiles [Geometric mean shown by solid black line] 
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Figure 25: AL Alone 
 
Figure 26: DTG +AL  
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0
10
20
30
40
50
60
70
80
90
0 24 48 72 96 120 144 168 192 216 240 264
D
B
L 
C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
Time (h)
1101
1102
1103
1104
1105
1106
1108
Gmean
0
10
20
30
40
50
60
70
80
90
0 24 48 72 96 120 144 168 192 216 240 264
D
B
L 
C
o
n
ce
n
tr
at
io
n
 (
n
g/
m
L)
Time (h)
1101
1102
1103
1104
1105
1106
1108
Gmean
137 
 
Figure 27: AL Alone  
 
Figure 28: DTG +AL  
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Table 4: Pharmacokinetic parameters [geometric mean (90% CI)] and Geometric 
Mean Ratio (GMR) of AS-AQ 
Study B 
AS-AQ alone (Arm 1, 
n=13) 
AS-AQ + DTG (Arm 2, 
n=12) GMR (90% CI) 
Artesunate  
Cmax (ng/mL) 61.29 (41.54, 81.04) 52.01 (31.70, 72.33) 0.85 (0.56, 1.28) 
Tmax (h) 1.17 (0.78, 1.56) 1.66 (1.14, 2.17) 1.41 (1.01, 1.98) 
AUC0-t 
(ng.h/mL) 128.38 (90.81, 165.94) 115.71 (83.22, 148.21) 0.90 (0.59, 1.37) 
Dihydroartemisinin  
Cmax (ng/mL) 217.66 (157.37, 277.95) 290.43 (197.26, 383.59) 1.33 (0.88, 2.02) 
Tmax (h) 1.58 (1.16, 2.00) 2.02 (1.52, 2.52) 1.28 (0.91, 1.79) 
AUC0-t 
(ng.h/mL) 788.25 (622.06, 954.43) 946.78 (760.15, 1133.40) 1.20 (0.89, 1.62)  
Amodiaquine 
Cmax (ng/mL) 17.79 (14.91, 20.68) 19.17 (15.95, 22.39) 1.08 (0.84, 1.38) 
Tmax (h) 2.36 (1.06, 3.65) 1.97 (1.43, 2.51) 0.84 (0.55, 1.27) 
AUC0-t 
(ng.h/mL) 256.14 (222.52, 289.76) 225.02 (198.93, 251.10) 0.88 (0.72, 1.07) 
N-desethylamodiaquine 
Cmax (ng/mL) 393.96 (325.91, 462.01) 385.57 (346.81, 424.33) 0.98 (0.79, 1.21) 
Tmax (h) 2.68 (1.88, 3.49) 3.38 (2.41, 4.36) 1.26 (0.89, 1.78) 
AUC0-t 
(ng.h/mL) 
31492.83 (28720.90, 
34264.76) 
26943.12 (22913.01, 
30973.23) 0.86 (0.70, 1.05)  
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Figure 29: Geometric means and 90% Confidence Intervals of Artesunate, DHA, 
Amodiaquine and DEAQ (GMR; Geometric mean ratio, LCL; lower confidence level, 
UCL; upper confidence level)
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STUDY B: (n=12)  
Geometric mean (90% confidence intervals) pharmacokinetic profile  
Figure: 30 
 
STUDY B: ARM 2 (n=12)  
Individual PK profiles [Geometric mean shown by solid black line] 
Figure 31:  DTG Alone  
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Figure 32: DTG +Artesunate Amodiaquine 
 
Pharmacokinetic Summary (Artesunate Amodiaquine; AS-AQ) 
Figure 33: Artesunate 
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Figure 34: Dihydroartemisinin (DHA) 
 
Figure 35: Amodiaquine 
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Figure 36: N-desethyl-amodiaquine 
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Table 5: Baseline Demographics and Laboratory markers of adverse events 
Parameters (n=39)  
[Mean (Range)] 
Study A (n=14) Study B (n=25) 
Sequence 1 
(n=7) 
Sequence 2 
(n=7) 
Arm 1 
(n=13) 
Arm 2 (n=12) 
Age (years) 29 (21-32) 
292929 
25 (23-29) 24 (23-28) 30.5 (23.5-34) 
Weight (Kg) 55.5 (54-64) 59 (54-62) 59.5 (57-
65) 
60.25 (58-
68.25) BMI (Kg/m2) 21.1 (17-
22.8) 
21.2 (20.1-
21.5) 
21.4 (19.8-
24.5) 
20 5 (18.95-
24.5) Haemoglobin (g/dL) 15 1 (13.3-
17.7) 
14 7 (13.7-
17.0) 
15 2 (13.5-
16.2) 
15 3 (14.5-
16.3) ALT (IU/L) 2 (9-20) 5 (12-17) 5 (13-19) 8 (13-20) 
Total bilirubin 
(mg/dL) 
0.7 (0.4-0.9) 0.6 (0.4-1.1) 0.5 (0.3-
0.7) 
0.6 (0.35-1.65) 
Potassium (mmol/ L) 4.3 (3.9-4.4) 4 (3.7-4.3) 4 (3.9-4.2) 4.5 (4.3-4.75)) 
Urea  (mg/dL) 7 (6-9) 7 (6-9) 7 (5-8) 8 (6.5-11) 
Creatinine (mg/dL) 0.76 (0.59-
0.93) 
0.75 (0.62-
0.79) 
0.82 (0.67-
0.92) 
0.85 (0.69-
0.92) Creatinine Kinase 
(U/L) 
102 (89-
245) 
183 (129-
251) 
136 (114-
238) 
142 (132-183) 
ECG corrected QT 
interval (ms) 
387 (378-
407) 
415 (397-
429) 
396 (369-
408) 
400.5 (373.5-
414.5)  
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CHAPTER 6 
 Impact of Pharmacogenetics and Pregnancy on Tenofovir and 
Emtricitabine Pharmacokinetics. 
 
6.1 INTRODUCTION 
Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in combination are the 
most common components of WHO-recommended first-line combination 
antiretroviral therapy (cART) regimens recommended for prevention of mother-to-
child transmission (PMTCT) of HIV (8, 161, 316, 317) and first-line regimens for 
treatment of adults, adolescents and pre-exposure prophylaxis (PrEP) (161). 
Knowledge of anticipated pharmacokinetic (PK) parameters has been derived in non-
pregnant adult (94, 172, 318), but physiologically, pregnancy alters absorption, 
distribution, metabolism and elimination of drugs (319). Pregnancy also induces 
changes in gastric pH, intestinal transit time, progesterone production and 
glomerular filtration rates, significantly changing pharmacokinetics (318, 319), 
inducing modifications in bioavailability, volume of distribution (Vd) and clearance of 
drug (CL) (319, 320). 
Genetic polymorphisms of drug transporters are known to influence the 
pharmacokinetics of FTC and TDF active moiety tenofovir (TFV) during pregnancy (8, 
316).  Marked increases in 17 β estradiol significantly influence FTC and TFV excretion 
due to genetic modulation of ABCC4 transporters (318, 321-323). ABCC4 transporters 
as potent inhibitors of 17 β estradiol also impact on TFV plasma exposure and TFV 
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elimination via the kidneys (324-326).  After an initial metabolic conversion of TDF to 
TFV by esterase hydroxylation and subsequent intracellular phosphorylation by 
nucleotide kinase to tenofovir phosphate, TFV is finally excreted unchanged by 
glomerular filtration and active tubular secretion via renal transporters (327, 328). 
Likewise, FTC is also excreted predominantly unchanged via the kidneys, but 
excretion is predominantly influenced by  ABCC2 in both pregnant and postpartum 
mothers (327, 329). Excretion of TFV and FTC in kidneys and trans-placental transport 
is regulated by substrate specific efflux and influx transporters (328). Single 
nucleotide polymorphisms (SNPs) of transporters regulatory genes have also been 
associated with maternal exposure and viral suppression during pregnancy (172, 319, 
320). These polymorphisms in ABCC class of transporters influences 
pharmacokinetics of FTC with consequential effect on drug distribution during 
pregnancy (325, 326, 330).  For instance, FTC is an ABCC1 substrate eliminated 
primarily unchanged via the kidneys (330). It is also excreted in breast milk and 
crosses placental membrane to the fetal compartment in significant amount, and can 
all be modulated by pregnancy (328). 
While these changes in pharmacokinetics of widely prescribed antiretroviral (ART), 
including TFV and FTC, have been reported in pregnancy, only limited data is available 
for combined influence of pregnancy and pharmacogenetics on TFV and FTC PK (319, 
321, 322, 331). This study hypothesised that combined effect of pregnancy and 
pharmacogenetics result in significant changes in FTC and TFV pharmacokinetics, and 
aimed at investigating the impact of pharmacogenetics on changes in FTC and TFV 
pharmacokinetics during pregnancy. 
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6.2 METHODS 
6.2.1 Study population and selection criteria   
HIV-positive pregnant and postpartum women were recruited from three hospitals 
in Benue State Nigeria: Bishop Murray Medical Centre, Makurdi; St. Monica’s 
Hospital, Adikpo; and St. Mary’s Hospital, Okpoga.  The original study was conducted 
between December 2012 and October 2013 to evaluate the pharmacogenetics of 
pregnancy-induced changes and breastfed infants’ exposure to efavirenz and 
nevirapine during pregnancy and postpartum, respectively (323, 332). For the 
present analysis, samples were selected to evaluate the influence of genetics and 
pregnancy on TFV and FTC. Pregnant and postpartum women taking ART regimens 
containing TDF and FTC were included. Participants were excluded if samples were 
collected within four hours of dosing. A total of 61 women (31 pregnant and 30 
postpartum) were eligible and evaluated for both drug concentrations and selected 
SNPs. 
Permission was obtained from the hospitals management and consent forms signed 
by participant before recruitment. Protocol and materials transfer agreements were 
approved by the National Health Research Ethics Committee (NHREC) Abuja Nigeria. 
 
6.2.2 Study Design 
This was an observational study of HIV-positive women conducted to evaluate the 
relationship between selected single nucleotide polymorphisms (SNP) and drug 
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concentrations in pregnant and postpartum women. Drug concentrations were 
quantified at single time points (4-18 h post observed dose) for each patient, and 
allele and genotype frequencies evaluated to determine association between TFV 
and FTC concentrations in pregnant and postpartum women. Five (5) ABCC2 and 
ABCC4 transporter SNPs were evaluated for impact of polymorphism on drug 
exposure in pregnancy and postpartum. SNPs with minor allele frequency (MAF) of 
≥25% were investigated for polymorphisms in renal tubular transporters that 
significantly affect drug pharmacokinetics in pregnancy. The choice of SNPs of MAF ≥ 
25% was because of the small sample size. The study was an additional evaluation of 
genetics and PK of TFV and FTC from samples of previous study where EFV and NVP 
pharmacogenetics and PK was evaluated. Therefore, samples that meet the study 
criteria were few. Drug concentrations in pregnant and postpartum women were also 
measured and relationship between genetic polymorphisms, TFV and FTC blood 
concentrations were assessed. The reference minor allele frequency of the Yoruba 
ethnic group, a subset of Nigerian population, was used to determine the 
polymorphic genes to be evaluated. Genes with minor allele frequency ≥25% include: 
ABCC2 154962860T>C, 35%, ABCC2 32293730T>C, 38% ABCC4 95020696A>G, 29%, 
ABCC4 95021537A>C, 25%, ABCC4 13: 95062722C>T 27%  [8]. 
 
6.2.3 Tenofovir and Emtricitabine Quantification  
TFV and FTC concentrations in blood was measured from dried blood spots (DBS) 
using validated LC-MS method (235). Assay calibration range 16- 4000 ng/mL and 
internal standards 2CA and TFV-d6 were used for assay proficiency. Measured drug 
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concentrations were used to evaluate the relationship between drug concentrations 
and genetic polymorphism of SNPs using a regression model.  
 
6.2.4 Genotyping 
Genotyping for ABCC2 12:g.154962860T>C, ABCC2 12:g.32293730T>C, ABCC4 
11:g.95020696A>G , ABCC4 11:g.95021537A>C  and ABCC4 13: 95062722C>T  was 
performed by real time polymerase chain reaction (PCR) allelic discrimination using 
standard Taqman assays. Genotypes assignment and allelic discrimination plots were 
performed on a chromo4 system (Bio-Rad Laboratories, Hercules, CA) and Opticon 
Monitor version 3.1 software (Bio-Rad Laboratories). The PCR protocol involved 
denaturation of DNA at 95oC for 10 minutes, 40 cycles of amplification at 95oC for 15 
seconds and annealing at 60 oC for 1 min.  
 
6.2.5 Statistical analyses 
Allelic and genotype frequencies were evaluated to ensure Hardy-Weinberg 
equilibrium was maintained. The following SNPs: ABCC2 12:g.154962860T>C, ABCC4 
11:g.95020696A>G and ABCC4 11:g.95021537A>C were in Hardy-Weinberg 
equilibrium (P value >0.05) except ABCC2 12:g.32293730T>C (X2 = 4.8, P<0.01) and 
ABCC4 13: 95062722C>T (X2 = 5.05, P<0.01) respectively which compromised their 
interpretation. Normality was checked for continuous variables using Shapiro Wilk 
test, which was statistically significant (p<0.001), and variables were log transformed. 
Univariate linear regression models were used to determine the relationship 
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between drug concentrations and other variables (age, regimen, time post dose) in 
SPSS version 23.0. Covariates with P-value ≤ 0.2 were further entered into a 
multivariate model in a stepwise fashion and analysed for relationship between the 
groups. Missing covariate >10% were managed by excluding the sample from the 
regression analysis. Within groups relationships were analysed by first creating 
dummy variables and subsequently entered into a model to determine specific 
relationships with genotypes. Output of this analysis enabled determination of the 
relationship between drug concentrations at different time points with pregnancy, 
postpartum and the SNPs. All charts were plotted using Graph pad prism 5.0 
(GraphPad Software Inc). 
 
 
6.3 RESULTS 
Pregnant and postpartum women on once daily FTC and TDF were evaluated at single 
time points median (range) 14 (4-18) h post dose for drug levels and associations with 
polymorphisms in genes using regression models. Of the 61 (31 pregnant and 30 
postpartum women) evaluated, the median (range) age and weight of pregnant 
women was 29 (17-42) years and 57 (48-79) kg respectively, and postpartum women 
were 30 (18-40) years and 59 (45-73) kg respectively (Table 1). Women on nevirapine 
(NVP) regimen were 9 (14.8%) and 52 (85.2%) were on efavirenz (EFV) regimens. 
Linear and multiple regression (for con-founders) models, were used to adjusted for 
associations with time post dose, pregnancy, postpartum and drug concentrations. 
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Genotype frequencies of both pregnant and postpartum women were similar to 
previously reported genotype and allele frequencies in the region (Table 2).  
For the pregnant women, the highest TFV concentration was 334.935ng/mL, and 
lowest was 35.520ng/mL at 18 and 14.5 h post dose respectively. Pregnancy was 
found to decrease plasma concentration of TFV by a factor of log10 0.13 (log10 β= -
0.131 (-0.228, -0.034), (P= 0.009) between 7-18.5 h post dose. Over 50% of pregnant 
women had TFV concentration greater than IC50 (2.3 μM or 10ng/ml) at 18 h post 
dose. The highest measured concentration was 553.259ng/mL at 12 h post dose and 
there was no significant association of drug concentration with any SNP. ABCC2 
12:g.154962860T>C T allele was associated with a significant increase concentration 
of FTC by a factor of log10 0.766 in both pregnant and postpartum women irrespective 
of time post dose (β = log 10 0.766 (0.084, 1.448) (P= 0.028). There was no association 
of FTC concentrations with other SNPs. 
 
 
Table 1: Demographic and genetic characteristics of study population 
Characteristic Pregnancy Postpartum 
Number (%) of women 31 (50.8%) 30 (49.2%) 
Median (Range) 
 Age (years) 
 Weight (Kg) 
 
29 (17-42) 
57 (48-79) 
 
30 (18-40) 
59 (45-73) 
Median (Range) CD4 Count (cells/mm3) 
 Baseline CD4 count 
 Last CD4 Count 
 
234 (9-533) 
443 (108-1206) 
 
336 (73-898) 
574 (96-1290) 
Median (Range) Time Post Dose (Hrs) 12 (7-18.5) 14 (4-16) 
Mean (Range) drug Concentrations (ng/mL) 
 TFV 
 FTC 
 
80.60 (35.52-334.93) 
122.95 (20.39-449.89) 
 
106.74 (17.23-192.16) 
157.23 (19.27-553.25) 
Drug Regimen  
 TDF/FTC/EFV 
 TDF/FTC/NVP 
 
24 (77.4%) 
7 (22.6%) 
 
28 (93.3%) 
2 (6.7%) 
Median (range) Duration on regimen (months) 27 (1-48) 13 (2-36) 
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Genotype Frequencies 
ABCC2 12:g.154962860T>C (rs2273897) 
TT 
CT 
CC 
MAF 
 
ABCC2 12:g.32293730T>C (rs3749966)** 
TT 
CT 
CC 
MAF 
 
ABCC4 11:g.95020696A>G (rs1059751) 
AA 
AG 
GG 
MAF 
 
 
ABCC4 11:g.95021537A>C (rs3742106) 
AA 
AC 
CC 
MAF 
 
ABCC4 13: 95062722C>T (rs1751034)** 
CC 
CT 
TT 
MAF 
 
 
0.13 
0.54 
0.33 
0.35 
 
 
0.33 
0.58 
0.08 
0.38 
 
 
0.54 
0.46 
0.00 
0.29 
 
 
 
0.50 
0.38 
0.13 
0.25 
 
 
0.04 
0.50 
0.46 
0.27 
 
0.23 
0.45 
0.32 
0.35 
 
 
0.27 
0.59 
0.14 
0.38 
 
 
0.59 
0.32 
0.09 
0.29 
 
 
 
0.55 
0.36 
0.09 
0.25 
 
 
0.00 
0.59 
0.41 
0.27 
 
 
 
Figure 2: Tenofovir and Emtricitabine Mean (Standard Deviation) concentrations 
compared between genotypes in pregnant and postpartum women 
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Table 2: Univariate and multivariate analysis of pregnant and postpartum women 
combined 
 
 
 
TDF Univariate analysis Multivariate analysis 
Log10 P-
value 
β(95%CI) P-
value 
β(95%CI) % 
Effect 
Age (years) 0.420 0.004 (-0.007, 
0.015) 
     
Time Post dose 0.047 0.028 (0.001, 0.055) 0.027 0.017 (0.002, 0.032) 4.0 
Pregnant 0.005 -0.154(-0.259, -
0.049) 
0.009  -0.131 (-0.228, -
0.034) 
26.0 
Genotype 
ABCC2 12:g.154962860T>C 
(rs2273897)  
0.106 0.141(-0.031, 0.312) 0.531  -0.081 (-0.105, 
0.055) 
17.02 
ABCC2 12:g.32293730T>C 
(rs3749966) 
0.431 0.046 (-0.071, 
0.163) 
     
ABCC4 11:g.95020696A>G 
(rs1059751) 
0.119 0.083(-0.022, 0.189)  0.119  0.194(-0.021, 
0.179) 
56.31 
ABCC4 11:g.95021537A>C 
(rs3742106) 
0.166 -0.082(-0.035,0.199)  0.166  0.188 (-0.035, 
0.199) 
54.17 
ABCC4 13: 95062722C>T 
(rs1751034) 
0.678 -0.021(-0.123,0.081) 
  
 
FTC Univariate analysis 
  
Multivariate analysis  
Log10 P-
value 
β(95%CI) P-
value 
β(95%CI)  
Age (years) 0.215 0.035 (-0.021,0.091)      
Time Post dose 0.941 -0.066(-1.845,1.712)      
Pregnant 0.820 0.061(-0.479, 0.602)      
Genotype 
ABCC2 12:g.154962860T>C 
(rs2273897) 
0.112 0.724 (-0.175,1.622) 0.028 0.766(0.084,1.448) 171.3
9 
ABCC2 12:g.32293730T>C 
(rs3749966) 
0.665 -0.130(-0.728, 
0.469) 
     
ABCC4 11:g.95020696A>G 
(rs1059751) 
0.791 -0.072 (-
0.615,0.471) 
   
ABCC4 11:g.95021537A>C 
(rs3742106) 
0.520 0.194 (-0.407,0.746)      
ABCC4 13: 95062722C>T 
(rs1751034) 
0.561 0.153 (-0.372,0.677) 
  
 
ABCC2 12:g.154962860T>C (rs2273897) 
 TT                                             CT                                        CC 
TFV (ng/mL) Mean (Range) 139.48 (62.88-334.935)       87.48 (17.48-192.16)       92.99 (35.52-
170.99) 
FTC (ng/mL) Mean (Range) 178.14 (58.74-256.12)         121.85 (19.27-411.74)     159.43 (20.39-
553.25) 
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6.4 Discussion 
This study report for the first time the link between increased FTC blood 
concentration and ABCC2 12:g.154962860T>C T allele. An estimated 1-2increase in FTC 
blood concentration was observed in pregnant and postpartum women with ABCC2 
12:g.154962860T>C T allele compared to women with CT and CC alleles. Other 
transporters evaluated in this study for their impact on TFV and FTC concentrations 
during pregnancy or postpartum were   ABCC2 12:g.32293730T>C, ABCC4 
11:g.95020696A>G, ABCC4 11:g.95021537A>C and ABCC4 13: 95062722C>T which 
showed no significant relationship with TFV or FTC concentration. All allele 
frequencies, genotype frequencies and common allele were consistent with 
previously reported genes in the region (318). TFV concentration was 26% lower in  
pregnant women, consistent with previous reports of PANNA and IMPAACT P1026 
studies (333, 334). This is an important finding in understanding ART exposure in 
pregnancy. Clinicians will need to be aware that that an overall decrease in blood 
exposure to TFV and FTC during pregnancy may not be limited to only physiological 
changes of pregnancy, but other factors such as genetic polymorphisms. Therefore 
may require therapeutic drug monitoring and dose adjustment if available. For 
instance, CYP2B6 516G homozygous reported in previous EFV studies of this patient 
suggest a significant decrease in EFV exposure during pregnancy (330).. The 
significance of this findings are not clear, since we are unsure of what happen to the 
intracellular active metabolites of TFV but optimal drug exposure without adverse side 
effect is required to ensure viral suppression and adherence to drugs. Good adherence 
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is an important factor of ensuring treatment efficiency and prevention of increasing 
clades of resistant mutant virus against a wide class of antiretroviral agents.. Good 
adherence is an important factor of ensuring treatment efficiency and prevention of 
increasing clades of resistant mutants virus against a wide class of antiretroviral 
agents (335, 336).  
This study was performed in a small sample size and PK sampling was inadequate since 
only single time point TFV and FTC blood concentrations were measured per patient. 
Furthermore, some important transporters such as ABCC1 that may be important in 
the elimination of TFV and FTC were not included in the analysis. We recognised these 
limitations   and advice further evaluation of the impact of pregnancy and 
pharmacogenetics on TFV and FTC across a wider population and larger sample size.  
. 
6.5 Conclusion 
In conclusion, pregnancy and the puerperium are periods of considerable 
physiological changes in women, and the interplay between pregnancy and 
pharmacogenetics have significant impact on FTC and TFV exposure. However, this 
study did not find any relationship between pregnancy and pharmacogenetics on FTC 
and TFV PK. TFV blood concentration was decreased during pregnancy, and the 
pharmacogenetic relationship of FTC exposure and ABCC2 12:g.154962860T>C  T 
allele was not related to pregnancy but associated with higher concentrations of FTC 
exposure irrespective of pregnancy 
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6.6 Future Perspective 
In view of these findings and limitations of this study, further pharmacogenetic 
investigation of ABCC1, ABCC2, ABCC4 and other transporters is required in larger 
population and multiple regions. Proposed intensified ART in sub-Saharan Africa and 
other low and middle income countries with TDF/FTC NRTI backbone will increase 
frequency of prescription of formulation containing TDF and FTC in pregnancy. 
Therefore, long term efficacy of these two important NRTI will need to be protected. 
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CHAPTER 7 
Widespread use of Herbal Medicines by people living with 
HIV (PLWH) and Herbal Medicines contamination with 
Antiretroviral (ART) in Nigeria 
 
Introduction 
Prevalence of herbal medication use among PLWH and contamination with medicinal 
products and certain pharmaceutical agents has previously been reported (337), 
though understudied. Herbal contamination has not been described for 
antiretrovirals (ART), despite suspicion and poor regulations of herbal practices in 
sub-Saharan Africa (SSA) (338, 339). Widespread use of herbals among HIV-infected 
patients could be detrimental  to the intensified efforts to end the HIV epidemic by 
2030 (340). Use of herbal medicines could be associated with toxicities, reduced ART 
adherence and poor health outcomes (341-343). Previous studies of herbal medicine 
use among PLWH reported 63.5% use after diagnosis and 32.8% concomitant use 
with other pharmaceutical products including ART in Uganda and 27.5% use among 
PLWH prior to starting ART treatment and 4.25% of concomitant users with ART in 
Nigeria respectively (344, 345) . 
Nigeria and South Africa account for over 40% of the HIV burden in SSA and over 3 
million PLWH in 2016 were living in Nigeria (18, 346). Furthermore, poor access to 
health care, lack of qualified healthcare personnel, health care cost, economic status, 
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education and cultural beliefs are all associated with concomitant use of ART with 
herbal medications (347-349). Other challenges of healthcare in Nigeria include; 
infrastructural, administrative and logistics challenges. These factors were 
recognised to be responsible for high cases of paediatric HIV in 2016 due to vertical 
transmission as a result of lack of power to analyse viral load samples for early infant 
diagnosis of HIV (3). Marked variability in access to ART across the country and 
complex peculiarities in the HIV programmes poses a significant challenge and 
promotes herbal medicines utilisation by patients (346). 
Globally, several studies have reported use of herbal medicines among PLWH either 
as part of complimentary medicines or as a component for treating other ailments 
(350) but few reports described the impact of herbal medication use on patient 
safety, adherence and health outcomes (341, 343). Although some studies reported 
that concomitant use of herbal medicines  is significantly associated with poor 
adherence to ART (351), and others found no relationship between adherence to ART 
and herbal medication use (345, 348), herbal use in HIV treatment should be 
discouraged because of potential interactions with ART (352). 
Herbal medicines are commonly taken by PLWH, but use in relation to the timing of 
ART initiation or safety is not well characterised (344, 353). Users and practitioners 
erroneously consider herbal medicines to be safe without any safety evaluation (354, 
355). Furthermore, practitioners have little or no understanding of modern 
approaches to evaluation of safety of medicinal products (354, 356).  
We sought to evaluate the prevalence of herbal medicine use by PLWH attending one 
rural and three urban HIV clinics, and related this to the time of ART initiation. In 
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addition, samples of traditional herbal medicines were collected from street vendors 
across Nigeria and were screened for the presence of ART using liquid 
chromatography-mass spectrometry. 
Methods 
a) Contamination of Herbal medications with ARVs 
Herbal medicines were collected across 8 states in Nigeria between December 2014 
and June 2015. The protocol for sample collection was as follows:  i) street vendors 
from both urban and rural settings were approached by study investigators or 
assigned personnel,  ii) herbal medicines were requested for the following 
indications: HIV, AIDS, fevers or non-specific symptoms (e.g. weakness) known to be 
associated with HIV, iii) herbal vendors were not informed that samples were to be 
used for research purposes to avoid any attempt to modify preparation by herbal 
vendors to conceal any secret, iv) only herbals sold as powders or liquids were 
purchased, v) instructions for use were recorded, as was the date and site. 
A semi-quantitative screen for ARV contamination of herbal medicines was 
performed at the University of Liverpool by liquid chromatography-mass 
spectrometry (LC-MS) for the following ARVs: efavirenz, nevirapine, lopinavir, 
darunavir, ritonavir, atazanavir, emtricitabine, tenofovir and lamivudine, using a 
method adapted from Else et al (357). This method enabled the simultaneous 
measurement of 9 ARVs and was modified based on the suspected polarity of the 
different ART.  
Sample pre-treatment 
163 
 
Herbal powders were weighed and dissolved in both water and dimethyl sulfoxide 
(DMSO) in order to optimise recovery due to different solubility of possible 
contaminants, at a stock concentration of 10 mg/mL. Working solutions were 
prepared by further diluting the stock (1:1) with mobile phase. Control (drug-free) 
mobile phase and blank herbal extracts (herbal controls) were prepared to check the 
background response of the LC-MS assay. Reference standards spiked with 9 ARV 
(efavirenz, nevirapine, lopinavir, darunavir, ritonavir, atazanavir, emtricitabine, 
tenofovir and lamivudine) at two concentrations (50 ng/mL and 100 ng/mL) were 
prepared.  
Semi-quantitative LC-MS/MS:  
Blanks, reference standards and unknown samples (sourced herbal extracts) were 
injected (10 µL) onto the LC column coupled to a triple quadrupole mass 
spectrometer (TSQ Ultra; Thermo Scientific, Hemel Hempstead, UK). Data acquisition 
and processing was performed using LC QuanTM software (Thermo Scientific, Hemel 
Hempstead, UK). Herbal contamination was determined by semi-quantitative LC-MS 
assay (no internal standard or calibrators were used). An estimate of the amount of 
drug within contaminated samples was derived by comparing chromatographic peak 
areas of the samples against peak areas of known concentrations of tenofovir, 
emticitabine and lamivudine spiked in water after correcting for background signal 
from a known negative herbal sample. Two rounds of analysis (initial screening using 
10 mg/mL and confirmatory tests using 50 mg/ mL) were performed before accepting 
the presence of ART contamination in the sample. Detectable drug was confirmed if 
the response (chromatographic peak area; arbitrary units) of the unknown sample 
164 
 
was at least five times greater than the response of the blank herbal extract (assay 
background). A semi-quantitative value per milligram of herbal powder was 
calculated based on the response of the reference standards minus the assay 
background interference. For samples that showed presence of drug during 
screening, additional confirmatory experiments were performed using higher (50 
mg/mL) concentrations of herbal extract.  
 
b) Survey of herbal medication use among PLWH 
A clinical survey of PLWH attending ARV facilities in one rural (Rural Hospital Idong) 
and three urban facilities (Specialist Hospital Gombe, Faith Alive Foundation Clinic, 
Jos and Dalhatu Araf Specialist Hospital, Lafia) was conducted. Using non-probability 
sampling technique, 500 PLWH were surveyed from Faith Alive Foundation Clinic, 199 
from Dalhatu Araf Specialist Hospital, 33 from Specialist Hospital Gombe and 10 from 
Rural Hospital Idong, respectively. The national prevalence rate of HIV in Nigeria is 
3.2%; Kaduna, Gombe, Plateau and Nassarawa states have HIV prevalence rate of 
9.2%, 8.1%, 3.4% and 2.3%, respectively. These surveyed clinics attend to over 6000 
PLWH and the Faith Alive Foundation Clinic in Jos attends to over 5000 PLWH per 
month, while Rural Hospital Idong, a primary health care setting, attends to less than 
50 PLWH. (171, 242).    
Inclusion criteria were: known HIV-antibody positive patients attending clinic, any 
age, willing to participate in the survey. For children less than18 years old, parents 
were asked for consent and if willing, provided responses to the survey. Hospitalised 
patients, patients who were acutely unwell and any unconfirmed patient in the clinic 
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were excluded. We utilised a structured questionnaire adapted from Langlois-Klassen 
et al (2007) who previously evaluated herbal medication use among PLWH (344). The 
questionnaire was modified for our purpose and was applied to evaluate use of 
herbal medications across age, gender, education, employment status, date of 
diagnosis, date of starting herbal medications, type of herbal medication, source of 
recommendation for herbal use, source of procurement of herbal, reasons for use 
and perceived effectiveness of the herbals. The primary outcome was prevalence of 
herbal medication use among PLWH. Secondary outcomes were use of herbals in 
relation to initiation of antiretroviral drugs, differences by gender, by age, by 
educational attainment, employment status, and perception of benefit from herbal 
use. Herbal sample collection was random, and collection at different regions of the 
country was ensured for fair representation of different regions of the country.  
 
Statistical Analysis 
Data were analysed using IBM SPSS statistics version 22.0 (IBM Corp. 2013). 
Participants who answered positively when asked, “Do you use herbal medicine?” 
were considered as herbal medicine users. Data on herbal use and baseline social and 
demographic factors were pooled across all four centres to produce aggregate, 
descriptive overall frequencies at 5% level of significance (Table 1). We then 
compared social and demographic factors in PLWH who used or did not use herbal 
medicines. First univariate analysis was performed using binary logistic regression 
with herbal use as the dependent variable. Next all univariate associations with 
P<=0.1 were included in the final multivariable model. Groups were compared for 
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relationships and confounders on the dependent variable (use of herbal medication) 
were resolved using multiple regression models (Table 2). 
Ethical approval 
Ethics approvals for the Survey were obtained from Dalhatu Araf Specialist Hospital 
Lafia, Faith Alive Foundation Hospital and PMTCT Centre Jos (protocol assigned 
number: FAFHREC/08/34/5) and parental consent for including children was sought 
from parents before interviewing the parents for their children’s information. Only 
verbal consent and permission from hospital management was obtained from patient 
in primary health care Idong and Gombe Specialist Hospital. 
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Results 
 
A total of 742 (approximately 12% of patients receiving treatments in these facilities) 
consecutively attending PLWH aged 2-91 years were surveyed across the 4 centres. 
A total of 715 (96.4%) were adults aged 18 and above, 457 (61.6%) were female, 281 
(37.9%) were males and details of gender were missing in 4 (0.9%). Further details of 
demographic characteristics are provided in Table 1. Of the 742 PLWH surveyed, 594 
(80.05%) were receiving ART.  
 
Prevalence of herbal medication use was 41.8% (310). Of the 310 individuals who 
used herbal remedies, 38.4% took herbals prior to diagnosis of HIV while 61.6% 
started taking herbals after HIV diagnosis (Table 2). Educational attainment and 
employment status were not determinants of herbal medication use (70% of herbal 
users vs 66% of non-users had secondary and tertiary education) and (70.7% of herbal 
users vs 65.1% non-herbal users were employed).  Time from diagnosis of HIV 
(P=0.73) and whether individuals were receiving ART (P= 0.53) were not significantly 
associated with herbal medication use. PLWH who use herbals did so for a variety of 
reasons: to cure HIV (46.8%), or following the advice of family (67.4%) or friends 
(31.6%). Altogether, 40.3% said they felt herbals were ineffective for HIV while 4.8% 
believed themselves cured (Table 2).  Ingestion of herbal medications while on ARVs 
was more likely in the elderly (OR 2.31 (95% CI 1.34, 3.99) and the employed (OR 1.23 
(CI 0.89, 1.70) compared to the unemployed (Table 3). 
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As an extension to this study, 138 herbal samples were sourced from herbal vendors 
in diverse locations across Nigeria to assay for presence of ART. Of 138 samples 
collected and analysed, 3 (2%) contained detectable ART. One sample from Jos 
contained tenofovir and emtricitabine (estimated as 0.02 ng/mg powder and ≤0.01 
ng/mg powder respectively), while two samples from Ibadan contained tenofovir 
(estimated as <0.01 and 0.13 ng/mg powder) and emtricitabine (estimated as <0.01 
ng/mg powder respectively), with one of these also containing lamivudine (estimated 
as 0.02 ng/mg powder). Other ART classes were not detected. 
 
Dosing recommendations provided by the herbal vendors are often not precise. We 
found a typical dose recommendation was ‘3 fingers’ or scoops of medicinal powder 
in the palm of the hand, conservatively estimated as 1-2 teaspoons (1 teaspoon 
estimated as 5 g). Based on these recommendations a single dose of 2 teaspoons 
(approximately 10 g) of contaminated herbal powder could potentially deliver up to 
1.3 µg of tenofovir, 0.1 µg of emtricitabine and 0.2 µg of lamivudine. Although 
amount of drug detected is small, repeated exposure, or exposure to higher doses 
with different batches or preparations, could promote drug resistance. 
 
In Nigeria, tenofovir and emtricitabine are available in fixed-dose combination as 
TRUVADA®. We wanted to examine if the discrepancy in the amount of tenofovir and 
emtricitabine observed could have been explained by differential degradation when 
crushed or dissolved, or recovery during the extraction process. Recovery from 
dissolved TRUVADA® tablets in water at room temperature carried out after 12 weeks 
and 9 months respectively was 63.2% and 1.47% for emtricitabine, compared with 
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0.8% and 1.47% for tenofovir. There were also considerable differences in drug 
solubility, recovery (extraction efficiency) and matrix effects (ion suppression) 
between different herbal preparations, which more likely explained the differences 
in measured quantity between both drugs. 
 
Discussion 
Like other studies (344, 358), we observed that use of herbal medicines was 
widespread (Table 1) regardless of age, gender, educational or employment status. 
Approximately 594 (80%) of PLWH were receiving ART, 40% use herbal or traditional 
medicines and of these 40% were using these remedies prior to initiation of ART.  
Of concern, a significant proportion of individuals (14.5%) use herbals prior to 
initiation of ART. Previous reports of low level ART exposure to neonate during 
PMTCT suggest that continuous low-level exposure to ART could drive resistance (48, 
359). Our finding of contamination of herbals with ART is a concern, though 
concentration was very small and may not be sufficient to drive resistance, finding 
contamination in herbals is detrimental to treatment and HIV programme success. 
Herbal medicine use was highly prevalent in patients receiving HIV treatment (43.6% 
of people on ART were also taking herbals). Around half of the subjects perceived use 
of herbal medicines to either moderately or completely relieve symptoms such as 
headaches, fever, and generalised body weakness.  
We found 2% of herbal medicines contained small, but detectable quantities of ART, 
yielding an estimated dose of 0.1-1.3 µg ingested per dosing occasion. The clinical 
relevance of this is unclear. However, continuous low-level exposure to drug below 
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PA IC50 can lead to resistance, provided sufficient drug is present to drive selection 
pressure for resistant mutants (360, 361). Considering the oral bioavailability of 
drugs, only small levels are likely to be achieved in this scenario since measured 
concentration is low. Therefore, its potential role in driving resistance is not clear. 
Furthermore, potential drug-drug interaction of herbals and ART as well as safety 
(342, 352) was difficult to ascertain since constituents of the herbal medicines were 
unknown (362). Although the concentrations detected were very low, actual 
concentrations may have been higher given the different efficiencies of extraction 
and degradation over time that were observed.  
The finding that traditional or herbal remedies may contain pharmaceutic agents is 
not new. Previously, herbal medicines have been found to contain antipyretics, anti-
inflammatory agents or steroids, diuretics, antidiabetics, sedatives, antihistamines 
and vasodilators through accidental or deliberate contamination (363).  Accidental 
contamination may result from carryover of drug during local manufacture of 
medicines; however, this is less likely here, as HIV drugs are not locally co-
manufactured with herbals to our knowledge. It is difficult to ascertain whether 
contamination was deliberate or accidental in this case.  HIV drugs are dispensed free 
of charge through the National Treatment Programme; their use and belief that they 
are beneficial for the treatment of HIV disease may provide both the opportunity and 
the motive for any deliberate contamination. Herbalists and their medicines can play 
an important role in supplementing and supporting HIV treatment in treatment 
settings (353, 364) where weak health systems and  complex cultural beliefs around 
symptom management (365) promote widespread herbal use. Enforcing the 
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regulation of herbal medicine practices (339) and re-evaluating policies guiding 
herbal practitioners in Nigeria is urgently required to avoid harmful practices that put 
the general public at risk.  
Limitations 
We were not able to ascertain how herbal use influenced engagement with HIV 
services, or adherence to ART although these are important questions to address in 
future research. Moreover, we were only able to assess PLWH already engaged with 
treatment services. There is currently no clear understanding of positive or negative 
effects of traditional medicines as adjunctive treatment in PLWH.  However, the lack 
of regulation and standardisation in these preparations argues strongly for further 
work to confirm our findings in other countries where herbal medicines use is 
prevalent, and to understand whether ART contamination of herbal medicines has a 
negative impact on ART programmes through the generation of drug resistance. 
Surveys were only conducted in small population from northern Nigeria, which may 
vary from other regions of the country. Therefore, a larger study that aims at 
ensuring fair representation of all the regions of Nigeria is required. 
Conclusion 
Herbal medicines were erroneously perceived by users to relieve symptoms or cure 
disease and use was widespread amongst PLWH, often after commencing ART. Co-
administering herbal medicines with ART is concerning, especially since constituents 
and safety profiles of the herbal medicines are unknown. Previous reports of drug- 
drug interaction, liver and kidney injuries due to toxicities from herbals medicines 
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favours urgent evaluation of policies by authorities and further evaluation of our 
findings by researchers to establish the best approach to monitor and enforce safe 
practices of herbalist for public safety of herbal products. 
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Table 1: Prevalence of social and demographic factors in PLWH who use, or do not 
use herbal medicines   
 
 
 
 
Variable Use Herbal Medications  
(n= 310) n (%) 
Do not Use Herbal 
Medications  
(n= 432) n (%) 
Age 
 <18 years 
 >18 years 
 
3 (1.0) 
307 (99.0) 
 
24 (5.6) 
408 (94.4) 
Gender 
 Male 
 Female 
 Missing data 
 
119 (38.4) 
191 (61.6) 
 
162 (37.9) 
266 (62.1) 
4 (0.9) 
Level of Education 
 Little or no education 
 Secondary & Tertiary 
education 
 Missing data 
 
81 (26.1) 
 
217 (70.0) 
 
12 (3.9) 
 
139 (32.1) 
 
285 (66.0) 
 
8 (1.9) 
Employment Status 
 Employed  
 Unemployed 
 Missing data 
 
219 (70.7) 
88 (28.4)  
3 (0.9) 
 
281 (65.1) 
140 (32.4) 
11 (2.5) 
Months since HIV diagnosis  
 < 6 months 
 >6 months 
 Missing data 
 
146 (47.1) 
152 (49.0) 
12 (3.9) 
 
136 (31.5) 
284 (65.7) 
12 (2.8) 
Commenced ART  
 Yes 
 No  
 Missing data 
 
259 (83.6) 
45 (14.5) 
6 (1.9) 
 
335 (77.5) 
78 (18.1) 
19 (4.4) 
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Table 2: Source of recommendations, reasons for use, when herbal was started 
and perceived effectiveness among PLWH who use herbal medication (n=310) 
 
 
 
 
 
 
 
 
Variable Use Herbal Medications  
(n= 310) n (%) 
When Did you Start Using Herbal 
Medications? 
 Pre-HIV Diagnosis 
 Post-HIV Diagnosis 
 
119 (38.4) 
191 (61.6) 
 
Who Recommended the herbal 
medications 
 Family 
 Friends 
 Missing data 
 
209 (67.4) 
98 (31.6) 
3 (1.0) 
Source of Herbal Medicines 
 City vendors 
 Village Herbalist 
 Others 
 Missing data 
 
108 (34.8) 
145 (46.8) 
15 (4.8) 
42 (13.6) 
Reasons For Herbal Medication Use 
 To Relieve Symptoms 
 To achieve cure of Disease 
 Others 
 Missing data 
 
108 (34.8) 
145 (46.8) 
15 (4.8) 
42 (13.6) 
Perceived effectiveness of herbal 
medication 
 No help 
 Moderate relieve of Symptoms 
 Completely relieved symptoms 
 Cures disease (HIV) completely 
 Missing data 
 
125 (40.3) 
89 (28.7) 
43 (13.9) 
14 (4.5) 
39 (12.6) 
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Univariate Analysis 
 
Multivariate analysis 
Variable β 
Odds Ratio (OR)  (95% 
Confidence Interval) P-Value β 
Odds Ratio (OR)  
(95% Confidence 
Interval) P-Value 
Age 0.688 1.990(1.183, 3.347) 0.009 0.839 2.314(1.343,3.987) 0.003 
Gender -0.039 0.797(0.712, 1.298) 0.797       
Level of 
Education 0.248 1.282(0.930, 1.766) 0.130 0.190 1.209 (0.868, 1.686) 0.262 
Employment 
Status 0.192 1.228 (0.887, 1.696) 0.228       
Months since HIV 
diagnosis 
- 
0.688 0.502 (0.370, 0.681) <0.001 -0.724 0.485(0.355, 0.663) <0.001 
Commenced 
ARV’s 0.154 1.167(0.080, 1.696) 0.418       
Table 3: Association of surveyed variables and herbal medication use among 
PLWH 
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CHAPTER 8 
 
8.0 GENERAL DISCUSSION 
Effectiveness of antiretroviral therapy (ART) in sub-Saharan Africa (SSA) within the 
framework of therapeutic drug safety in pregnant women and their neonates and 
drug-drug interactions with commonly prescribed medications is an important 
consideration in care of PLWH. Co-administration of ART with tropical disease 
treatments is common, often dependent on the assumption that there is a clinically 
insignificant influence of the aforementioned factors in drug exposure to patients. 
Most preliminary clinical studies of ART are often dependent on healthy male 
volunteers and population pharmacokinetic modelling to draw conclusions on safety 
and potential interactions. Recent advances in pharmacokinetics (PK) and 
pharmacogenetics have unravelled significant amount of subtle differences in the 
way medications are handled by different individuals of different populations, 
thereby requiring much more evaluation before conclusions on drugs safety profiles 
can be drawn. DTG, an ART agent used in HIC since 2013 for treatment of HIV, 
requires further evaluation before roll out to LMIC including sub-Saharan Africa. Since 
recommendation by WHO in 2016 guidelines as alternative first line treatment of HIV, 
efforts have been made for roll out in LMIC and it is currently being evaluated for 
safety in the sub-Saharan African populations of Botswana, Uganda and South Africa 
by different research groups before it is approved by for wider use in countries of the 
region. Pregnancy and paediatric safety data as well as drug-drug interaction data 
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with commonly prescribed medications for treatment of tropical diseases such as 
malaria is lacking for DTG.  In recognition of this research gap and insufficient data, 
several clinical trials are currently being conducted by several research groups. 
Notably among these are IMPAACT P1026s, National Institute of Allergy and 
Infectious Diseases (NIAID) funded trial known as VESTED which evaluated the 
efficacy and safety of DTG-containing versus EFV-containing ART regimens in HIV-1-
infected pregnant women and their infants, DOLPHIN 1 and 2, and DolACT which will 
provide pregnancy and paediatrics safety profiles and drug-drug interaction data. 
Intensified HIV treatment in regions with high prevalence is a major determinant of 
ambitious vision 90-90-90 success. Therefore, more effort is required by stakeholders 
to ensure DTG safety is evaluated and rolled out for treatment of over 25 out of the 
over 36 million PLWH for successful achievement of the set targets. Chapters 2 of this 
thesis reviewed the PK of DTG in different studies to identify baseline of safety data 
available. Chapter 3 developed and validated robust method of DTG measurements 
in DBMS, to support sample analysis in DOLPHIN 1 and 2, while chapter 5 evaluated 
DTG safety and drug-drug interactions with ACT (frequently prescribed antimalarials 
that could potentially be co-administered with DTG in PLWH). Chapters 4,  and  
evaluated the changes in ART PK, safety, viral load changes of DTG in pregnant 
mothers and their neonates, as well as DTG changes in postpartum period and 
excretion in breastmilk of mothers in relation to their plasma concentration 
(DOLPHIN 1). The pharmacogenetic impact of pregnancy on FTC and TFV PK was 
evaluated in chapter 6 and potential role of herbal medication in influencing 
adherence to ART in Nigerian PLWH was evaluated in chapter 7.   
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DTG was hypothesised to be safe and effective across diverse populations when 
deployed as first line ART in sub-Saharan Africa and this thesis aimed at testing the 
hypothesis by evaluating DTG safety in some thematic areas of HIV treatment. This 
involved developing and validating robust methods of DTG measurement that can be 
easily applied in the region for clinical studies or therapeutic drug monitoring and 
studying DTG safety in the sub-Saharan African populations. 
DTG was well tolerated by patients in the two studies (DolACT and DOLPHIN 1), with 
a linear PK in both studies (chapters 4 and 5). DTG metabolism is known to be 
influenced by CYP enzymes and UGT enzymes and PGx of these enzymes would be 
evaluated in DOLPHIN 2 for their role in influencing DTG PK in both pregnant and 
postpartum women. Chapter 2 was a review of DTG PK and PGx safety in different 
population groups as reported by different clinical studies. The reviewed data 
revealed limited pregnancy and paediatric safety data of DTG from early studies. This 
resulted in the pregnancy and paediatric clinical trials. These are essential as DTG use 
is likely to be increased following its recommendation for first line treatment of HIV 
in 2016 WHO guidelines; consequently, more studies are needed to determine safety 
in these population of patients to ensure safety. Clinical studies involving 
measurement of drug concentrations in body fluids in sub-Saharan Africa is 
challenging due to lack of basic infrastructures, and often require complex transport 
logistics to regions of the world with appropriate infrastructures and expertise for 
sample analyses. Chapter 3 described a method that was easy to apply in the region 
for sample collection and transport under ambient conditions. Recently, the use of 
protein saver cards by researchers for drug measurements in body fluids has increase 
and it is fast gaining popularity for potential use in therapeutic drug monitoring of 
180 
 
ART and other pharmacological agents. It is hoped that this method will contribute 
significantly to DTG measurement in BM. Though microsampling is also increasingly 
becoming popular and likely to be a LMIC friendly sample collection technique, it may 
take time to become readily available in the region. Therefore, this method could 
become a reliable and robust alternative before microsampling techniques are made 
available (366, 367).  
Despite integrated antenatal care in sub-Saharan African countries, late booking and 
ART initiation in HIV infected pregnant women are common, leaving very little or no 
time for viral suppression before labour. Chapter 4 evaluated time to undetectable 
viral suppression, safety and pharmacokinetic changes of DTG during pregnancy 
compared to EFV. Over 50% of women achieved <50 copies/mL viral load after 2 
weeks of commencing DTG compared to just about 10% of women of EFV in the 
interim report. At 2 weeks postpartum, 100% of women who had no resistance to 
DTG and adherent to medication achieved viral suppression with VL < 50 copies/mL. 
DTG also appeared safe as adverse events recorded (stillbirth, hypertension, 
polydactyly and elevated liver enzymes) were likely to be unrelated to DTG. Recently, 
preliminary report of DTG in pregnancy known as the Tsepamo observational study 
in Botswana reported an increased incidence of neural tube defect in infants of 
women who conceived while on DTG compared to incidence with other ART (368). 
Therefore, cautious use is now recommended until study is completed and more data 
is made available. AUC0-24, C0-24 and Cmax were slightly lower in pregnancy compared 
to postpartum but not statistically significant. Pregnancy is known to be associated 
with physiological changes and decrease in plasma levels of drugs seen in both 
chapter 4 and 6. In chapter 6 there was also an associated 1-2 fold increase in FTC 
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concentration 12-18.5 h post dose with ABCC2 12:g.154962860T>C  T allele. This 
finding will need to be further verified since FTC and TFV are important components 
of the proposed co-formulation of DTG likely to be rolled out in LMIC. Evaluation of 
the pharmacogenetics of FTC and TFV in pregnancy will elicit better understanding of 
the factors influencing ART exposure during pregnancy and the general population.  
Outcomes of malaria, like many diseases, could be worsen by background HIV 
infection or immunosuppression and vice versa. Geographical overlap of these 
diseases makes frequent treatment of the two diseases simultaneously likely. The 
potential of drug-drug interaction between the commonly prescribed antimalarials 
ACT and DTG was suspected since they are metabolised by similar CYP and UGT 
enzymes. Chapter 5 described interactions of DTG with ACT and found no need of 
dose adjustment or contraindication of co-administering DTG and ACT together 
despite statistically significant decrease in DTG Ctrough by 37% with AL, 42% with AS-
AQ and 24% decrease in AUC0-24 with AS-AQ. All values were still above the protein 
adjusted IC90 for the Ctrough despite the decrease and does not require dose 
adjustment. No significant changes in ACT concentrations were observed making 
recrudescence highly unlikely. Considering the usual short duration of malaria 
treatment, any impact on DTG concentration is likely to be brief and within the 
accepted minimum concentration. 
Adherence to ART is a complex challenge in treatment of HIV, due to poor ART 
forgiveness and easy mutation of viral targets, resulting in resistance against ART and 
therapeutic failure. Optimal ART adherence (>90%) is required for viral control (369, 
370). Herbal medication use is a recognised driver of poor ART adherence among 
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PLWH (343). Herbal medication culture in a complex system of poor health 
infrastructures is a challenge to treatment success since details of impact of herbal 
medications on ART is limited. Challenges of herbal medication use are not just 
limited to the unknown composition of herbals cocktails, the dose and chemical 
composition of the compounds are also unknown. Chapter 7 described 
contamination of herbal medications with ART and widespread use among PLWH in 
a Nigerian population. The finding of over 40% use in PLWH with 38% preceding ARV 
initiation, 61.1% concomitantly used with ART and contamination of herbals with ART 
is concerning. It may serve to sabotage intensified treatment efforts and long term 
consequence is unknown. Further evaluation in other countries of the region to 
understand the trend of contamination and introduce programmes that aim at 
curbing the practice is required. Evaluation of the effect on ART outcomes and 
appropriate recommendations to regulatory organisations to prevent and/or 
eliminate the practice will be an important step in ensuring good outcomes. A 
negative effect of herbal medication use was experienced in DOLPHIN 1, where an 
adverse event was experienced by a participant but it was unclear whether the 
elevated liver enzyme were caused by the herbal medication or DTG (chapter 4). 
Future perspectives (Recommendations) 
 More microsampling techniques and use of portable electrospray or paper 
spray mass spectrometry methods that are robust and adaptable to remote 
areas of the world should be evaluated. This will enable samples to be 
evaluated by the bedside or in local laboratories and results produced faster, 
easier and at a reduced cost. Technologies such as handheld desorption 
183 
 
atmospheric pressure chemical ionization (DAPCI)(371) should be further 
developed and evaluated for potential use as bedside means of measuring 
ART in body fluids for PK studies and therapeutic drug monitoring. While 
these technologies are being evaluated for future use in LMIC, use of protein 
saver cards and automated extraction processes should be intensified for 
TDM since these are now readily available and the new technologies may take 
a while to be finally made available. 
 Potential of adopting and co-opting DBMS method principles with 
microsampling techniques to develop easier and more robust methods of 
sample analyses should also be evaluated for possible use in future. 
Development of protein saver cards that absorb specific volumes and made 
in form of swab sticks will be much easier, requiring less expertise for sample 
collection and small sample volume. 
 Use of calibrated capillary tubes or capillary tubes with dispensers will require 
less expertise for sample collection without compromise to the accuracy of 
volumetric pipetting.  
 Although cellulose in protein saver cards is inert and not expected to interact 
with other molecules, formation of biopolymers with polysaccharides and 
peptides of BM is possible. Therefore collaboration with organic or polymer 
chemists to evaluate the formation of these biopolymers during sample 
processing may help to clarify the reasons why sample processing with DBMS 
is much easier compare to liquid BM.  
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 Pharmacogenetics (CYP 3A4 and UGT1A1) should be further evaluated in large 
clinical trials to determine the impact of UGT and CYP 3A4 on DTG exposure 
across different populations of the SSA region.  
 Evaluation of the interaction of DTG with the treatments of other tropical 
diseases including treatments of neglected tropical diseases that uses CYP 3A 
or UGT metabolic pathways such as ivermectin, praziquantel, mebendazole 
and albendazole for drug-drug interactions. Drug-drug interactions with 
commonly prescribed antibiotics and antimicrobial agents should also be 
evaluated in future. 
 Although, no toxic effect of DTG due to transplacental transfer to neonates 
has been observed so far, toxic effects of high drug exposure should be 
investigated for any subtle problems that could be posed by high DTG 
exposure in utero especially since poorly developed liver UGT1A1 promotes 
DTG accumulation in neonates over a long period of time. A greater than 2 
fold increase in plasma half-life (t1/2) of DTG was observed in DOLPHIN 1 and 
IMPAACT P1026s (ClinicalTrials.gov NCT00042289) (266). Further 
investigation of the risk of more accumulation in children at risk of 
hyperbiluribinaemia should be evaluated due to shared metabolic pathway 
(via UGT enzyme) for markers of increased risk of neonatal DTG exposure. 
Developmental dynamics of liver should also be evaluated for potential 
interventions that could improve liver maturity and improved enzyme 
development (372, 373). Safety of DTG is unknown in children, and only 
recommended for children >12 years. Studies should be designed to evaluate 
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DTG safety in children <12 years especially considering its robustness in viral 
control and potential benefits to affected children. 
 Although it is ethically difficult to conduct clinical studies in children, its 
potential benefit should encourage a balanced method that combines 
preclinical physiological based modelling and outcomes of neonatal exposure 
to predict potential safety and cautious trials be conducted within an ethically 
acceptable framework.  
 Safety of DTG use in chronic diseases of the liver and kidneys should be further 
evaluated. 
 Further evaluation of the role of ABCC2, ABCC1, ABCC4 and p-glycoprotein in 
FTC and TFV PK and pharmacogenetics in large sample size across SSA 
countries will increase genetic libraries for research and improvement of 
clinical outcomes of HIV treatment with FTC and TFV combinations. 
 Evaluation of the role of herbal medications in determining adherence to ART, 
prevalence of herbal medication contamination with ART and prevalence of 
herbal medication use among PLWH in different centres across different 
countries of sub-Saharan Africa and making appropriate recommendations to 
regulatory authorities. 
 Furthermore, collaborative research with Botanist, organic phytochemists, 
medicinal chemist and pharmacologist to investigate the commonly utilised 
plant products and other natural products using evidenced based scientific 
techniques will provide better understanding of the role of African herbs in 
antiretroviral outcomes. Designing studies that describes the taxonomy of the 
plants, investigate the chemical composition of the herbal products, describe 
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the chemical structure and potential modification of the structures to form 
new molecules. Beyond studying the interactions and impact on antiretroviral 
therapy, evaluating herbal medications may provide an opportunity for 
synthesis of novel molecules of medicinal importance. 
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